Advanced Cell Technology Enters Into Letter of Intent to Acquire Mytogen, Inc. and Proceed with the Human Clinical Trials Utilizing Myoblasts for the Treatment of Heart Failure
May 31, 2007 12:34:23 (ET)
ALAMEDA, Calif., May 31, 2007 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. (ACTC, Trade ) today announced that it has entered into a letter of intent to acquire Mytogen, Inc. and its Myoblast Program for the treatment of heart failure. The letter of intent provides for an aggregate purchase price of $5 million payable in ACTC common stock plus the assumption of certain Mytogen liabilities of approximately $1 million. Mytogen will also receive a warrant to purchase an additional 1.5 million shares of ACTC common stock at $1.00 subject to achievement of certain milestones. The letter of intent is subject to several closing conditions including requisite approvals from the Food and Drug Administration (FDA), final intellectual property due diligence and execution of a definitive agreement. The transaction is scheduled to close by July 15, 2007. Upon completion of the acquisition, Advanced Cell Technology will transition from a development stage to a clinical stage company. Mytogen brings to the Company over ten years of experience in clinical trial and FDA experience in developing and advancing cellular therapies including the area of stem cells.
In regard to the Myoblast Program, Mytogen has completed successful Phase I Human Clinical Trials utilizing the therapy safely in over forty patients. The FDA has reviewed the "end-of-Phase I" data and allowed Mytogen to proceed with a Phase II Human Clinical Trial. Upon the close of the acquisition, Advanced Cell Technology plans to commence the Phase II Human Clinical Trial for the treatment of heart failure in approximately 160 patients. If successful, the Company expects to proceed with a pivotal Phase III Trial for the therapy.
The Myoblast Program may prove particularly beneficial for patients who have experienced a serious heart attack and have a high risk of heart failure. The stem cell therapy involves transplantation of expanded autologous Myoblasts (adult progenitor stem cells) derived from a small biopsy of skeletal muscle from a patient's leg. The Mytogen technology allows expansion of Myoblasts into hundreds of millions of cells over a period of two to three weeks. The resulting Myoblasts are then transplanted back into the patient's scarred heart tissue through the use of a catheter-based procedure. While the Phase I Human Clinical Trials were focused on the safety of the therapy, the clinical data from those trials suggests that the Myoblasts persist, often improve function in the heart and can lead to a significant increase in quality of life for the patient.
Advanced Cell Technology is interested in the Myoblast Program because of its potential to treat heart attack and heart failure. This is an area of significant focus for Company because of its Hemangioblast program. The catheter-based procedure of the Myoblast Program is similar to procedures that ACTC anticipates using with its Hemangioblast cell therapy. Advanced Cell Technology believes the combination of the Myoblast Program's target indication of heart failure, the catheter method of administration, and the stage of its human clinical trials, will likely generate significant findings and expertise relevant to the Company's Hemangioblast Program. The Company believes that the "here and now" of the autologuous adult stem cell therapy enables the treatment of patients today and importantly will also help deliver on the "promise of tomorrow" of human embryonic stem cell therapies.
Dr. Pedro Huertas, Chief Development Officer of Advanced Cell Technology remarked, "Mytogen has a very experienced team and is the only company that has successfully brought its technology into clinical trials in accordance with FDA regulations. The Myoblast Program takes us directly into Phase II clinical trials and is thoroughly aligned with various applications of our Hemangioblast Program."
William M. Caldwell, IV, Chairman and CEO of Advanced Cell Technology remarked, "We remain fully committed to the field of human embryonic stem cells and we believe that the promise of the Myoblast Program combined with the synergies with our Hemangioblast program provides a diverse technology platform in stem cell therapy focused on the treatment of heart attack and heart failure. We are excited to welcome Dr. Jonathan Dinsmore and the entire Mytogen team who have been together for over ten years to Advanced Cell Technology and look forward to the continued success of the Myoblast Program. We look forward to closing the transaction with Mytogen as quickly as practicable and integrating their technology and scientific team within our organization."
Additional details regarding the letter of intent with Mytogen will be included in a Current Report on Form 8-K to be filed by the Company with the Securities and Exchange Commission.
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying embryonic stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts.
Mytogen, Inc. is a Massachusetts based company developing autologous myoblast transplantation designed to restore cardiac function in patients with heart failure. The incidence and progressive nature of heart disease make it the leading cause of morbidity and mortality in the U. S. Mytogen is advancing a proprietary formulation of cultured human myoblasts and an optimized delivery system to deliver cells to the site of cardiac damage. Mytogen represents the consolidation of experts in areas including clinical manufacturing of biologics, cell transplantation, and stem cell biology and benefits from intellectual property assets and clinical trial experience acquired from Genvec and Diacrin, Inc. Currently, Mytogen is conducting U.S. human clinical trials of its myoblast therapy with FDA oversight, and is positioned to launch multi-center phase II studies in the near future.
Forward-Looking Statements
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended March 31, 2007. Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
SOURCE: Advanced Cell Technology, Inc.
The Investor Relations Group Investors: James Carbonara or Joseph Kessler, 212-825-3210 or Media: Bill Douglass, 212-825-3210
Posted by IMAKEMONEY on :
OK RUN BOY, IM LOADED!!! Posted by IMAKEMONEY on :
Related Quotes Sym. Price Chg. ACTC Trade News 0.66 0 Advanced Cell Technology to Host Conference Call and Webcast to Discuss Recent Developments and Planned Acquisition of Mytogen
Jun 4, 2007 12:40:30 (ET)
ALAMEDA, Calif, Jun 04, 2007 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. (ACTC, Trade ) will host a conference call, which will be simultaneously webcast, on Thursday, June 7th, at 1:00PM ET. The purpose of the call is to discuss recent company developments. Among the topics to be discussed is the Company's entry into a Letter of Intent to purchase Mytogen, Inc. and its Myoblast Program for the treatment of heart failure, and its plans to commence Phase II human clinical trials to treat heart failure using Mytogen's Autologous Myoblast Stem Cell Therapy.
The call will be hosted by William M. Caldwell, IV, Chairman and Chief Executive Officer, and Pedro Huertas, M.D., Ph.D., Chief Development Officer.
William M. Caldwell, IV commented, "This planned acquisition, if completed, will hasten Advanced Cell's transformation from a preclinical development company to a clinical therapeutic company. Our Chief Development Officer, Dr. Pedro Huertas, and I are excited to have the opportunity to discuss this and other company developments with our investors and other interested parties, on Thursday's call."
Details of the call are below. Participants should dial in at least ten minutes prior to the call.
Thursday, June 7, 1:00PM ET ---------------------------
Live participant dial-in: Toll-free: 866-585-6398 International: 416-849-9626
A webcast of the call will be available through Advanced Cell's website, at www.advancedcell.com . The webcast will be available for replay through July 7, 2007.
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts. For more information about the company visit www.advancedcell.com
Forward-Looking Statements
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended March 31, 2007. Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
SOURCE: Advanced Cell Technology, Inc.
The Investor Relations Group Investors: James Carbonara or Joseph Kessler 212-825-3210 or Media: Bill Douglass 212-825-3210
Posted by IMAKEMONEY on :
ADVANCED CELL TECH (OTC BB:ACTC.OB)
Last Trade: 0.6700 Trade Time: 1:56PM ET Change: 0.0100 (1.52%) Prev Close: 0.66 Open: 0.67 Bid: 0.6620 x 2500 Ask: 0.6700 x 2500 1y Target Est: 2.51
Posted by IMAKEMONEY on :
LL2s HEATING UP!! PPS .69
Posted by Mortimer on :
Good eye IMAKE.
I like the Mytogen news.
Posted by IMAKEMONEY on :
ALAMEDA, Calif, Jun 04, 2007 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. (ACTC, Trade ) will host a conference call, which will be simultaneously webcast, on Thursday, June 7th, at 1:00PM ET. The purpose of the call is to discuss recent company developments. JMO BUT WE MAY GET A BUMP UP HERE Posted by IMAKEMONEY on :
LETS GET THAT HOD BACK! Posted by IMAKEMONEY on :
Related Quotes Sym. Price Chg. ACTC Trade News 0.65 0 Advanced Cell Technology's VP of Research & Scientific Development, Dr. Robert Lanza, to Deliver Opening Keynote Address at TERMIS NA 2007 Conference on Regenerative Medicine
Jun 13, 2007 10:35:12 (ET)
ALAMEDA, Calif., Jun 13, 2007 (BUSINESS WIRE) -- Advanced Cell Technology's (ACTC, Trade ) Vice President of Research and Scientific Development, Robert Lanza, M.D., will be delivering the opening keynote address at TERMIS NA 2007, a conference focusing on challenges in the fields of regenerative medicine. In Dr. Lanza's address, scheduled for Thursday, June 14, at 8:30 am, he will speak on the use of embryonic stem cells and the role they play in regenerative medicine.
TERMIS, or Tissue Engineering & Regenerative Medicine International Society, is a globally recognized group of scientific professionals practicing in the fields related to regenerative medicine. The conference will include more than 100 scientific presentations comprising the most comprehensive regenerative medicine event in North America.
Advanced Cell Technology, Inc. is a biotechnology company applying embryonic stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts.
The Tissue Engineering & Regenerative Medicine International Society (TERMIS) brings together the international community of persons engaged or interested in the field of tissue engineering and regenerative medicine and promotes education and research within the field of tissue engineering and regenerative medicine through regular meetings, publications and other forms of communication. The Society also serves as an international forum to promote the informed discussion of challenges and therapeutic benefits of the application of tissue engineering and regenerative medicine technologies.
Most importantly, the Society is committed to bringing you closer to key professionals to support your mutual understanding of the field, accelerate your research in the field and to enable you to contribute to the ultimate care of patients in this very important way. To affect this interchange of information, the Society has endorsed the journal, Tissue Engineering, as its official publication and has negotiated a reduced subscription rate for members. In addition, the TERMIS publishes a quarterly newsletter for its members to keep them abreast of developments in the field. The TERMIS World Congress Meeting will be held every three years. In the interim years the Continental Chapters will host annual meetings to promote tissue engineering and regenerative medicine research regionally.
Forward-Looking Statements
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ending March 31, 2007.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
SOURCE: Advanced Cell Technology, Inc.
The Investor Relations Group Media Bill Douglass, 212-825-3210 or Investors Joseph Kessler or James Carbonara, 212-825-3210
Posted by IMAKEMONEY on :
Related Quotes Sym. Price Chg. ACTC Trade News 0.66 0.02 Advanced Cell Technology Announces Critical Advancements in Its RPE Program for the Treatment of Macular Degeneration and Other Retinal Degenerative Diseases
Jun 20, 2007 08:30:18 (ET)
ALAMEDA, Calif., Jun 20, 2007 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. (ACTC, Trade ) today announced major advancements in the process of bringing its Retinal Pigment Epithelial (RPE) program into the clinic to treat various retinal degenerative diseases, including Age-Related Macular Degeneration (AMD). After preliminary discussions earlier this year with staff from the Office of Cellular, Tissue, and Gene Therapies within the Center for Biologics Evaluation and Research at the Food and Drug Administration (FDA), the company has contracted with a leading contract research organization in order to commence work on an extensive preclinical program. Earlier this month, MPI Research, located in Mattawan, Michigan, initiated pilot studies under Good Laboratory Practices (GLP) for Advanced Cell Technology's (ACT) ongoing RPE program.
This study is the first of several that will provide substantial safety data for an Investigational New Drug (IND) application, necessary for the initiation of a clinical trial. Due to the complex nature of stem cell derived cellular therapies, these studies are original, unique, and state-of-the-art. The protocols utilize therapeutic dosage levels of RPE cells based on recent data obtained through pharmacological dosage studies in the RCS rat, a key animal model of retinal disease. For the preliminary GLP studies, the company is utilizing RPE cells that have been differentiated from human embryonic stem cells, under current Good Manufacturing Practice (cGMP) conditions in its Worcester, Massachusetts facility. Applying appropriate controls as specified in the FDA's cGMP regulations, ACT staff was able to produce master and working cell banks of human embryonic stem cells. In working out a controlled, compliant manufacturing methodology, an unlimited amount of RPE cells can be derived by ACT for clinical use.
ACT scientists have also developed novel methodology to cryopreserve the RPE cell product, thereby overcoming various clinical issues faced by other cell therapy companies. ACT is planning for further dialogue with the FDA, as well as additional safety testing and other innovative analyses of the RPE cell product. ACT believes the commencement of these studies with all the work that lead up to them represents a significant milestone towards the program's success and future clinical trial.
Pedro Huertas, M.D., Ph.D., Chief Development Officer of Advanced Cell Technology remarked, "This is an important step for us and a tribute to the efforts of our team in translating a scientific finding into a potential therapeutic application. We expect that the GLP studies will move us closer to the successful filing of an IND and to FDA regulated clinical trials of RPE cells to treat retinal degenerative diseases."
Mr. William M. Caldwell, IV, Chairman and CEO of ACTC commented, "I am very proud to announce the extensive work to date on the RPE program for our company. We remain steadfast in our commitment to drive our therapeutic programs to the clinical stage."
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying embryonic stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts.
About MPI Research
MPI Research, with headquarters in Mattawan, Michigan, is one of the worlds leading providers of comprehensive preclinical research and development services. More information on the company's services can be obtained through the website at www.mpiresearch.com .
Forward-Looking Statements
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended March 31, 2007. Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
SOURCE: Advanced Cell Technology, Inc.
The Investor Relations Group Investors: James Carbonara or Joseph Kessler, 212-825-3210 or Media: Bill Douglass, 212-825-3210
Posted by BooDog on :
crank it up
Posted by IMAKEMONEY on :
Related Quotes Sym. Price Chg. ACTC Trade News 0.76 0.1 Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
Jun 21, 2007 09:35:48 (ET)
ALAMEDA, Calif., Jun 21, 2007 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. (ACTC, Trade ) has successfully produced a human embryonic stem cell (hESC) line without destroying an embryo at its lab in Worcester, Massachusetts. This development was announced by Robert Lanza, M.D., V.P. of Research and Scientific Development of Advanced Cell Technology (ACT) on Tuesday at the fifth annual meeting of the International Society for Stem Cell Research (ISSCR) in Cairns, Australia.
In August 2006, ACT published a paper in Nature Magazine documenting a technique for removing a single cell (known as a blastomere) from an eight-cell human embryo, and using that cell to generate multiple hESCs without destroying the embryo.
At the ISSCR meeting, Dr. Lanza definitively announced that he and his team have now reproduced the work of removing a single cell blastomere from a human embryo with the surviving embryo cryo-preserved. Dr. Lanza noted at the meeting, "These are the first human embryonic stem cells in existence to be made without destroying an embryo."
This development comes on the heels of President Bush's veto of federal legislation which would have provided funding for embryonic stem cell research.
In an appearance yesterday on Bloomberg Television's "On the Economy," juxtaposed with the President's press conference relating to his stem cell funding veto, William M. Caldwell, IV, Chairman and CEO of ACT, commented on ACT's single cell blastomere development: "It does address the President's concern. We're very excited about this technology, and we're using it today to develop treatments for (addressing) macular degeneration."
Today Mr. Caldwell said, "The American people spoke through their representatives in Congress when federal funding legislation was passed by both houses and presented to the President. We are, of course, very disappointed with his veto yesterday. Our single cell blastomere technology directly addresses the President's ethical concerns and is available today, unlike the science projects announced by the President yesterday. Despite the veto, and particularly in light of this new advance, we call on the National Institutes of Health to reflect the will of the American people and approve funding for research applications of our single cell blastomere technology."
Advanced Cell Technology, Inc. is a biotechnology company applying embryonic stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts.
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended March 31, 2007. Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
SOURCE: Advanced Cell Technology, Inc.
The Investor Relations Group Investors: James Carbonara or Joseph Kessler, 212-825-3210 or Media: Bill Douglass, 212-825-3210
Posted by BooDog on :
U.S. company says grows embryo-safe stem cells Fri Jun 22, 2007 2:21pm ET Market View ACTC (Advanced Cell Technology Inc ) Last: $0.70 Change: -0.02 (-2.78%) Revenue (ttm): $0.5M EPS: -1.46 Market Cap: $35.62M Time: 3:59pm ET
Company News: U.S. company says grows embryo-safe stem cells More Company News... Email This Article | Print This Article | Reprints [-] Text [+] By Maggie Fox, Health and Science Editor
WASHINGTON, June 22 (Reuters) - Researchers at a U.S. company trying to push the margins of stem cell research said on Friday they had grown human embryonic stem cells using a non-controversial method that did not harm the embryos.
They said they had grown several lines, or batches, of the cells using a single cell taken from an embryo, which they then froze unharmed.
"We generated three new lines," Dr. Robert Lanza of Advanced Cell Technology Inc. (ACTC.OB: Quote, Profile , Research) told Reuters.
Reuters Pictures
Editors Choice: Best pictures from the last 24 hours. View Slideshow
"These are first human embryonic cell lines in existence that didn't result from the destruction of an embryo."
Lanza gave a brief summary of the work to a meeting of the International Society for Stem Cell Research in Cairns, Australia this week. He plans to publish details in a medical journal.
ACT hopes the approach might bypass objections to human embryonic stem cell research. U.S. President George W. Bush vetoed a bill this week that would have broadened federal funding of such work.
Researchers say these cells, taken from days-old embryos, might provide a way to regenerate all sorts of tissues, blood and perhaps even organs. And studying them might help them learn how to reprogram ordinary cells. Continued...
Posted by IMAKEMONEY on :
WTF???????
Posted by $Eastwood$ on :
My exact words money....
Posted by IMAKEMONEY on :
COMPANY NEWS AND PRESS RELEASES FROM OTHER SOURCES:
ADVANCED CELL TECHNOLOGY, INC. files Prospectus Pursuant to Rule 424
Filed Pursuant to Rule 424(B)(3) Registration No. 333-140265
PROSPECTUS
ADVANCED CELL TECHNOLOGY, INC.
13,516,367* SHARES OF COMMON STOCK
*Does not include 20,397,296 previously registered shares that are covered by this Prospectus
This prospectus relates to the resale to the public by the selling security holders of up to 13,516,367 shares of our common stock, par value $.001 per share, underlying (i) convertible debentures issued in 2006 in the aggregate original principal amount of $10,981,250, convertible at a conversion price of $0.288, (ii) common stock purchase warrants issued in 2006 at an exercise price of $0.3168, (iii) common stock purchase warrants, with an exercise price of $0.3168, issued to a broker-dealer as commissions paid in connection with the private placement of the 2006 debentures and the 2006 warrants. Additionally, this prospectus also relates to the resale to the public by the selling security holders of up to 20,397,296 shares of our common stock, par value $.001 per share underlying (i) convertible debentures issued in 2005 in the aggregate principal amount of $22,276,250, convertible at a conversion price of $0.90, and (ii) common stock purchase warrants issued in 2005 at an exercise price of either $0.95 or $0.90.
The conversion price of each of the convertible debentures and the exercise price of the warrants described above is subject to anti-dilution and other customary adjustments.
This prospectus also covers the resale to the public by the selling security holders of up to 20,397,296 shares of common stock previously registered pursuant to that certain Registration Statement No. 333-129019, which was filed on October 14, 2005, originally declared effective October 28, 2005, and subsequently amended, including (i) shares of common stock underlying convertible debentures issued in 2005 and held by certain selling security holders, and (ii) shares of common stock issuable upon the exercise of common stock purchase warrants issued in 2005 and held by certain of the selling security holders.
This prospectus will act as a single combined prospectus as permitted by Rule 429 of the Securities Act of 1933, as amended. The selling security holders named herein may sell common stock from time to time in the principal market on which the stock is traded at the prevailing market price or in negotiated transactions. We will not receive any proceeds from the sales by the selling security holders, but we receive funds from the exercise of warrants held by selling security holders, if and when exercised. We will pay the expenses of registering these shares.
Our common stock is quoted on the OTC Bulletin Board under the symbol “ACTC.” On March 22, 2007, the closing bid and ask prices for one share of our common stock were $0.76 and $0.79, respectively, as reported by the OTC Bulletin Board. These over-the-counter quotations reflect inter-dealer prices, without retail mark-up, mark-down or commission and may not necessarily represent actual transactions.
These securities are speculative and involve a high degree of risk. You should consider carefully the “Risk Factors” beginning on Page 6 of this prospectus before making a decision to purchase our stock.
Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.
--------------------------------------------------------------------------------
Posted by IMAKEMONEY on :
BOUGHT MORE AT .37 Posted by BooDog on :
wtg imake. I thought this would happen but not in one day. lol. end of week gapper? or more conversions to drive it lower? many were waiting for this. Bush's veto didn't help matters but twill be business as usual finding financing. getting warmer on their research as well so finding the money shouldn't be too difficult. imo
Posted by IMAKEMONEY on :
I AGREE BOO, I REALLY LIKE THIS ONE!!
Posted by IMAKEMONEY on :
Related Quotes Sym. Price Chg. ACTC Trade News 0.43 0.035 Registration Statement for Equity Related to Advanced Cell Technology's September 2006 PIPE Becomes Effective
Jun 28, 2007 10:50:11 (ET)
ALAMEDA, Calif., Jun 28, 2007 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. (ACTC, Trade ) announced that the registration statement related to new shares of common stock underlying the company's September 2006 PIPE (private investment in public equity) transaction became effective, and those shares became eligible for trading on June 27, 2007.
In September 2006, Advanced Cell Technology (ACT) raised over $10 million by selling senior secured convertible debentures in a PIPE transaction. On June 27, 2007, 13,516,367 additional shares of common stock became eligible for trading and over 21 million shares of ACTC changed hands, creating the highest volume day in company history.
"We are pleased that the conversion of the debentures issued in the September 2006 financing will eliminate debt from our balance sheet and mitigating a portion of the equity overhang presented by the September 2006 transaction," noted William M. Caldwell, IV, Chairman and CEO of Advanced Cell Technology. "While we are disappointed by the downward pressure on our stock price resulting from the availability of additional shares, our company remains committed to applying regenerative medicine to develop novel therapies for the treatment of diseases and indications with little or no alternatives such as retinal degenerative disorders and cardiovascular disease. We believe that as we continue to reach our developmental and clinical milestones, the market will recognize the value of our technology platform and the potential for the commercialization of our stem cell therapies."
Recently, ACT announced significant progress in both its retinal pigment epithelium (RPE) and hemangioblast (HG) programs for which the company plans to file investigational new drug (IND) applications in 2008. In May 2007, the company entered into a letter of intent to acquire Mytogen, Inc., an autologous adult stem cell company with a therapy for cardiovascular disease that has successfully completed Phase I clinical trials. Upon closing the Mytogen transaction, ACT plans to begin Phase II trials. In addition, last week ACT announced that it had developed the world's first human embryonic stem cell line without destroying an embryo, which could circumvent President Bush's objections to embryonic stem cell research.
For additional information about the registration statement (Form SB-2), please visit www.sec.gov .
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying embryonic stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts.
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended March 31, 2007. Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
SOURCE: Advanced Cell Technology, Inc.
The Investor Relations Group Investors: James Carbonara or Joseph Kessler, 212-825-3210 or Media: Bill Douglass, 212-825-3210
Posted by BooDog on :
i'm sure the M&Ms are happy filling those convertibles eh? now get it back to .81 lol
Posted by IMAKEMONEY on :
ADVANCED CELL TECH (OTC BB:ACTC.OB)
Last Trade: 0.4200 Trade Time: 12:46PM ET Change: 0.0250 (6.33%) Prev Close: 0.40 Open: 0.42 Bid: 0.4200 x 5000 Ask: 0.4250 x 5000 1y Target Est: 2.51
RUNNING FAST NOW BOO!!! PPS .48
Posted by IMAKEMONEY on :
EOD .47 Posted by BooDog on :
and I was swingin. Guess it paid off to wait a lil before getting back in. Very nice. Should have had my alerts set.
Posted by Homersbud on :
Bring on the .50's!!
Posted by IMAKEMONEY on :
AGREED! Homersbud
Posted by IMAKEMONEY on :
Advanced Cell Technology Applauds Inclusion of Stem Cell Provision In $152 Billion Federal Funding Measure
Jul 2, 2007 09:51:07 (ET)
ALAMEDA, Calif., Jul 02, 2007 (BUSINESS WIRE) -- Advanced Cell Technology, Inc.(ACTC, Trade ): On June 21, 2007, the U.S. Senate Appropriations Committee voted overwhelmingly in favor of a $152 billion Labor-HHS-Education appropriations bill. An amendment to the bill would expand federal funding for embryonic stem cell research by changing a critical date relating to the eligibility of stem cell lines. The amendment would fundamentally change current federal embryonic stem cell policy by permitting federally-funded research on stem cell lines that were derived before June 15 of this year, as opposed to the current marker of August 9, 2001. The committee noted that this moving of the date forward by almost six years will advance progress toward treatments and cures by significantly expanding the number of stem cell lines eligible for federally funded research.
Key among those lines would be upwards of twenty from Advanced Cell Technology (ACTC). These would include the Company's single cell blastomere lines, created without the destruction of embryos. This technique was documented in a major paper in Nature magazine in August 2006. Moreover, the Company recently announced additional lines using this embryo-safe technique, as discussed by ACTC's Chairman and CEO, William M. Caldwell, IV, in an interview on Bloomberg TV on June 20, juxtaposed with President Bush's press conference on related topics.
The legislation would provide more than $29 billion to fund biomedical research at the 27 Institutes and Centers that comprise the National Institutes of Health (NIH). This represents an increase of $1 billion over the fiscal year 2007 level and more than $1.2 billion over the President's most recent budget request.
Subcommittee Chairman Tom Harkin (D-IA) said, "We have written a bill that, I believe, reflects the real priorities and values of the American people. The bill provides $29 billion for life-saving biomedical research at the National Institutes of Health." In this same regard, Senate Appropriation Committee Chairman Robert C. Byrd (D-WV) noted, "The future of our nation and its ability to dominate in the global economy depends on the strength of our workforce, our ability to give our children access to an education that is second to none, and invest in our research facilities so that our doctors and scientists can continue to find cures for illnesses that affect millions of Americans every year."
William M. Caldwell IV urged the NIH to look favorably on all current grant applications utilizing the Company's single cell blastomere technology, saying, "If the NIH approves funding for human embryonic stem cell lines derived from a well-established, widely-used medical procedure, pre-implantation genetic diagnosis (PGD), the United States scientific and biotechnology community will have the opportunity to accelerate this technology platform which does not destroy the embryo, and translate the existing body of science into therapies destined for clinical trials. Over 2,500 children have been born in the past few years through PGD. They are alive and healthy, with loving parents and are a walking testament to the viability of PGD, which is the basis for our single cell blastomere technology."
Mr. Caldwell added, "Unlike a recently-announced technique for deriving embryonic stems cells in mice, this is not a science project years away from being utilized for therapeutic work. These embryonic stem cell lines we have developed are available today, here and now, and may be used immediately."
To watch Mr. Caldwell's June 20 interview on federal stem cell funding on Bloomberg Television, please visit ACTC's website at http://www.advancedcell.com
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying embryonic stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts.
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ending March 31, 2007.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
SOURCE: Advanced Cell Technology, Inc.
The Investor Relations Group Media: Bill Douglass, 212-825-3210 or Investors: Joseph Kessler/James Carbonara, 212-825-3210
Posted by BooDog on :
fAR OUT
Posted by IMAKEMONEY on :
SOUNDS GOOD TO ME!!!!!!!! Posted by IMAKEMONEY on :
pps .50 Posted by jdiddy on :
any left in this IMAKE? im lookin to catch a friday deal..
Posted by IMAKEMONEY on :
COULD GO INTO THE .70s SOON JMO
Posted by fulleroots on :
i believe i am going to buy some stocks in ADVANCED CELL TECH monday morning does everybody still feel pretty good about it, i am real new to stock investing and my first attempt i ended up getting burned worse than 2 year baby in the california dessert with no sunblock i am new to the forum thanks for all the positive info
Posted by BooDog on :
quote:Originally posted by fulleroots: i believe i am going to buy some stocks in ADVANCED CELL TECH monday morning does everybody still feel pretty good about it, i am real new to stock investing and my first attempt i ended up getting burned worse than 2 year baby in the california dessert with no sunblock i am new to the forum thanks for all the positive info
thanks alot i am going to start reading it now
Posted by mcant137 on :
I went to put in an order for ACTC this morning, but my broker appears to be restricting buys and making you buy through your local office. Anyone know why this may be?
Posted by BooDog on :
call your broker. please pass on what they say.
Posted by mcant137 on :
Thanks Boo Dog.
I called my broker and was able to place an order at the internet rate.
I was told that periodically the risk management dept review stocks on the pinks and OTC and place certain stocks on a restricted list for various reasons including sudden drop in price, (which I am guessing is why ACTC found its way onto this list) unusual trading, activity or volume.
He was unable to give more specifics or tell me when this restriction would be lifted.
Posted by BooDog on :
lemme guess... scottrade.
a few days late since the drop in pps from their convertibles. like to see this get back up in the .70 range over the next month or so. we'll see.
Posted by mcant137 on :
Got it in one BooDog!! Are they notorious for this sort of thing? (But I dont want to turn this into a broker thread!)
I am thinking this is going to be back to its levels prior to the convertibles one day in the not too distant future.
Posted by BooDog on :
yep
Posted by IMAKEMONEY on :
MIGHT GET SOME NEWS HERE, JMO
Posted by BooDog on :
Advanced Cell, Mytogen Extend Letter Of Intent For 15 Days
Jul 17, 2007 09:33:28 (ET)
Advanced Cell Technology Inc. (ACTC) disclosed Tuesday that it has extended its letter of intent to acquire acquire Mytogen Inc. and its Myoblast program for the treatment of heart failure.
According to a filing with the Securities and Exchange Commission, the term of the letter was extended for an additional 15 days. The original deadline for closing the transaction was Tuesday, but the extension gives the parties until July 31.
The letter of intent provides for a purchase price of $5 million, payable in common stock, plus the assumption of certain Mytogen liabilities of around $1 million.
Mytogen will also receive a warrant to purchase an additional 1.5 million Advanced Cell shares for $1, subject to achievement of certain milestones.
The letter is subject to several closing conditions including approvals from the Food and Drug Administration, final intellectual-property due diligence and execution of a definitive agreement.
Shares of Advanced Cell Technology closed Monday at 44 cents each.
-Chad Clinton, Dow Jones Newswires; 202-862-1349; chad.clinton*dowjones.com
(END) Dow Jones Newswires
July 17, 2007 09:33 ET (13:33 GMT)
Posted by BooDog on :
i'll take 1.5 for $1!!!!
Posted by jdiddy on :
picked up some at .41 today you guys still here?
Posted by IMAKEMONEY on :
YEP, STILL HERE.
Posted by BooDog on :
me 3
Posted by mcant137 on :
Count me in! Just bought more at $0.40
Posted by BooDog on :
ADVANCED CELL TECH (OTC BB:ACTC.OB)
Last Trade: 0.39 Trade Time: 3:58PM ET Change: 0.02 (4.88%) Prev Close: 0.41 Open: 0.41 Bid: 0.39 x 5000 Ask: 0.40 x 5000 1y Target Est: 2.51
Day's Range: 0.39 - 0.41 summer time taking its toll a bit imo.
I've been waiting for the .30's. May trace down a bit until we hear about their financing. imo.
Posted by jdiddy on :
.37 PPS
Posted by BooDog on :
alert set for .32. anything is possible. low volumes really make these tricky imo. Can be hazardous if you were looking for a quick play. get the right news and you'll be left in the dust too. I'll leave a small position while looking for the dip to add. .32 is just a guess from what happened during the conversions. if there are more it could happen quickly, if not and no news it may take even longer. A few more shares out there to be gobbled up to start having some decent swings again. i'll re-asses as the days go by. all imo.
Posted by BooDog on :
lol .33
Posted by jdiddy on :
not good Posted by BooDog on :
would have been a good flip if i was ready for it. already retracing back up.
Posted by BooDog on :
NIII on the ask. could be looking at some good accumulation over the next few days even with a little down trend. Just need the news! 5 mm's at .30.
had it pegged but missed it by just .01 imake.
Posted by IMAKEMONEY on :
I BOUGHT 5000 AT .37
Posted by BooDog on :
wtg M8. I wasn't ready yet!!! i'm down on shares bigtime though so i'll be awaitin for the next one. Posted by BooDog on :
whatchya think imake??? charts lookin to dip purdy good. imo I'm thinkin we may see this as the first of 3 strikes that started 19 jul.
Posted by BooDog on :
Press Release Source: Advanced Cell Technology, Inc.
Advanced Cell Technology Enters Into Definitive Merger Agreement With Mytogen, Inc. Wednesday August 1, 8:00 am ET ACTC Prepares to Take Therapy to Phase II Clinical Trials
ALAMEDA, Calif., Aug. 1 /PRNewswire-FirstCall/ -- Advanced Cell Technology, Inc. (OTC Bulletin Board: ACTC - News) today announced that it has entered into a definitive merger agreement to acquire all of the outstanding capital stock of Mytogen, Inc. In May 2007, the company announced that it had entered into a letter of intent to acquire Mytogen, Inc. and its Myoblast Program for the treatment of heart failure. With the definitive merger agreement approved and executed by both parties, ACT and Mytogen will move quickly to close the transaction, which is signed subject to certain closing conditions. The merger agreement provides for an aggregate purchase price of $5 million payable in ACTC common stock plus the assumption of certain Mytogen liabilities. Mytogen shareholders will also receive a warrant to purchase an additional 1.5 million shares of ACTC common stock at $0.75 subject to the achievement of certain milestones. ADVERTISEMENT
Mytogen brings to the company over ten years of experience in clinical trial and FDA experience in developing and advancing cellular therapies including the area of stem cells. Mytogen has successfully completed Phase I human clinical trials utilizing the myoblast therapy safely in over forty patients. The FDA has reviewed the "end-of-Phase I" data and allowed Mytogen to proceed with a Phase II human clinical trial. Upon closing the acquisition, Advanced Cell Technology plans to begin the Phase II human clinical trial for the treatment of heart failure in approximately 160 patients. If successful, the company expects to proceed with a pivotal Phase III trial for the therapy. The Myoblast Program may prove particularly beneficial for patients that have experienced a serious heart attack and have a high risk of heart failure. This stem cell therapy involves transplantation of expanded autologous myoblasts (adult progenitor stem cells) derived from a small biopsy of skeletal muscle from a patient's leg. The technology allows for the expansion of myoblasts into hundreds of millions of cells over a period of two to three weeks. The resulting myoblasts are then transplanted back into the patient's scarred heart tissue through the use of a catheter- based procedure. While the Phase I human clinical trials were focused on the safety of the therapy, the clinical data from those trials suggests that the myoblasts often improve function in the heart and can lead to a significant increase in quality of life for the patient.
"Advanced Cell Technology has always been on the cutting edge of regenerative medicine and we are excited to join their team," noted Dr. Jonathan Dinsmore, President and Chief Scientific Officer of Mytogen, Inc. "By merging with Advanced Cell, we can now more rapidly move forward with our clinical trials and bring our novel therapies to cardiac patients in need of treatment."
William M. Caldwell, IV, Chairman and CEO of Advanced Cell Technology remarked, "We remain committed to the field of human embryonic stem cell research and believe that the promise of the Myoblast Program combined with the synergies with our Hemangioblast Program provide a diverse technology platform in stem cell therapy focused on the treatment of heart attack and heart failure. We are excited about this merger and look forward to focusing our efforts on commencing the Phase II clinical trials. The signing of this definitive agreement signals ACTC's transition from a development stage to a clinical stage company."
Additional details regarding the definitive merger agreement with Mytogen will be included in a Current Report on Form 8-K to be filed by the Company with the Securities and Exchange Commission.
Posted by BooDog on :
far out. could be a nice day
Posted by IMAKEMONEY on :
JUST GOT UP BOO, VERY NICE!
Posted by IMAKEMONEY on :
MIGHT GET GOING HERE WHEN WE HIT THE TEN DAY MOVING AVG.
Posted by IMAKEMONEY on :
ARE NOT, LOL
Posted by BooDog on :
wanna keep busy for a bit... check this link out. kinda old but worth a look.
ITEM 1.01 Entry into a Material Definitive Agreement. On July 31, 2007, Advanced Cell Technology, Inc., a Delaware corporation (the "Company"), entered into that certain Agreement and Plan of Merger (the "Merger Agreement") with Mytogen, Inc., a Delaware corporation ("Mytogen"). The Merger Agreement provides that, upon the terms and subject to the conditions set forth therein, ACT Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Company ("Merger Sub"), will merge with and into Mytogen, with Mytogen continuing as the surviving entity and a wholly owned subsidiary of the Company (the "Merger").
General Terms and Conditions of Merger Agreement
Consideration
At the effective time of the Merger, all of the issued and outstanding shares of Mytogen will be canceled, and certain equity holders of Mytogen will receive (i) shares of common stock of the Company having an aggregate value of $5,000,000 based on a per share price of $0.62 (the "Consideration Shares"), and/or (ii) warrants to purchase an aggregate of 1,500,000 shares of common stock of the Company at an exercise price of $0.75 per share. In the event the Company fails to consummate an equity and/or debt financing of at least $3,000,000 prior to the date which is ninety (90) days from the date of the Merger Agreement, the Company will be required to issue warrants to purchase an additional 1,500,000 shares of common stock of the Company.
Representations and Warranties
The Company, Merger Sub and Mytogen have made customary representations and warranties in the Merger Agreement, including, among others, representations and warranties relating to (i) proper corporate organization and similar corporate matters, (ii) capitalization, (iii) the authorization, performance and enforceability of the Merger Agreement, (iv) financial statements, (v) taxes, (vi) absence of undisclosed liabilities, (vii) real and personal property interests, (viii) material contracts, (ix) title to assets, (x) absence of certain changes, (xi) employees and employee benefits matters, (xii) compliance with applicable laws, (xiii) absence of litigation, (xiv) environmental matters, (xv) regulatory matters, (xvi) compensation matters and (xvii) insurance.
Covenants
The Company, Merger Sub and Mytogen have also made customary covenants in the Merger Agreement, including, among others, that Mytogen will (i) conduct its business in the ordinary course consistent with past practice during the interim period between the execution of the Merger Agreement and the closing of the Merger (the "Closing"), and (ii) not engage in certain types of transactions during such period.
Closing Conditions
Each party's obligation to effect the Merger is subject to the fulfillment of customary conditions, including, among others, (i) approval by all of the stockholders and other equity holders of Mytogen, (ii) the absence of any injunction or order prohibiting the Closing, subject to certain limited exceptions, (iii) subject to certain exceptions, the accuracy of representations and warranties of the other party, (iv) the modification of certain third-party contractual obligations, which such modification must be in a form satisfactory to the Company, and (v) material compliance of the other party with its covenants. The transaction is expected to close within ten (10) days following the satisfaction of all closing conditions.
Indemnification Obligations
The Merger Agreement provides for indemnification of the Company by Mytogen's stockholders for any losses suffered as a consequence of violation, breach or misrepresentation of any representation, warranty or covenant of Mytogen and/or its stockholders, provided, however, the indemnification obligations are capped at $1,000,000; provided further that, with respect to the first $750,000 of losses covered by the indemnification obligations, the sole and exclusive source of the payment of any such indemnification obligations is limited to 1,209,677 shares of common stock of the Company otherwise issuable as part of the merger consideration which are
to be deposited into escrow at the Closing of the Merger. Such shares shall be held in escrow for a twelve-month period following the Closing, in accordance with the terms and conditions of an escrow agreement to be entered into at the Closing between a representative of the Company, the stockholder representative and a designated escrow agent. For indemnification purposes, the shares of common stock held in escrow shall be valued at $0.62.
Termination
The Merger Agreement provides certain termination rights for both the Company and Mytogen.
The foregoing description of the Merger Agreement does not purport to be complete and is qualified in its entirety by reference to the Merger Agreement, a copy of which the Company will file as an exhibit to its Quarterly Report on Form 10-Q for the quarter ended June 30, 2007. There are representations and warranties contained in the Merger Agreement which were made by the parties to each other as of specific dates. The assertions embodied in these representations and warranties were made solely for purposes of the Merger Agreement and may be subject to important qualifications and limitations agreed to by the parties in connection with negotiating its terms. Moreover, certain representations and warranties may not be accurate or complete as of any specified date because they are subject to a contractual standard of materiality that is different from certain standards generally applicable to shareholders or were used for the purpose of allocating risk between the parties rather than establishing matters as facts. Based upon the foregoing reasons, you should not rely on the representations and warranties as statements of factual information.
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
ADVANCED CELL TECHNOLOGY, INC.
By: /s/ William M. Caldwell, IV William M. Caldwell, IV Chairman and Chief Executive Officer Dated: August 6, 2007
Posted by BooDog on :
whatchya think? ima thinkin a good chance for some dilution and a few more shares to hit the street. 90 days to rock and roll to .62 or they issue 1.5m. Debt financing to raise 3mm if failed results in warrants. Just my opinion based on watchin these guys it could happen quick and we could be sittin 20 -30% lower imo. push it into the low .20's. A good pr campaign with some financing news and it could work out. Gonna need to bring in the audience somehow to keep this moving. imo.
Posted by IMAKEMONEY on :
THEY WILL, WATCH,JMO Posted by IMAKEMONEY on :
MOMMA, SHAKE IT!!
Posted by IMAKEMONEY on :
New Edition of Definitive Resource in Tissue Engineering Released Today
Aug 16, 2007 09:00:00 (ET)
WORCESTER, Mass., Aug 16, 2007 /PRNewswire-FirstCall via COMTEX/ -- Three of the world's leading authorities in regenerative medicine, Robert Lanza, M.D., VP Research & Scientific Development for Advanced Cell Technology (ACTC, Trade ), Robert Langer, ScD, Institute Professor at MIT (recent recipient of the National Medal of Science), and Joseph Vacanti, MD, John Homans Professor at Harvard Medical School, have released the third edition of Principles of Tissue Engineering, the widely recognized definitive resource in the field of tissue engineering (Academic Press/Elsevier, August 15, 2007, Hardcover).
Principles of Tissue Engineering, Third Edition provides a much needed update of the rapid progress that has been achieved in the field, combining the prerequisites for a general understanding of tissue growth and development, the tools and theoretical information needed to design tissues and organs, as well as a presentation by the worlds experts of what is currently known about each specific organ system. The new edition includes greatly expanded focus on stem cells, including adult and embryonic stem cells and progenitor populations that may soon lead to new tissue engineering therapies for heart disease, diabetes, and a wide variety of other diseases that afflict humanity. This up-to-date coverage of stem cell biology and other emerging technologies is complemented by a series of new chapters on recent clinical experience in applying tissue engineering. The result is a comprehensive textbook that we believe will be useful to students and experts alike.
"Dr. Lanza is an industrial expert in the area of stem cells and regenerative medicine, with groundbreaking research that is widely respected throughout the scientific community," said William M. Caldwell, IV, Chairman and CEO of Advanced Cell Technology. "He has the unique ability to cut through the confusion and controversy, while articulating the issues and defining the benefits that surround the important research he and others are doing with embryonic stem cells for the betterment of humanity.
"Principles of Tissue Engineering, Third Edition includes contributions by almost 200 scientists and thought leaders, including Douglas Lauffenburger at the Massachusetts Institute of Technology, Bjorn Olsen at the Harvard Medical School, Robert Nerem at Georgia Institute of Technology, Alan Russell at the McGowan Institute for Regenerative Medicine, A. Hari Reddi at the University of California Davis, Ioannis Yannas at the Massachusetts Institute of Technology, George Whitesides at Harvard University, Alan Trounson at Monash Univeristy, Anthony Atala at the Wake Forest Institute for Regenerative Medicine, Charles Vacanti at Harvard Medical School and Massachusetts General Hospital, Eugene Bell at TEI Biosciences, and Laurie Zoloth at Northwestern University, among others.
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying embryonic stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts.
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward- looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended June 30, 2007. Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
SOURCE Advanced Cell Technology, Inc.
Jordan Markwith of Chad Griffin Consulting, Inc., +1-310-888-3523
ALAMEDA, Calif., Aug 20, 2007 /PRNewswire-FirstCall via COMTEX/ -- Advanced Cell Technology, Inc. (ACTC, Trade ) (ACTC) announced today that subject to market conditions, it plans to privately offer up to $10,000,000 of senior secured convertible debentures and warrants. The timing of the closing of the offering will be subject to market conditions. The proceeds of the financing are expected to be used to fund working capital, including costs associated with advancing the technology we expect to acquire in our pending acquisition of Mytogen to Phase II clinical trials.
The financing is expected to be in the form of up to $10,000,000 principal amount of senior secured convertible debentures, with accompanying warrants. The debentures are expected to have a term of no more than 36 months, amortizing on a basis that will result in full payment by maturity, with amortization payable in cash or stock, at the Company's option. The debentures are also expected to be convertible into common stock and to be accompanied by warrants for the Company's common stock, with conversion and exercise prices based on market conditions. Both the warrants and the debentures are anticipated to contain customary anti-dilution provisions.
All terms are subject to market conditions and may vary materially from those set forth above. No assurance is given that the Company will be able to close the financing described herein, or that if a financing is closed that the terms and conditions of the financing will not differ materially from those described herein.
The offering will be conducted as a private placement made only to accredited buyers in accordance with Section 4(2) of the Securities Act. The Securities will not be registered under the Securities Act and may not be offered or sold without registration unless an exemption from such registration is available. This notice is issued pursuant to Rule 135c of the Securities Act, and does not constitute an offer to sell the Securities, nor a solicitation for an offer to purchase the Securities.
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts. For more information about the company, please visit http://www.advancedcell.com .
Forward-Looking Statements
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended June 30, 2007.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
SOURCE Advanced Cell Technology, Inc.
Jordan Markwith of Chad Griffin Consulting, Inc., +1-310-888-3523, for Advanced Cell Technology, Inc.
Advanced Cell Technology's Dr. Robert Lanza Makes List of '100 Most Inspiring People in the Life-Sciences Industry'
Aug 21, 2007 09:00:00 (ET)
WORCESTER, Mass., Aug 21, 2007 /PRNewswire-FirstCall via COMTEX/ -- Advanced Cell Technology, Inc. (ACTC, Trade ) is proud to announced that Dr. Robert Lanza, the company's Vice President of Research and Scientific Development, has been recognized for his research and contributions to stem cell science and technology in the current issue of PharmaVOICE (cover story July/August issue). Dr. Lanza is one of only five researchers and scientists to be acknowledged for his discoveries "behind the medicines making a significant impact on the pipelines of today and of the future."
"Though his work has sometimes been attacked by political and religious establishments, Robert Lanza, M.D., forges ahead with research based on the right thing to do scientifically," PharmaVOICE stated. "Dr. Lanza is boldly leading Advanced Cell Technology's team of scientists toward bringing the benefits of human embryonic stem cell (hESC) technology to the tens of millions of people worldwide who are suffering from a host of degenerative diseases and other conditions," the journal continued. "Committed to the science, Dr. Lanza believes treatments using hESCs have the potential to eventually offer not just treatments, but actual cures for Parkinson's disease, macular degeneration, heart disease, and a whole host of other debilitating diseases .... Inspired by enlightened thinkers and human kindness, Dr. Lanza believes in the mission of advancing research, and he is looking forward to the next goal: to start human clinical trials using embryonic stem cells."
"We are pleased that highly regarded journals such as PharmaVOICE continue to recognize the contributions and achievements of our researchers," remarked William M. Caldwell, IV, Chairman and CEO of Advanced Cell Technology. "Moreover, we are excited by the novel therapies our research may yield to treat indications that have few alternatives."
Over the past year, Advanced Cell Technology has made significant progress in its RPE (retinal pigment epithelium) and its HG (hemangioblast) programs to treat degenerative retinal disorders and cardiovascular disease, and expects to file INDs for both programs by the end of 2008. Furthermore, the company announced last month that it had entered into a definitive merger agreement to acquire autologous adult stem cell company Mytogen, Inc. and its Myoblast Program for the treatment of heart failure. Mytogen has successfully completed Phase I clinical trials and will begin Phase II trials after the merger with ACT. Upon the transaction's closing, Advanced Cell Technology will transition from a development stage to a clinical stage company.
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying embryonic stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts.
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended June 30, 2007. Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
SOURCE Advanced Cell Technology, Inc.
Jordan Markwith of Chad Griffin Consulting, Inc., +1-310-888-3523, for Advanced Cell Technology, Inc.
on the see saw M8. MMID Bid Bid Size MMID Ask Ask Size ACTC Bullet Quote PulseChart SBSH 0.302 5000 SALI 0.305 5000 UBSS 0.30 5000 HDSN 0.31 5000 LABS 0.295 5000 LABS 0.31 5000 ETRD 0.29 5000 FRAN 0.32 5000 NITE 0.28 5000 NITE 0.32 5000 PERT 0.28 5000 ABLE 0.32 5000 ABLE 0.28 5000 UBSS 0.32 5000 BMIC 0.27 5000 SBSH 0.32 5000 HDSN 0.27 5000 ETRD 0.345 5000 HILL 0.27 5000 DOMS 0.35 5000 DOMS 0.27 5000 HILL 0.40 5000 WDCO 0.26 5000 PERT 0.40 5000
Posted by IMAKEMONEY on :
UP ON LIGHT VOLUME, HMM
Posted by IMAKEMONEY on :
UP AGIAN, NEWS??
Posted by IMAKEMONEY on :
Related Quotes Sym. Price Chg. ACTC Trade News 0.37 0.018 Advanced Cell Technology Completes $10 Million Private Placement
Sep 4, 2007 08:00:15 (ET)
ALAMEDA, Calif., Sep 04, 2007 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. (ACTC, Trade ) (ACTC) announced today that it completed a private placement with institutional and other accredited investors resulting in gross proceeds of $10 million. The company intends to use the proceeds of the offering towards the further development of the company's clinical programs, for general corporate purposes, including additions to working capital, and to finance certain costs related to its recently-announced plans to acquire Mytogen, Inc.
On August 31, 2007, Advanced Cell Technology closed on the private placement of $12,550,000 principal amount of amortizing senior secured convertible debentures. The issuance of the debentures generated $10,000,000 in gross proceeds. In connection with this financing, the company has agreed to file registration statements with the Securities and Exchange Commission registering on behalf of the purchasers the resale of all or such maximum portion of the shares of common stock, issuable upon conversion of the debentures and the exercise of the warrants, as permitted pursuant to Securities and Exchange Commission guidance regarding offerings made on a continuous basis pursuant to Securities and Exchange Commission Rule 415.
William M. Caldwell, IV, Chairman and CEO of Advanced Cell Technology remarked, "This transaction represents a significant event for Advanced Cell Technology and reflects the growing recognition of the potential of the company's stem cell technology. The proceeds from this financing will allow ACTC to accelerate its development programs focused on novel therapies for diseases and indications that have few medical alternatives. Cardiovascular disease and regenerative retinal disorders represent substantial unmet medical needs that we believe our cell based therapies address."
Additional details regarding the financing will be included in a Current Report on Form 8-K to be filed by the Company with the Securities and Exchange Commission.
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts. For more information about the company, please visit http://www.advancedcell.com .
Forward-Looking Statements
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended June 30, 2007.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
SOURCE: Advanced Cell Technology, Inc.
Chad Griffin Consulting, Inc. Jordan Markwith, 310-888-3523 or Investors: CEOcast, Inc. Andrew Hellman, 212-732-4300
Posted by IMAKEMONEY on :
ACTC.OB > SEC Filings for ACTC.OB > Form 8-K on 7-Sep-2007 All Recent SEC Filings
Show all filings for ADVANCED CELL TECHNOLOGY, INC. | Request a Trial to NEW EDGAR Online Pro
ITEM 1.01 ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT. 1. Amortizing Convertible Debenture and Warrant Financing.
On August 31, 2007, Advanced Cell Technology, Inc. (the "Company"), closed on the issuance of $12,250,000 of its amortizing senior secured convertible debentures and associated warrants ("2007 Financing"). Proceeds escrowed at closing were released to the Company on September 7, 2007. In connection with the closing of the 2007 Financing, the Company entered into a Securities Purchase Agreement (the "Securities Purchase Agreement"), dated as of August 31, 2007, with the purchasers of the debentures (the "Purchasers"). The Purchasers purchased from the Company senior secured convertible debentures and warrants to purchase shares of the Company's common stock. The Company also entered into a Registration Rights Agreement with the Purchasers, which requires that the Company file a registration statement with the Securities and Exchange Commission within 30 days after the closing of the 2007 Financing registering on behalf of the Purchasers the resale of all or such maximum portion of the shares of common stock issuable upon conversion of the debentures and the exercise of the warrants, as permitted pursuant to Securities and Exchange Commission guidance regarding offerings made on a continuous basis pursuant to Securities and Exchange Commission Rule 415.
The amortizing senior secured convertible debentures issued at the closing of the 2007 Financing will be due and payable in full three (3) years from the closing, and will not bear interest. The debentures begin amortizing on the earlier of (i) September 1, 2008, (ii) the first trading day of the month following the effective date of the initial Registration Statement filed pursuant to the Registration Rights Agreement, but in no event prior to February 1, 2008. The aggregate cash purchase price for the debentures purchased at the 2007 Financing was $10,000,000, which is a 20.3187% discount to the full principal amount of the debenture of $12,550,000. At any time from the closing date until the maturity date of the debentures, the Purchasers have the right to convert the debentures, in whole or in part, into common stock of the Company at the then effective conversion price. The debentures are initially convertible into 36,911,765 shares of common stock at a price of $0.34 per share. The conversion price shall be subject to adjustment under circumstances set forth in the debentures. The investors also received warrants to purchase 36,911,765 additional shares of common stock at a price of $0.38 per share exercisable for five (5) years.
The Company's obligations to Purchasers in the 2007 Financing are secured by a senior security interest and lien granted upon all Company assets pursuant to the terms of a Security Agreement entered into in connection with the closing. The security interest granted under the Security Agreement also secures the Company's obligations to the holders of debentures in the Company's existing 2005 and 2006 debenture financings. Inclusion of holders of the Company's 2005 and 2006 debentures was a condition of obtaining from such holders the necessary consents to the 2007 Financing.
The Securities Purchase Agreement, debentures and warrants contain covenants that will limit the ability of the Company to, among other things: incur or guarantee additional indebtedness; incur or create liens; amend its certificate of incorporation, bylaws or other charter documents so as to adversely affect any rights of the holders of the debentures; and repay or repurchase more than a de minimis number of shares of common stock other than as permitted in the debentures and other documents executed with the Purchasers. The debentures include customary default provisions and an event of default includes, among other things, a change of control of the Company, the sale of all or substantially all of the Company's assets, the failure to have registration statements declared effective on or before the deadlines set forth in the Registration Rights Agreement, the lapse of the effectiveness of registration statements for more than 30 consecutive trading days or 60 non-consecutive days during any 12-month period (with certain exceptions), the failure of the Company to timely deliver certificates to holders upon conversion, the termination of William M. Caldwell, IV as Chief Executive Officer of the Company and a default by the Company in any obligations under any indebtedness of at least $100,000 which results in such indebtedness being accelerated. Upon the occurrence of an event of default, each debenture may become immediately due and payable, either automatically or by declaration of the holder of such debenture. The aggregate amount payable upon an acceleration by reason of an event of default shall be equal to the greater of 120% of the principal amount of the debentures to be prepaid or the principal amount of the debentures to be prepaid, divided by the conversion price on the date specified in the debenture, multiplied by the closing price on the date set forth in the debenture.
In connection with this transaction, each Purchaser has contractually agreed to restrict its ability to convert the debentures, exercise the warrants and additional investment rights and receive shares of the Company's common stock such that the number of shares of the Company's common stock held by them and their affiliates after such conversion or exercise does not exceed 4.99% of the number of shares of the Company's common stock outstanding immediately after giving effect to such conversion or exercise.
Certain officers of the Company have entered into a lock-up agreement that restricts their right to dispose of any shares of common stock of the Company for a period of one year following the effective date of a registration statement registering the shares of common stock of the Company as provided in the Registration Rights Agreement.
The following served as the placement agents for the securities sold in this transaction: T.R. Winston & Company, LLC, Burrill Merchant Advisors Group, LLC, Rodman & Renshaw. Total fees paid to placement agents in connection with the 2007 Financing were $813,800 in cash and warrants to purchase 6,262,450 shares of common stock with the same terms as the warrants issued in the financing.
The representations and warranties set forth in the Securities Purchase Agreement and Security Agreement are the result of negotiations between the parties to such agreement and are solely for the benefit of such parties. These representations and warranties speak only as of the date of the agreement, are prepared in the context of the transaction contemplated by the agreement, and are intended in part to allocate risk between the parties. Therefore, such representations and warranties are not necessarily true, complete and accurate statements of fact about the matters addressed therein. As a result, we caution investors that they should read such representations and warranties in light of this context.
As of September 6, 2007, the Company has 63,938,528 shares of common stock issued and outstanding.
ITEM 9.01 Financial Statements and Exhibits.
(d) EXHIBITS
Exhibit No. Exhibit Description
10.1 Securities Purchase Agreement dated August 31, 2007 10.2 Registration Rights Agreement dated August 31, 2007 10.3 Form of Common Stock Purchase Warrant 10.4 Form of Amortizing Convertible Debenture 10.5 Form of Security Agreement dated August 31, 2007 10.6 Form of Subsidiary Guaranty dated August 31, 2007 10.7 Form of Lock-up Agreement 99.1 Press Release dated September 4, 2007
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
ADVANCED CELL TECHNOLOGY, INC.
By: /s/ William M. Caldwell, IV William M. Caldwell, IV Chairman and Chief Executive Officer Dated: September 7, 2007
Posted by BooDog on :
back in at .27 buddy. thinkin this pr will be met with dilution but we'll see.
News for 'ACTC' - (Dr. Robert Lanza, VP of Research & Scientific Development, to Speak at the First Albany Capital Regenerative Technologies Conference Advance Cell Technology Scientist to Participate on Luncheon Panel Regarding Current Issues in Stem Cell Therapy, Tissue Engineering, and Bone Regeneration)
WORCESTER, Mass., Sep 11, 2007 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. (OTCBB:ACTC) announced that Dr. Robert Lanza, the company's Vice President of Research and Scientific Development, will be participating in the First Albany Capital Regenerative Technologies Conference in New York City on Tuesday, September 11, 2007 at 12:00PM EST. Dr. Lanza will be taking part in the Luncheon Panel regarding current issues in stem cell therapy, tissue engineering, and bone regeneration. The conference is expected to include more than 20 private and publicly-traded companies in the regenerative medical technologies industry.
Last week, Advanced Cell Technology, Inc. announced that it completed a private placement resulting in gross proceeds of $10 million, which should allow the company to accelerate its development programs focused on novel therapies for diseases and indications that have few medical alternatives. Over the past year, Advanced Cell Technology has made significant progress in its RPE (retinal pigment epithelium) and its HG (hemangioblast) programs to treat degenerative retinal disorders and cardiovascular disease, and expects to file INDs for both programs by the end of 2008. Furthermore, the company announced last month that it had entered into a definitive merger agreement to acquire autologous adult stem cell company Mytogen, Inc. and its Myoblast Program for the treatment of heart failure. Mytogen has successfully completed Phase I clinical trials and will begin Phase II trials after the merger with ACT. Upon the transaction's closing, Advanced Cell Technology will transition from a development stage to a clinical stage company.
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying embryonic stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts.
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended June 30, 2007. Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
Copyright Business Wire 2007
Posted by BooDog on :
i shoulda stayed with the ax and gone for my .2598 mighta gotten it. saw nite move to .29 so i moved to .27. prolly still hit .24. lots sittin lower. spank em to the left! up up up!
Posted by IMAKEMONEY on :
NEVER KNOW! I STILL LIKE IT!
Posted by BooDog on :
ADVANCED CELL TECH (OTC BB:ACTC.OB)
Last Trade: 0.30 Trade Time: 3:56PM ET Change: 0.03 (9.09%) Prev Close: 0.28 Open: 0.27 Bid: 0.28 x 5000 Ask: 0.30 x 5000 1y Target Est: 2.51
got a few nice buys in there! just in the last 2 mins. Posted by IMAKEMONEY on :
I FEEL NEWS COMING, JMO Posted by glassman on :
hey imake, i am still waiting to find out if they catch the guys who did this on ACTC last year when the "big news" came out...
SEC charges hedge fund manager, funds in PIPE case
By Karey Wutkowski
WASHINGTON (Reuters) - The Securities and Exchange Commission on Thursday filed fraud charges against hedge fund manager Robert Berlacher and the Lancaster group of hedge funds, alleging they engaged in an illegal trading scheme involving at least 10 unregistered securities offerings.
The SEC charged that Berlacher implemented an unlawful scheme from 2000 through 2005 that helped Lancaster realize more than $1.7 million in illegal gains by investing in private-investment-in-public-equities (PIPE) offerings.
In a PIPE deal, an underwriter sells a company's restricted shares, while the company agrees to file paperwork with regulators allowing investors to resell those shares to the public.
According to the SEC's complaint, Berlacher and Lancaster, after learning about a PIPE transaction, sold short the issuer's stock.
Once the SEC declared the resale registration statement effective, Berlacher and Lancaster would use the PIPE shares to cover the short position, which is prohibited by federal securities laws, the SEC said.
Nick Morgan, an attorney representing the defendants, said, "We anticipate vigorously contesting the allegations."
The SEC said the defendants used deceptive trading techniques to make it appear they were covering their short sales with open market shares.
Also, on at least one occasion, the defendants engaged in illegal insider trading by selling short the PIPE securities before the public announcement of the offering, while using nonpublic information they received when being solicited to invest in the PIPE, the SEC said.
"We've been devoting substantial resources to investigating unlawful trading practices by hedge funds and other investors in PIPE deals, including cases involving insider trading and other deceptive trading schemes," Scott Friestad, associate director of enforcement at the SEC, told Reuters.
The SEC is seeking civil penalties and disgorgement of ill-gotten gains from the defendants.
"Litigation Release No. 20278 / September 13, 2007 SEC v. Robert A. Berlacher, Lancaster Investment Partners, L.P., Northwood Capital Partners, L.P., Cabernet Partners, L.P., Chardonnay Partners, L.P., Insignia Partners, L.P., VFT Special Ventures, Ltd., LIP Advisors, LLC, NCP Advisors, LLC, and RAB Investment Company, LLC, Civil Action No. 07-cv-3800 (ER) SEC Files Fraud Charges Against Hedge Fund Manager Robert A. Berlacher and the Lancaster Hedge Funds for Engaging in Illegal "Pipe" Trading Scheme and Insider Trading The Securities and Exchange Commission filed securities fraud and related charges today against Robert A. Berlacher, Lancaster Investment Partners, L.P., Northwood Capital Partners, L.P., Cabernet Partners, L.P., Chardonnay Partners, L.P., Insignia Partners, L.P., VFT Special Ventures, Ltd., LIP Advisors, LLC, NCP Advisors, LLC, and RAB Investment Company, LLC (collectively, "Lancaster") in the U.S. District Court for the Eastern District of Pennsylvania. The Commission's complaint alleges that the defendants collectively perpetrated an illegal trading scheme to evade the registration requirements of the federal securities laws in connection with at least ten unregistered securities offerings, which are commonly referred to as "PIPEs" (Private Investments in Public Equities), made materially false representations to the PIPE issuers in connection with those offerings, and engaged in illegal insider trading."
if ACTC gains anything back (which I doubt) maybe they can give it to us as a div eh?
Posted by BooDog on :
glass... did you see a list of who the 10 are?? I've just been picking up needles. TIA
Posted by IMAKEMONEY on :
F-ME!! GLASS DID YOU SEE THAT LIST?
Posted by BooDog on :
I just needed one more click. lol Have a nice weekend!
Posted by glassman on :
i am surprised the list is so short...
check this out: SEC Charges 69 Audit Firms and Partners for Issuing Audit Reports While Not Registered with the PCAOB FOR IMMEDIATE RELEASE 2007-183
Washington, D.C., Sept. 13, 2007 — The Securities and Exchange Commission today charged 69 auditors with issuing audit reports on the financial statements of public companies while they were not registered with the Public Company Accounting Oversight Board. The SEC administrative orders name 37 unregistered audit firms and 32 audit partners who participate
i wonder how many filings they all signed off on...
Posted by IMAKEMONEY on :
GREEN!
Posted by BooDog on :
Testicles Tested As Stem Cell Source Technique A Success In Mice; Might Be Tried On Men Within A Few Years Comment On This Post TORONTO, Sept. 20, 2007
(AP) Researchers hope to one day extract stem cells from testicles that could be directed to grow into all kinds of tissues to repair everything from a damaged heart to brains destroyed by Alzheimer's to insulin-producing cells to cure diabetes.
So far, the researchers have found a way to grow different tissues from stem cells isolated from the testes of laboratory mice, but they believe the same technology could work in humans.
"For male patients, it could someday mean a readily available source of stem cells that gets around ethical issues linked to embryonic stem cells," said co-author Dr. Shahin Rafii, director of the Stem Cell Center for Regenerative Medicine at Weill Cornell Medical College in New York.
"It also avoids issues linked to tissue transplant rejection, since these autologous stem cells are derived from the patient's own body."
The Weill Cornell-led research team began by extracting what are known as spermatogonial progenitor cells (SPCs) from the rodents' testicles, which were then induced in the lab to form adult stem cells capable of developing into various tissue types.
These tissues continued to grow both in lab dishes and after being implanted into mice, said co-author Dr. Marco Seandel, a researcher at the Howard Hughes Medical Institute and an oncology fellow at Memorial Sloan-Kettering Cancer Center.
"The first thing that was the most exciting was that in vitro (in lab dishes) even, we've seen these cells become what's very clearly heart tissue because it contracts rhythmically," Seandel said Wednesday from New York. "That's one type of tissue that you can't really miss."
"In terms of blood vessels, we did extensive staining (an identification test) on cells in vitro and after they were implanted to prove not only were they blood vessels but they were also connected with the mouse's blood circulation, to prove that they're actually functional."
Rafii and Seandel, the principal researchers, had been working for more than ten years on the concept of testicular stem cells, but it was a new method developed by Seandel that allowed their team to efficiently grow large quantities of SPCs - and hence stem cells.
While acknowledging it's a big leap from mice to men, the researchers believe their findings - published in Thursday's issue of Nature - could be applied to human health.
"We don't have any reason to think that it won't work, but it's early days," Seandel said with a note of caution. The next step is to try growing stem cells from the testicles of primates, perhaps those of macaques or rhesus monkeys, he said.
Rafii said he's more optimistic than Seandel about how long it would take before the research could move to clinical trials in humans.
"There are no ethical issues attached to this, so we are going to move very fast to implement this technology in humans," said Rafii. "I would say five years."
SPCs lie within a specific area of the testes and their sole function is to generate the precursors to sperm, keeping men fertile well into advanced age. Retrieving the SPCs, which are plentiful, would involve a small biopsy of the testicle, a procedure Rafii said is commonly performed on men undergoing fertility testing.
Not only could tissue generated from testicular stem cells help the individual, but he predicted it could also be transplanted into another man - or woman - as long as they were a genetically compatible match, similar to someone receiving a bone marrow transplant.
Besides regenerating organs, brain, skin and other tissues, the scientists say stem cells could also be harnessed as cancer fighters.
"For some reason, tumors love to recruit these cells to their environment because they are very juicy," said Rafii. "They go after them, they make blood vessels from them, they provide a lot of good stuff for (tumors)."
He said stem cells conceivably could be loaded with a cancer-killing agent, which could be switched on once they arrive at a tumor.
"So we can take advantage of this unique homing towards the tumor to deliver a toxic load." Posted by BooDog on :
News for 'ACTC' - (NIH Announces Advanced Cell Technology's 'Single Cell Embryo Biopsy Technique' as a Means to Derive Embryonic Stem Cells to be Considered for Federal Funding ACT Applauds NIH Plan to Implement President Bush's Stem Cell Executive Order)
LOS ANGELES, Sept 20, 2007 /PRNewswire-FirstCall via COMTEX/ -- (OTC Bulletin Board: ACTC) On Tuesday, September 18, 2007, the National Institutes of Health (NIH) announced that it would begin implementing President George W. Bush's Executive Order to explore methods to expand the number of approved pluripotent stem cell lines "without creating a human embryo for research purposes or destroying, discarding, or subjecting to harm a human embryo or fetus."
This announcement follows an Executive Order issued by President Bush on June 20, 2007, requiring that "The Secretary of Health and Human Services ... conduct and support research on the isolation, derivation, production, and testing of stem cells that are capable of producing all or almost all of the cell types of the developing body and may result in improved understanding of or treatments for diseases and other adverse health conditions, but are derived without creating a human embryo for research purposes or destroying, discarding, or subjecting to harm a human embryo or fetus."
ACT's groundbreaking Single Cell Biopsy technique was cited by the NIH as an alternative method in its implementation plan -- a technique successfully demonstrated by Robert Lanza, M.D., Vice President of Research and Scientific Development at Advanced Cell Technology, and his team. The NIH plan calls for "aggressively pursuing an assessment of the potential of alternative sources of pluripotent stem cell lines, including altered nuclear transfer; single cell embryo biopsy, and reprogramming, or dedifferentiation of somatic cells, such as skin cells."
In August 2006, ACT published a paper in Nature documenting the technique for removing a single cell (known as a blastomere) from an eight-cell human embryo, and using that cell to generate multiple human embryonic stem cells without destroying the embryo. The NIH referred to ACT's Nature article in its implementation plan. In June of this year, ACT announced that it had successfully produced 4 human embryonic stem cell lines without destroying the embryos at its lab in Worcester, Massachusetts. The embryo from which the cell was removed remains cryogenically preserved and remains a viable embryo. Should the company's blastomere technique satisfy NIH qualifications, ACT could qualify for federal funding from the NIH.
"Our single cell blastomere technology directly addresses the President's ethical concerns and, unlike the other potential solutions described in the order, is available today. We are encouraged by the NIH's willingness to explore ways to increase the federally approved stem cell lines available and hope they will consider our technique for federal funding," remarked William M. Caldwell IV, Chairman and CEO of Advanced Cell Technology. "We believe that such consideration reflects the will of the American people to bring novel therapies derived from stem cell research to patients with few or no alternatives."
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying stem cell technology in the emerging field of regenerative medicine. The company operates facilities in California and Massachusetts.
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward- looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended June 30, 2007. Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
NIH Announces Advanced Cell Technology's 'Single Cell Embryo Biopsy Technique' as a Means to Derive Embryonic Stem Cells to be Considered for Federal Funding
Sep 20, 2007 09:00:00 (ET)
LOS ANGELES, Sept 20, 2007 /PRNewswire-FirstCall via COMTEX/ -- (ACTC, Trade ) On Tuesday, September 18, 2007, the National Institutes of Health (NIH) announced that it would begin implementing President George W. Bush's Executive Order to explore methods to expand the number of approved pluripotent stem cell lines "without creating a human embryo for research purposes or destroying, discarding, or subjecting to harm a human embryo or fetus."
This announcement follows an Executive Order issued by President Bush on June 20, 2007, requiring that "The Secretary of Health and Human Services ... conduct and support research on the isolation, derivation, production, and testing of stem cells that are capable of producing all or almost all of the cell types of the developing body and may result in improved understanding of or treatments for diseases and other adverse health conditions, but are derived without creating a human embryo for research purposes or destroying, discarding, or subjecting to harm a human embryo or fetus."
ACT's groundbreaking Single Cell Biopsy technique was cited by the NIH as an alternative method in its implementation plan -- a technique successfully demonstrated by Robert Lanza, M.D., Vice President of Research and Scientific Development at Advanced Cell Technology, and his team. The NIH plan calls for "aggressively pursuing an assessment of the potential of alternative sources of pluripotent stem cell lines, including altered nuclear transfer; single cell embryo biopsy, and reprogramming, or dedifferentiation of somatic cells, such as skin cells."
In August 2006, ACT published a paper in Nature documenting the technique for removing a single cell (known as a blastomere) from an eight-cell human embryo, and using that cell to generate multiple human embryonic stem cells without destroying the embryo. The NIH referred to ACT's Nature article in its implementation plan. In June of this year, ACT announced that it had successfully produced 4 human embryonic stem cell lines without destroying the embryos at its lab in Worcester, Massachusetts. The embryo from which the cell was removed remains cryogenically preserved and remains a viable embryo. Should the company's blastomere technique satisfy NIH qualifications, ACT could qualify for federal funding from the NIH.
"Our single cell blastomere technology directly addresses the President's ethical concerns and, unlike the other potential solutions described in the order, is available today. We are encouraged by the NIH's willingness to explore ways to increase the federally approved stem cell lines available and hope they will consider our technique for federal funding," remarked William M. Caldwell IV, Chairman and CEO of Advanced Cell Technology. "We believe that such consideration reflects the will of the American people to bring novel therapies derived from stem cell research to patients with few or no alternatives."
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying stem cell technology in the emerging field of regenerative medicine. The company operates facilities in California and Massachusetts.
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward- looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended June 30, 2007. Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
Advanced Cell Technology Inc (OTCBB: ACTC) up 7.4% on 1.5 million shares traded.
Advanced Cell Technology Inc. is a biotechnology company applying stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts.
Posted by IMAKEMONEY on :
I LIKE WHAT IM SEEING BOO!
Posted by BooDog on :
mR. pEABODY IS LEAVIN bUT i STILL LIKE IT TOO!
Posted by BooDog on :
keep hittin it! go away nite!!
Posted by BooDog on :
News for 'ACTC' - (Advanced Cell Technology Completes Acquisition of Mytogen, Inc. Transaction Significantly Accelerates Stem Cell Clinical Development Activities; Phase II Clinical Trials to Begin Shortly)
LOS ANGELES, Sep 24, 2007 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. (OTCBB: ACTC) today announced that it has completed the acquisition of all of the outstanding capital stock of Mytogen, Inc. In May 2007, the company announced that it had entered into a letter of intent to acquire Mytogen, Inc. and its Myoblast Program for the treatment of heart failure. A definite merger agreement was signed on July 31, 2007 subject to certain closing conditions. ACTC issued a total of approximately 8.2 million restricted shares of common stock, valued at $5 million and assumed certain Mytogen liabilities. Mytogen shareholders also received a warrant to purchase an additional 1.5 million shares of restricted common stock at $0.75 per share subject to the achievement of certain milestones.
Mytogen brings to the company over ten years of experience in clinical trial and FDA experience in developing and advancing cellular therapies including the use of stem cells. This stem cell therapy involves transplantation of expanded autologous myoblasts (adult progenitor stem cells) derived from a small biopsy of skeletal muscle from a patient's leg. The technology allows for the expansion of myoblasts into hundreds of millions of cells over a period of two to three weeks. The resulting myoblasts are then transplanted back into the patient's scarred heart tissue through the use of a catheter-based procedure. The Myoblast Program has successfully completed Phase I human clinical trials using the myoblast platform, utilizing the therapy safely in over 40 patients. Safety of the company's myoblast therapy has been demonstrated in four independent studies. While the Phase I human clinical trials were focused on the safety of the therapy, the clinical data from those trials suggests that the myoblasts often improve function in the heart and may lead to a significant increase in quality of life for the patient. The company applied its myoblast therapy without the use of accompanying arrhythmia preventatives mandated by the FDA for similar programs. The FDA has reviewed the "end-of-Phase I" data and will allow Advanced Cell Technology to proceed with a Phase II human clinical trial.
The company plans to begin the Phase II human clinical trial for the treatment of heart failure in approximately 160 patients. If successful, the company expects to proceed with a pivotal Phase III trial. The Myoblast Program may prove particularly beneficial for patients that have experienced a serious heart attack and have a high risk of heart failure.
"Advanced Cell Technology has always been on the cutting edge of regenerative medicine and we are excited to join their team," noted Dr. Jonathan Dinsmore, President and Chief Scientific Officer of Mytogen, Inc. "By merging with Advanced Cell, we can now move forward with our clinical trials and bring our therapies to cardiac patients in need of this novel treatment."
William M. Caldwell, IV, Chairman and CEO of Advanced Cell Technology remarked, "The completion of this acquisition marks a transformation for our company, as it significantly advances our clinical development activities, placing the company among the most clinically advanced stem cell companies. We now have three distinct programs in various stages of clinical and preclinical development. Our Myoblast Program for the treatment of heart failure will begin Phase II clinical trials shortly, while two of our human embryonic stem cell programs, our Hemangioblast Program for treating blood and cardiovascular disease and our RPE Program for treating retinal degenerative disorders, are in preclinical studies. We expect to file IND's for those programs next year."
Additional details regarding the definitive merger agreement with Mytogen are included in a Current Report on Form 8-K filed by the Company on August 6, 2007, with the Securities and Exchange Commission.
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying stem cell technology in the emerging field of regenerative medicine. The company operates facilities in California and Massachusetts.
Mytogen, Inc. is a Massachusetts based company developing autologous myoblast transplantation designed to restore cardiac function in patients with heart failure. The incidence and progressive nature of heart disease make it the leading cause of morbidity and mortality in the U.S. Mytogen is advancing a proprietary formulation of cultured human myoblasts and an optimized delivery system to deliver cells to the site of cardiac damage. Mytogen represents the consolidation of experts in areas including clinical manufacturing of biologics, cell transplantation, and stem cell biology and benefits from intellectual property assets and clinical trial experience acquired from Genvec and Diacrin, Inc. Currently, Mytogen is conducting U.S. human clinical trials of its myoblast therapy with FDA oversight, and is positioned to launch multi-center phase II studies in the near future.
Forward-Looking Statements
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended June 30, 2007. Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
SOURCE: Advanced Cell Technology, Inc.
CONTACT: Chad Griffin Consulting, Inc.Jordan Markwith, 310-888-3523orInvestors:CEOcast, Inc.Andrew Hellman, 212-732-4300
Copyright Business Wire 2007
Posted by BooDog on :
time to get back to that $1
Posted by IMAKEMONEY on :
SEEMS LIKE WE HAVE STRONGER SUPPORT NOW.JMO
Posted by IMAKEMONEY on :
PPS .30
Posted by juice on :
see lots of form 144's over the last few months...is ACTC toast?
CRANSHIRE CAPITAL L.P. IL 9/21/2007 Form 144 221,545 55,555 N/A / N/A BRISTOL INVESTMENT FUND LTD. VGB 9/21/2007 Form 144 44,849 12,782 N/A / N/A OVERBROOK FUND 1, LLC NY 9/20/2007 Form 144 626,210 175,338 N/A / N/A JGB CAPITAL LP SHR NY 9/20/2007 Form 144 626,210 175,338 N/A / N/A GOLDMAN, JAY MASTER LIMITED PARTNERSHIP NY 9/18/2007 Form 144 439,385 123,027 N/A / N/A ROCKMORE INVESTMENT MASTER FD LTD. NY 9/18/2007 Form 144 27,610 7,454 N/A / N/A JMB CAPITAL PARTNERS MASTER FUND, LP CA 9/12/2007 Form 144 626,210 187,863 N/A / N/A JMG TRITON OFFSHORE FUND, LTD. CA 9/12/2007 Form 144 150,000 42,000 N/A / N/A JMG CAPITAL PARTNERS, LP CA 9/12/2007 Form 144 155,000 42,000 N/A / N/A ARONSON, GARY D. NV 9/12/2007 Form 144 13,175 3,623 N/A / N/A NEWBERG FAMILY TRUST UTD 12/18/90 CA 9/11/2007 Form 144 350,000 105,000 N/A / N/A RUNNELS FAMILY TRUST DTD 1/11/2000 CA 9/11/2007 Form 144 231,710 69,513 N/A / N/A HIGH TIDE, LLC CA 9/11/2007 Form 144 231,710 69,513 N/A / N/A MM&B HOLDINGS, A CALIFORNIA GENERAL PARTNERSHIP CA 9/11/2007 Form 144 525,000 157,200 N/A / N/A PROFITSIDE GROWTH AND OPPORTUNITY FUND SHR NY 9/10/2007 Form 144 298,000 87,910 N/A / N/A PORTSIDE GROWTH AND OPPORTUNITY FUND SHR NY 9/10/2007 Form 144 298,000 87,910 N/A / N/A SMITHFIELD FIDUCIARY LLC NY 9/7/2007 Form 144 626,210 184,731 N/A / N/A BRISTOL INVESTMENT FUND LTD. VGB 9/7/2007 Form 144 235,000 69,325 N/A / N/A BRISTOL INVESTMENT FUND LTD. VGB 9/6/2007 Form 144 200,000 62,000 N/A / N/A SHAPIRO, ALAN C. DIR CA 9/6/2007 Form 4 JB 17,431 $0.240 Indirect / Indirect 333,396 SHAPIRO, ALAN C. DIR CA 9/4/2007 Form 4 JB 28,851 $0.290 Indirect / Indirect 315,965 GOLDMAN, JAY MSTR LP NY 9/4/2007 Form 144 626,210 225,435 N/A / N/A NEWBERG FAMILY TRUST UTD 12/18/90 CA 8/23/2007 Form 144 41,013 13,124 N/A / N/A ARONSON, GARY D. NV 8/21/2007 Form 144 120,394 35,757 N/A / N/A BRISTOL INVESTMENT FUND LTD. VGB 8/16/2007 Form 144 149,015 44,705 N/A / N/A PORTSIDE GROWTH AND OPPORTUNITY FUND SHR NY 8/10/2007 Form 144 312,000 118,560 N/A / N/A JMG CAPITAL PARTNERS, LP CA 8/8/2007 Form 144 235,000 94,000 N/A / N/A ARONSON, GARY D. NV 8/2/2007 Form 144 65,505 23,582 N/A / N/A SHAPIRO, ALAN C. DIR CA 8/1/2007 Form 4 JB 24,608 $0.340 Indirect / Indirect 287,114 GORTON, JOHN S. SEPARATE PROPERTY TRUST CA 7/27/2007 Form 144 50,000 18,500 N/A / N/A ARONSON, GARY D. NV 7/12/2007 Form 144 58,000 27,550 N/A / N/A ARONSON, GARY D. NV 7/10/2007 Form 144 125,000 59,375 N/A / N/A JMG CAPITAL PARTNERS, LP CA 7/9/2007 Form 144 150,000 72,000 N/A / N/A JMG TRITON OFFSHORE FUND, LTD. CA 7/9/2007 Form 144 150,000 72,000 N/A / N/A BRISTOL INVESTMENT FUND LTD. VGB 7/6/2007 Form 144 135,455 64,341 N/A / N/A ARONSON, GARY D. NV 7/5/2007 Form 144 223,816 100,717 N/A / N/A SHAPIRO, ALAN C. DIR CA 7/2/2007 Form 4 JB 16,405 $0.510 Indirect / Indirect 262,506 GORTON, JOHN S. SEPARATE PROPERTY TRUST CA 7/2/2007 Form 144 50,000 22,500 N/A / N/A MM&B HOLDINGS, A CALIFORNIA GENERAL PARTNERSHIP CA 6/20/2007 Form 144 100,420 66,277 N/A / N/A GORTON, JOHN S. SEPARATE PROPERTY TRUST CA 6/18/2007 Form 144 30,000 19,200 N/A / N/A ARONSON, GARY D. NV 6/14/2007 Form 144 33,495 23,949 N/A / N/A PORTSIDE GROWTH AND OPPORTUNITY FUND SHR NY 6/7/2007 Form 144 295,000 203,550 N/A / N/A SHAPIRO, ALAN C. DIR CA 6/1/2007 Form 4 JB 14,425 $0.580 Indirect / Indirect 246,101 BRISTOL INVESTMENT FUND LTD. VGB 6/1/2007 Form 144 95,206 144,253 N/A / N/A BRISTOL INVESTMENT FUND LTD. VGB 6/1/2007 Form 144 144,253 95,207 N/A / N/A SMITHFIELD FIDUCIARY LLC NY 6/1/2007 Form 144 26,063 23,440 N/A / N/A BRISTOL INVESTMENT FUND LTD. VGB 5/10/2007 Form 144 173,535 121,474 N/A / N/A SMITHFIELD FIDUCIARY LLC NY 5/3/2007 Form 144 34,350 22,327 N/A / N/A JMG TRITON OFFSHORE FUND, LTD. CA 5/2/2007 Form 144 200,012 130,007 N/A / N/A
Posted by BooDog on :
Convertibles.
Toast? I highly doubt it. JMO.
Would be nice to see some decent projections or study status news to absorb some of the conversions.
Posted by juice on :
gotcha, thanks boodog.
Posted by BooDog on :
Cheers
Posted by BooDog on :
quote:Originally posted by BooDog: Convertibles.
Toast? I highly doubt it. JMO.
Would be nice to see some decent projections or study status news to absorb some of the conversions.
Dude...
News for 'ACTC' - (BioTime Names Dr. Michael D. West as CEO and Announces Entry Into Stem Cell Research and Regenerative Medicine)
EMERYVILLE, Calif., Oct 11, 2007 (BUSINESS WIRE) -- BioTime, Inc. (OTCBB:BTIM) today announced that Michael D. West, Ph.D. has become BioTime's new Chief Executive Officer. Dr. West will help spearhead BioTime's entry into the field of regenerative medicine by developing advanced human stem cell products and technology for diagnostic, therapeutic and research use.
Dr. West, who has served on the BioTime Board of Directors since 2002, has played a pioneering role in organizing the original collaborative effort to isolate human embryonic stem cells and in cloning and stem cell research. He has extensive academic and business experience in age-related degenerative diseases, telomerase molecular biology and human embryonic stem cell research and development. Prior to joining BioTime, Dr. West served as Director, President and Chief Scientific Officer of Advanced Cell Technology, Inc., a company engaged in developing human stem cell technology for use in regenerative medicine. Prior to Advanced Cell Technology, Inc., Dr. West founded Geron Corporation where he initiated and managed programs in telomerase diagnostics, telomerase inhibition as anti-tumor therapy, and the cloning and use of telomerase to immortalize human cells. He is an inventor named on over 60 patents and patent applications in the field of biotechnology and is an Adjunct Professor of Bioengineering at the University of California, Berkeley. Dr. West received a B.S. Degree from Rensselaer Polytechnic Institute in 1976, an M.S. Degree in Biology from Andrews University in 1982, and a Ph.D. from Baylor College of Medicine in 1989 concentrating on the biology of cellular aging.
"The timing is right for important new business opportunities in the emerging field of regenerative medicine and stem cell research," said Michael D. West, Ph.D., BioTime's new Chief Executive Officer. "I couldn't be more enthusiastic about working with BioTime's experienced team, that has successfully navigated a therapeutic product, Hextend(R), through regulatory approval, and has brought its second product, PentaLyte(R), through a Phase II clinical trial. BioTime's goal will be to expand its research and development efforts into the new field of regenerative medicine, while continuing to develop and create markets for its line of blood plasma volume expander products."
Regenerative medicine refers to therapies based on human embryonic stem cell technology that are designed to rebuild cell and tissue function lost due to degenerative disease or injury. Embryonic stem cells are the first cells ever discovered that are capable of infinite cell division while possessing the potential to differentiate into all of the cell types of the human body. Stem cells may also have commercial uses in the development of experimental new drugs.
"We are very excited to have Dr. West join BioTime as our new CEO," says Dr. Hal Sternberg, VP Research, and Member Office of the President. "We expect that his leadership capabilities and great expertise in human embryonic stem cell technology will enable BioTime to develop important innovative products for this rapidly expanding industry."
In addition to entering this emerging field of medicine, BioTime will continue to seek new markets for its physiologically balanced blood plasma volume expander products. BioTime's lead product, Hextend(R), is distributed in the United States and South Korea and is undergoing clinical trials in Japan, while BioTime is continuing to offer licensing rights to Hextend in other countries. Hextend has become the standard plasma volume expander at a number of prominent teaching hospitals and leading medical centers and is part of the United States Armed Forces Tactical Combat Casualty Care protocol. PentaLyte(R) has undergone Phase II clinical testing in the United States and BioTime is now offering pharmaceutical companies in the U.S. and abroad the opportunity to license PentaLyte(R).
BioTime plans to seek up to $5,000,000 of new funding to finance its operations and its entry into the stem cell field. BioTime has not yet determined the amount or terms of any securities that may be offered in connection with such financing. Any securities that may be offered have not been registered under the Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from such registration requirements.
BioTime also plans to apply for research funding grants from private and public sources, including the California Institute for Regenerative Medicine ("CIRM"). CIRM was established in early 2005 with the passage of Proposition 71, the California Stem Cell Research and Cures Initiative. The statewide ballot measure, which provided $3 billion in funding for stem cell research at California universities and research institutions, was approved by California voters on November 2, 2004, and called for the establishment of a new state agency to make grants and provide loans for stem cell research, research facilities and other vital research opportunities. CIRM will use bond proceeds to fund basic and applied biomedical research focused on developing diagnostics and therapies and on other vital research opportunities that will lead to life-saving medical treatments. All proposals are peer-reviewed to support the most promising scientific research. Research grants are made only to California-based research institutions.
About BioTime, Inc.
BioTime, headquartered in Emeryville, California, develops blood plasma volume expanders, blood replacement solutions for hypothermic (low temperature) surgery, organ preservation solutions, and technology for use in surgery, emergency trauma treatment and other applications. BioTime's lead product Hextend is manufactured and distributed in the U.S. by Hospira, Inc. and in South Korea by CJ Corp. under exclusive licensing agreements. BioTime has recently entered the field of regenerative medicine where it plans to develop new medical and research products using embryonic stem cell technology. Information about BioTime can be found on the web at www.biotimeinc.com. Hextend(R) and PentaLyte(R) are registered trademarks of BioTime, Inc.
Forward Looking Statements
The matters discussed in this press release include forward-looking statements which are subject to various risks, uncertainties, and other factors that could cause actual results to differ materially from the results anticipated. Such risks and uncertainties include but are not limited to the success of BioTime in developing new stem cell products and technologies; results of clinical trials of BioTime products; the ability of BioTime and its licensees to obtain additional FDA and foreign regulatory approval to market BioTime products; competition from products manufactured and sold or being developed by other companies; the price of and demand for BioTime products, and the ability of BioTime to raise the capital needed to finance its current and planned operations. Other factors that could affect BioTime's operations and financial condition are discussed in BioTime's Annual Report on Form 10-KSB filed with the Securities and Exchange Commission.
SOURCE: BioTime, Inc.
CONTACT: BioTime, Inc.Judith Segall, 510-350-2940
Copyright Business Wire 2007
-0-
KEYWORD: United States
North America
California
INDUSTRY KEYWORD: Health
Biotechnology
Clinical Trials
-------------------------------------------- AND -------------------------------------------- News for 'ACTC' - (Advanced Cell Technology Announces the Promotion of Dr. Robert Lanza to Chief Scientific Officer Dr. Michael West Transitions to Non-Executive Director)
LOS ANGELES, Oct 11, 2007 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. (OTCBB: ACTC) today announced the promotion of Dr. Robert Lanza, M.D., to the position of Chief Scientific Officer. Dr. Lanza joined Advanced Cell Technology in 1999 and has developed and managed several of the company's human embryonic stem cell (hESC) research programs including, but not limited to, the Retinal Pigment Epithelial (RPE) Cell Program, the Hemangioblast (HG) Cell Program and the Somatic Cell Nuclear Transfer (SCNT) research. Dr. Lanza will continue to work closely with Dr. Pedro Huertas, M.D., Ph.D., ACT's Chief Development Officer, to drive these hESC therapies to the clinical development stage. The company expects to file INDs for its RPE and HG Programs in 2008.
Moreover, with the acquisition of Mytogen, Dr. Huertas and Dr. Lanza together with Dr. Jonathan Dinsmore, Ph.D., expect ACT's Myoblast Program, an adult autologous stem cell therapy for the treatment of heart failure, to begin Phase II human clinical trials shortly, after having successfully completed four Phase I human clinical trials. Dr. Nabil Dib, an interventional cardiologist at University of California at San Diego's School of Medicine, will serve as a consultant to the company and lead the cellular transplantation process which is at the center of the Myoblast Program clinical trials.
"We are excited to elevate Dr. Lanza to this position after his contributions to the company and look forward to his leadership and guidance," stated William M. Caldwell, IV, Chairman and CEO of Advanced Cell Technology. "Following the acquisition of Mytogen, Inc., we have streamlined this company to more effectively and expeditiously move our stem cell therapies from the research stage to the clinical trial phase of development. We believe the combination of Dr. Lanza, Dr. Huertas and Dr. Dinsmore provide us with a world-class research and development team."
Dr. Lanza has over 25 years of research and industrial experience in stem cell research and regenerative medicine. From 1990 to 1998, he was Director of Transplantation Biology at BioHybrid Technologies, Inc., and is currently an Adjunct Professor at the Institute for Regenerative Medicine at Wake Forest University School of Medicine. Dr. Lanza has several hundred scientific publications and patents, and has authored and/or edited 20 books, including the Handbook of Stem Cells (as Editor-in-Chief), Principles of Tissue Engineering, XENO, Yearbook of Cell & Tissue Transplantation, and One World: The Health & Survival of the Human Species in the 21st Century (as editor, with forewords by C. Everett Koop and former President Jimmy Carter). He is a former Fulbright Scholar, and studied as a student in the laboratories of Richard Hynes (MIT), Jonas Salk (The Salk Institute), and Nobel laureates Gerald Edelman (Rockefeller University) and Rodney Porter (Oxford University). Dr. Lanza also worked closely and coauthored a series of papers with the late Harvard psychologist B.F. Skinner and heart transplant pioneer Christiaan Barnard. Dr. Lanza received his B.A. and M.D. degrees from the University of Pennsylvania, where he was both a University Scholar and Benjamin Franklin Scholar.
Simultaneous with Dr. Lanza's promotion, Advanced Cell Technology has announced that Michael D. West, Ph.D., is voluntarily stepping down as the company's President and Chief Scientific Officer to pursue new opportunities primarily relating to continued research on the ACTcellerate technology platform, which was exclusively developed by Dr. West. The company is in current discussions with several companies to license the ACTcellerate technology program. Dr. West will remain as a director of the company and has entered into a consulting arrangement through the end of 2007 to assist the company with certain scientific and intellectual property projects. "On behalf of the company, the board of directors, and the employees at Advanced Cell Technology, we want to thank Dr. West for his dedication and leadership and for all of the contributions he has made both to our company as well to the field of regenerative medicine." stated Mr. Caldwell.
"I look forward to working with ACT in my consulting capacity to help move the first embryonic stem cell-derived products into the clinic," said Dr. Michael West.
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying cellular technology in the emerging field of regenerative medicine. The company operates facilities in California and Massachusetts.
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended June 30, 2007. Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
You might think they read my post. lol Posted by IMAKEMONEY on :
LOL, MAYBE BOO. Posted by IMAKEMONEY on :
Related Quotes Sym. Price Chg. ACTC Trade News 0.295 0.017 ACT's Myoblast Trial Selected as Late Breaking Trial for AHA Conference
Oct 16, 2007 08:59:03 (ET)
LOS ANGELES, Oct 16, 2007 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. (ACTC, Trade ) today announced that the American Heart Association (AHA) has selected the company's Myoblast Phase I(b) trial as a featured late breaking trial for its annual Scientific Sessions Conference in Orlando Florida on November 4, 2007 through November 7, 2007. The AHA's Scientific Sessions Conference is among the premier cardiovascular research and instructional meetings worldwide bringing together interventional cardiologists, electrophysiologists, and nurses and other professionals with content from the forefront of research and clinical practice, including more than 4,000 abstracts of original research and a variety of invited programs. In addition, an International Congress on Stem Cells and Myocardial Regeneration will run concurrently with Scientific Sessions, featuring the most internationally renowned investigators in the field.
Advanced Cell Technology's myoblast therapy (acquired via its acquisition of Mytogen, Inc.) involves the transplantation of expanded autologous myoblasts (adult progenitor stem cells) derived from a small biopsy of skeletal muscle from a patient's leg. The technology allows for the expansion of myoblasts into hundreds of millions of cells over a period of two to three weeks. The resulting myoblasts are then transplanted back into the patient's scarred heart tissue through the use of a 3-D electromechanical mapping based-catheter procedure, which differs from a number of competitive therapies that may require open heart surgery or a less precise catheter-based system to deliver new cells. Since ACT's technology has never necessitated the use of accompanying arrhythmia preventatives usually required for similar programs, ACT will be permitted to conduct its Phase II trials without anti-arrhythmia precautions as well. The FDA has required studies of competitive therapies to use anti-arrhythmia medications and/or implanted defibrillators because of the safety risks involved with those treatments. In contrast, because of ACT's positive safety record with its Myoblast Program, the FDA has not put such restrictions on the ACT myoblast therapy.
"We have spent many years of research devoted to making our myoblast product the safest and most effective in the industry," noted Dr. Jonathan Dinsmore, Ph.D., Vice President and General Manager at Advanced Cell Technology. "It is gratifying to see that work translate into positive, clinical safety and survival data."
The Myoblast Program has successfully completed Phase I human clinical trials utilizing the therapy safely in over forty patients. Safety of the company's myoblast therapy has been demonstrated in four independent studies, all conducted under FDA oversight. The FDA has reviewed the "end-of-Phase I" data and will allow Advanced Cell Technology to proceed with a Phase II human clinical trial. The company plans to begin the Phase II human clinical trial for the treatment of heart failure in approximately 160 patients. Dr. Nabil Dib, an interventional cardiologist at University of California at San Diego's School of Medicine, will serve as a consultant to the company and lead the cellular transplantation team to advance the Myoblast Program clinical efficacy trials. If the Phase II human clinical trials are successful, the company expects to proceed with a pivotal Phase III trial. The Myoblast Program may prove particularly beneficial for patients that have experienced a serious heart attack and have a high risk of heart failure.
William M. Caldwell, IV, Chairman and CEO of Advanced Cell Technology commented, "We are delighted that the American Heart Association has recognized the potential for our Myoblast Program to effectively treat patients with heart failure via its inclusion of the study in its November conference. We look forward to moving into Phase II human clinical trials and ultimately bringing this and other stem cell therapies to the bedside."
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying cellular technology in the emerging field of regenerative medicine. The company operates facilities in California and Massachusetts.
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended June 30, 2007. Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
SOURCE: Advanced Cell Technology, Inc.
Media: Chad Griffin Consulting, Inc. Jordan Markwith, 310-888-3523 or Investors: CEOcast, Inc. Andrew Hellman, 212-732-4300
Posted by BooDog on :
HEYYYYYY!! you beat me!
Advanced Cell Technology, Inc. (ACTC, Trade ) today announced that the American Heart Association (AHA) has selected the company's Myoblast Phase I(b) trial as a featured late breaking trial for its annual Scientific Sessions Conference in Orlando Florida on November 4, 2007 through November 7, 2007.
SWEEEEEEET Posted by IMAKEMONEY on :
Posted by IMAKEMONEY on :
Research and Markets: New Company Profile Analyses (ACTC) Advanced Cell Technology Inc
Oct 17, 2007 12:00:01 (ET)
DUBLIN, Ireland, Oct 17, 2007 (BUSINESS WIRE) -- Research and Markets ( http://www.researchandmarkets.com/reports/c71679 ) has announced the addition of (ACTC)ADVANCED CELL TECHNOLOGY INC - Quantitative Valuation Report to their offering.
Advanced academic research that brings you superior investment strategies in an actionable format. The most comprehensive and useful report available. Our three models: Valuation Model, Forecast Model and Ratings Model are incorporated to give you a well-rounded analysis from three different perspectives. Consensus EPS trend and Earnings Surprise statistics provide additional insights. Also, detailed Company Profile, Fair Valuation; 1-3-6 month and 1-2-3 yr forecasts, 1-5 Engine Rating, Multi-stock comparison, Financials, Earnings Estimates, Risk Assessment, Data Summary and much more.
Each of our Quantitative Valuation reports Provides:
-- Overview
-- Our Rating
-- Fair Value
-- Investment-Style Rating
-- Return Forecasts
-- Market Ratio-Based Valuation
-- Quantitative Summary
-- Comparisons
-- Earnings Report
-- Analyst Expectations
-- Annual Financials
-- Quarterly Financial
Independent, numbers-based, objective Equity Research
Use this report to help to:
-- Optimize your equity portfolio for the best risk/return ratio.
-- Forecast equity portfolios value next year.
-- Find a fair value for stocks and forecast their future prospects.
-- Determine the chances of gain or loss on current holdings.
-- Find momentum & volatility ranks for stocks.
Our valuation reports are updated on each trading date.
Yale finance professor Dr. Zhiwu Chen has done an excellent job of transforming academic research and rigorous mathematics into a practical investing tool. The valuation model combines 12-month trailing EPS, consensus analyst estimates, and the 30-year Treasury yield to come up with a fair value price for any stock. Then its forecast model uses common market trends such as momentum and price reversals, and runs simulations to determine the most probable price outcomes over three years. - Forbes
Research and Markets Laura Wood Senior Manager Fax: +353 1 4100 980 press*researchandmarkets.com
Posted by BooDog on :
dagumit. My alerts must be off. where'd you find that IMAKE?? tia
Looks like you have to pay for it if you want it. Do you use these guys with any reliability? I think we can draw our own opinions these days with all the internet resources. Why pay for it if you don't havta??
Anyway, just wondering how you came about it.
cheers
Posted by IMAKEMONEY on :
BUSINESS WIRE) BOO
Posted by BooDog on :
roger that. I saw it finally.
Posted by BooDog on :
By: mailman2007 17 Oct 2007, 07:20 PM EDT Msg. 3508 of 3510 Jump to msg. # Dinsmore has plans for the heart of the initiativeMass High Tech: The Journal of New England Technology - by Lloyd Gray Mass High Tech Print Article Email Article Reprints RSS Feeds Add to Del.icio.us Digg This Though the picture in his mind was a wee bit fuzzy back then, Jonathan Dinsmore pretty much knew at age 10 what he wanted to be when he grew up. With a strong interest in science and biology, the leading choices were medical doctor, veterinarian, or medical researcher.
"It was going to be (one of) those, but it was a moving target," he said recently with a chuckle.
Several years, pedigreed schools and hard-earned degrees later, Dinsmore is now president, director and chief scientific officer of Mytogen Inc.
Based in Charlestown and privately held, Mytogen develops cell-therapy products using stem cells. Its employees comprise experts specializing in clinical manufacturing of biologics, cell transplantation, and stem cell biology.
Most of the attention the company receives these days is for its patented work using myoblasts -- also known as stem cells that form muscle -- to treat patients with congestive heart failure.
After completing an initial safety and feasibility clinical trial, Mytogen, with U.S. Food and Drug Administration clearance, is now set to begin a second phase, this one aimed at confirming the initial results.
Dinsmore estimates that with 5 million U.S. citizens experiencing heart complications, and with 500,000 new cases being diagnosed each year, market potential is in the billions.
That potential led Advanced Cell Technology Inc. -- a company with locations in Worcester and Alameda, Cailf. -- to buy Mytogen for about $6 million.
Executives from ACT, which has most of research operations in Worcester, have been meeting with Bay State Lt. Gov. Tim Murray to discuss how the developer of stem cell treatments could take advantage of a state plan to invest $1 billion in the life sciences sector, said the company's CEO William Caldwell.
This stock has been consolidating for 8 weeks now. I think we'll see a move to the upside sooner than later. Selling has definetly dried up, just need new buyers before this takes off. Looks good from here.
Posted by IMAKEMONEY on :
Advanced Cell Presents Phase I(b) Data Demonstrating Safety and Optimal Dosage for Myoblast Program at TCT Conference and Exposition
Oct 25, 2007 07:33:01 (ET)
LOS ANGELES, Oct 25, 2007 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. (ACTC, Trade ) announced today that Dr. Nabil Dib presented interim, 6 month safety and dosage data for ACT's Myoblast Phase I(b) Program at TCT 2007 - the Transcatheter Cardiovascular Therapeutic Conference and Exposition, in Washington D.C. from October 20-25, 2007. TCT is one of the leading conferences for the field of interventional cardiology. The interim data showed myoblast safety, with no evidence for increased risk of arrhythmia. The safety data presented by Dr. Dib distinguish the ACT Myoblast Program, which in contrast to other clinical programs does not require the use anti-arrhythmia medications and/or an implanted defibrillator device.
Further, as noted by Dr. Dib, the current study provides support for the hypothesis that myoblasts can help repair scarred myocardium. This was achieved by use of a control group and echocardiology core lab analysis. Dr. Dib presented the six-month interim data at "Interventional Heart Failure II: Endovascular and Surgical Approaches Session IV: Abstract session-therapeutics in heart failure. "I am pleased that we were selected to participate in this high-profile event," said Dr. Jonathan Dinsmore, Ph.D. "Our highly experienced clinical and cell manufacturing teams have demonstrated that through years of research we have achieved a superior safety profile enabling us to conduct all of our trials without the need for assist devices or arrhythmia preventative drugs. Our continuing safety results should provide for the most effective development of the myoblast technology through upcoming larger efficacy studies."
TCT 2007 is the essential gathering place for physicians, allied healthcare professionals, academics, and regulators to review critically and openly the status of cardiovascular intervention and to chart pathways to further improve outcomes for patients with coronary, endovascular, and structural heart disease.
Advanced Cell Technology's myoblast therapy (acquired via its acquisition of Mytogen, Inc.) involves the transplantation of expanded autologous myoblasts (adult progenitor stem cells) derived from a small biopsy of skeletal muscle from a patient's leg. The technology allows for the expansion of myoblasts into hundreds of millions of cells over a period of two to three weeks. The resulting myoblasts are then transplanted back into the patient's scarred heart tissue through the use of a 3-D electromechanical mapping based-catheter procedure, which differs from a number of competitive therapies that may require open heart surgery or a less precise catheter-based system to deliver new cells.
About TCT 2007
With rapid changes occurring in the field of interventional vascular medicine, TCT 2007 will be the essential gathering place for physicians, allied healthcare professionals, academics, and regulators to review critically and openly the status of cardiovascular intervention and to chart pathways to further improve outcomes for patients with coronary, endovascular, and structural heart disease.
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying cellular technology in the emerging field of regenerative medicine. The company operates facilities in California and Massachusetts.
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended June 30, 2007. Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
SOURCE: Advanced Cell Technology, Inc.
Media: Chad Griffin Consulting, Inc. Jordan Markwith, 310-888-3523 or Investors: CEOcast, Inc. Andrew Hellman, 212-732-4300
Posted by IMAKEMONEY on :
Advanced Cell Presents Phase I(b) Data Demonstrating Safety and Optimal Dosage for Myoblast Program at TCT Conference and Exposition
Oct 25, 2007 08:00:15 (ET)
LOS ANGELES, Oct 25, 2007 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. (ACTC, Trade ) announced today that Dr. Nabil Dib presented interim, 6 month safety and dosage data for ACT's Myoblast Phase I(b) Program at TCT 2007 - the Transcatheter Cardiovascular Therapeutic Conference and Exposition, in Washington D.C. from October 20-25, 2007. TCT is one of the leading conferences for the field of interventional cardiology. The interim data showed myoblast safety, with no evidence for increased risk of arrhythmia. The safety data presented by Dr. Dib distinguish the ACT Myoblast Program, which in contrast to other clinical programs does not require the use anti-arrhythmia medications and/or an implanted defibrillator device. Further, as noted by Dr. Dib, the inclusion of a control group in the current study and the use of echocardiography core lab analysis for blinded assessment of effects of the myoblasts on ventricular remodeling provide support for the hypothesis that myoblasts can help repair scarred myocardium. Dr. Dib presented the six-month interim data at "Interventional Heart Failure II: Endovascular and Surgical Approaches Session IV: Abstract session-therapeutics in heart failure.. "I am pleased that we were selected to participate in this high-profile event" said Dr. Jonathan Dinsmore, Ph.D. "Our highly experienced clinical and cell manufacturing teams have demonstrated that through years of research we have achieved a superior safety profile enabling us to conduct all of our trials without the need for assist devices or arrhythmia preventative drugs. Our continuing safety results should provide for the most effective development of the myoblast technology through upcoming larger efficacy studies.
TCT 2007 is the essential gathering place for physicians, allied healthcare professionals, academics, and regulators to review critically and openly the status of cardiovascular intervention and to chart pathways to further improve outcomes for patients with coronary, endovascular, and structural heart disease.
Advanced Cell Technology's myoblast therapy (acquired via its acquisition of Mytogen, Inc.) involves the transplantation of expanded autologous myoblasts (adult progenitor stem cells) derived from a small biopsy of skeletal muscle from a patient's leg. The technology allows for the expansion of myoblasts into hundreds of millions of cells over a period of two to three weeks. The resulting myoblasts are then transplanted back into the patient's scarred heart tissue through the use of a 3-D electromechanical mapping based-catheter procedure, which differs from a number of competitive therapies that may require open heart surgery or a less precise catheter-based system to deliver new cells.
About TCT 2007
With rapid changes occurring in the field of interventional vascular medicine, TCT 2007 will be the essential gathering place for physicians, allied healthcare professionals, academics, and regulators to review critically and openly the status of cardiovascular intervention and to chart pathways to further improve outcomes for patients with coronary, endovascular, and structural heart disease.
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying cellular technology in the emerging field of regenerative medicine. The company operates facilities in California and Massachusetts.
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended June 30, 2007. Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
SOURCE: Advanced Cell Technology, Inc.
Media: Chad Griffin Consulting, Inc. Jordan Markwith, 310-888-3523 or Investors: CEOcast, Inc. Andrew Hellman, 212-732-4300
Posted by IMAKEMONEY on :
Advanced Cell Technology's Chief Scientific Officer Delivers Keynote Address at Leading International Stem Cell Conference
Oct 31, 2007 07:08:01 (ET)
LOS ANGELES, Oct 31, 2007 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. (ACTC, Trade ) announced today that Dr. Robert Lanza, M.D., the company's Chief Scientific Officer, delivered yesterday the keynote address at the 7th International Stem Cell Conference, a leading international stem cell conference held October 29-30th in Pittsburgh. The conference featured speakers and presenters from leading stem cell companies and academic researchers. Dr. Lanza was joined as a featured presenter by James F. Battey, Jr., M.D., Ph.D., Director - National Institute on Deafness and Other Communication Disorders.
Dr. Lanza discussed in his address Advanced Cell Technology's new technologies to address immune tolerance issues that are increasingly a focus of the stem cell industry, along with the company's single biopsy technology that was recently identified by the Department of Health and Human Services as one of the technologies that merits further evaluation for potential financial support.
Recently, Advanced Cell Technology announced that the American Heart Association (AHA) has selected the company's Myoblast Phase I(b) trial as a featured late breaking trial for its annual Scientific Sessions Conference in Orlando Florida on November 4, 2007 through November 7, 2007. The AHA's Scientific Sessions Conference is among the premier cardiovascular research and instructional meetings worldwide bringing together interventional cardiologists, electrophysiologists, and nurses and other professionals with content from the forefront of research and clinical practice, including more than 4,000 abstracts of original research and a variety of invited programs.
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying cellular technology in the emerging field of regenerative medicine. The company operates facilities in California and Massachusetts.
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended June 30, 2007. Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
SOURCE: Advanced Cell Technology, Inc.
Media: Chad Griffin Consulting, Inc. Jordan Markwith, 310-888-3523 or Investors: CEOcast, Inc. Andrew Hellman, 212-732-4300
Posted by BooDog on :
YES YES YES i DO like this.
Investors Overview Advanced Cell Technology, Inc. (OTCBB:ACTC – News) is applying stem cell technology in the field of regenerative medicine to bring effective, patient-specific therapies to the bedside. The company’s Myoblast program is an autologous adult stem cell therapy for the treatment of heart disease. The Myoblast program has successfully completed four Phase I clinical trials and has clearance from the FDA to begin Phase II trials shortly. The company is also rapidly moving towards human clinical trials for its embryonic stem cell therapies including its RPE and HG programs. ACT published positive data from animal studies for its RPE (retinal pigment epithelial) cell program for the treatment of retinal degenerative disorders completed in collaboration with the Casey Eye Institute at Oregon Health and Science University. The company also has GLP Safety Studies in process for its RPE Program. ACT published positive data in the journal NATURE Methods for its HG (hemangioblast) cell program for the treatment of blood and cardiovascular diseases. The company expects to file INDs for its RPE and HG programs in 2008. In August 2006, ACT announced a novel technique to generate embryonic stem cell lines without destroying embryos, a breakthrough in the ethical debate surrounding the industry. Less than one year later, the company announced the creation of a human embryonic stem cell line without destroying the embryo. ACT owns or licenses over 380 patents and patent applications.
Click to Download our Company Presentation.
We are currently focused on three product areas.
1) Our myoblast program , which could yield novel therapies for cardiac diseases such as heart failure, successfully completed Phase I human clinical trials. The program has clearance from the FDA to begin Phase II human clinical trials and we expect to commence those trials shortly.
2) Our retinal pigment epithelium (RPE) program , which we believe could yield new therapies for treating indications such as age-related macular degeneration. We announced a collaboration to conduct preclinical trials and we expect to file an IND in 2008.
3) Our hemangioblast (HG) cell program for which we are currently conducting preclinical research programs investigating the possibility of using the cells to treat cardiovascular disease, stroke, and cancer. Our research, published in Nature Methods, demonstrated success in treating vascular indications such as heart attack and limb loss due to vascular damage. We expect to file an IND in 2008.
The company is led by an experienced management team and scientific experts in the field, including Chairman and CEO William M. Caldwell IV, VP of Research and Scientific Development Dr. Robert Lanza, and Chief Development Officer Dr. Pedro Huertas. The company operates GMP capable laboratories in Massachusetts California.
The company is actively pursuing strategic collaborations in the United States (e.g., in California, where in 2004, the state passed Proposition 71, often referred to as the “Stem Cell Initiative,” which will provide $3.0 billion of funding over the next ten years for stem cell research) and around the world with members of academia, industry and foundations to further accelerate the pace of our research efforts.
Investment Highlights Completed acquisition of Mytogen and its Myoblast program, an autologous adult stem cell therapy for treating cardiac disease. The Myoblast program has successfully completed Phase I clinical trials. Expects to begin Phase II clinical trials shortly. Published positive results from HG program demonstrating hemangioblasts’ ability to repair vascular damage in animals. Therapy could be effective for treatment of blood and cardiovascular diseases. Expects to file IND in 2008. Made progress in macular degeneration indication by reporting positive data for RPE cell animal study. Entered into collaboration with the Casey Eye Institute to conduct preclinical trials. Expects to file IND in 2008. Developed technique to generate embryonic stems that maintain developmental potential of the embryo and therefore has potential to shift the ethical debate. Announced hESC line created without destroying an embryo in June 2007. Owns or licenses over 380 patents and patent applications related to stem cell therapy. Large Target Market: Regenerative Medicine has potential to treat diseases of the eye, blood disorders, heart disease, neurodegenerative diseases, liver disease, diabetes, and others. Led by experienced management team and scientific experts including CEO William Caldwell, VP of Research and Scientific Development, Robert Lanza M.D., and Chief Development Officer Pedro Huertas M.D.,Ph.D. Growing Legislative Support CA Prop. 71 provides $3.0 billion in funding over 10 years for stem cell research, with preference given to research that is ineligible for NIH funding. Other states (e.g., NJ, CT, FL, IL, MD, NY, MA and MO) have passed or proposed similar initiatives. New Congress elected 11/06 has promised to make stem cell research a priority. - this part needs work how bout a new administration! lol Posted by BooDog on :
Next step in stem cells: Human tests Companies are planning to submit applications for FDA approval to begin human testing of treatments based on embryonic stem cell research. By Aaron Smith, CNNMoney.com staff writer October 31 2007: 11:56 AM EDT
PITTSBURGH (CNNMoney.com) -- Companies that develop drugs using embryonic stem cell research could soon enter a bold new phase: human testing.
Geron Corp. and Advanced Cell Technology Inc. are preparing Food and Drug Administration applications to begin human testing of experimental treatments that are based on embryonic stem cells. If the companies get the go-ahead, they could begin tests as soon as next year.
More stem cell news... Stem cells could treat diabetes Stem cell industry set to break out Rats walk but money waits Video More video Esther Dyson of EDventure Holdings discusses how she thinks medical possibilities will broaden by making her own genetic code available on the web. Play video "What we're seeing now in the stem cell field is like a chess match," said Stephen Brozak, analyst for WBB Securities. "The early moves will ultimately dictate who succeeds in the stem cell space."
In the past, the FDA has approved human tests of products based on stem cells taken from adult tissue. But Geron and Advanced Cell Technologies could be the first to begin human testing of treatments based on the more controversial research using stem cells derived from embryos.
Human tests are the most advanced form of testing and one of the final hurdles before the FDA approves a drug.
Geron (Charts), based in Menlo Park, Calif., has been using rats in its experiments of a potential treatment for spinal cord injuries. Geron has already met with the FDA and will submit its plans for human testing to the agency by the end of this year, according to Sion Rogers, a spokesman for the company.
"We expect to be in the clinic [for human testing] next year," said Rogers.
Advanced Cell Technology (Charts) plans to submit its application for human testing to the FDA by the middle of next year, said Chief Executive Robert Lanza, who spoke at the 7th International Stem Cell Conference on Tuesday.
His company is developing potential treatments for vision loss diseases, including macular degeneration and Stargardt's, based on studies involving monkeys. If the treatment is successful, it would most likely compete with Genentech Inc.'s (Charts) vision loss treatment Lucentis, a fast-growing drug that had $600 million in sales during the first nine months of 2007.
Geron and Advanced Cell Technology are unlikely to compete with each other because their potential products are unrelated, said Ren Benjamin, analyst for Rodman & Renshaw.
"We think that it doesn't matter who gets to the clinic first, because the entire stem cell space will benefit when someone gets there," said Benjamin. "It will create a lot of excitement in investors, because it's a big milestone for the embryonic stem cell space."
Stem cells bring sight to the blind in India The process of testing drugs on humans can take years to complete - in the case of drugs developed with human embryonic stem cells, a minimum of five years, said Lanza of Advanced Cell Technology. Typically, after studies are completed, an experimental drug is submitted to the FDA for review, a step that can take a minimum of six months to finish.
Small-scale biotech companies and universities have spearheaded embryonic stem-cell research in developing treatments for heart disease, diabetes, Parkinson's and injuries to the spine and brain.
Novocell Inc. also uses stem cells from human embryos for research, while other biotechs like Cytori Therapeutics (Charts) and Osiris Therapeutics, Inc. (Charts) use adult human tissue as a source.
Osiris, based in Columbia, Md., has the only stem cell-based product that has been approved by the FDA. The treatment, Osteocel, stimulates bone growth and is considered an implant, rather than a drug or device. The product was launched in 2005 and totaled about $5 million in sales during the first half of 2007, accounting for most of the company's revenue.
Companies that work with stem cells derived from adult tissue are insulated from the controversy surrounding embryonic stem cells. Many researchers prefer the use of human embryonic stem cells because they can rapidly reproduce themselves for years at a time in a lab environment.
But the use of embryonic stem cells, which are obtained through in vitro fertilization, is opposed by the pro-life contingent, including President George W. Bush. Bush has said that he opposes "the creation, destruction, or harming of living human embryos." Proponents of embryonic stem cells research dispute this notion, saying that the blastocysts used as sources for stem cells would otherwise be discarded as medical waste.
In 2001, Bush restricted federal funding for embryonic stem cell research to the stem cell lines that existed at the time, and in June 2007 vetoed a Congressional bill to lift these restrictions. The presidential lines, as they are called, represent only about 5 percent of the stem cells available in the world today, according to Dr. James Battey Jr., co-chair of the stem cell task force for the National Institutes of Health.
Novocell, a privately-held biotech based in San Diego, uses embryonic stem cell research in developing treatments for diabetes. Chief Executive Alan Lewis said that he is a couple of years behind Geron and Advanced Cell Technologies, and he is yet to finish studies using mice.
"The study needs to be completed before we got out and bang a drum and talk about curing diabetes," said Lewis.
The analysts interview for this story do not own stock in the companies mentioned here, and their firms have not conducted business with the companies within the last 12 months.
Stem cells could treat diabetes
someone's putting fresh coals in the fire eh??
Posted by Lani on :
Could anyone please give me a list of websites where I could get statistics for daily price list on OTCBB stocks? I'm a beginner in this business! My e-mail address is: ifetoba2001*yahoo.com
Posted by BooDog on :
Advanced Cell Technology to Present at The Rodman & Renshaw BioFin 9th Annual Healthcare Conference in New York City on November 5th
Nov 1, 2007 09:00:22 (ET)
LOS ANGELES, Nov 01, 2007 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. (ACTC, Trade ) today announced that William M. Caldwell, IV, its Chairman and Chief Executive Officer, will present at The Rodman & Renshaw Acumen BioFin 9th Annual Healthcare Conference in New York City on Monday, November 5th, 2007 at 11:15 AM Eastern Time. The conference will be held at The New York Palace Hotel, New York City. The Company's audio portion and slides of its presentation will also be webcast live and archived for future reference at http://www.wsw.com/webcast/rrshq12/cgxp.ob .
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying cellular technology in the emerging field of regenerative medicine. The company operates facilities in California and Massachusetts.
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended June 30, 2007. Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
SOURCE: Advanced Cell Technology, Inc.
Media: Chad Griffin Consulting, Inc. Jordan Markwith, 310-888-3523 or Investors: CEOcast, Inc. Andrew Hellman, 212-732-4300 Steven S. Porter, 720-946-6440
Posted by BooDog on :
This is picking up more on other boards M8. Holding strong.
Posted by IMAKEMONEY on :
YEP, IMHO ITS GONNA GOOOOO!!
Posted by IMAKEMONEY on :
LOS ANGELES, Nov 02, 2007 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. (ACTC, Trade ) announced today that it has appointed Jonathan H. Dinsmore, Ph.D. to the position of Senior Vice President - Regulatory and Clinical and Ivan Wolkind to the position of Senior Vice President - Finance, Administration & Chief Accounting Officer. Dr. Dinsmore was previously the company's Vice President and General Manager, while Mr. Wolkind was previously Vice President of Finance and Chief Accounting Officer.
"I am pleased to recognize the contributions of Jonathan and Ivan with expanded roles and responsibilities," said William M. Caldwell, IV, its Chairman and Chief Executive Officer. "Today, Advanced Cell Technology has positioned itself to become a leading participant in the field of regenerative medicine, helped by the contributions of these talented executives."
Dr. Jonathan H. Dinsmore was formerly responsible for all aspects of Mytogen's cell production operations, basic science program, and research and development efforts. He was also actively engaged in evaluating partnership opportunities and complimentary technologies. Prior to his position with Advanced Cell Technology and Mytogen, he directed both clinical and preclinical research programs at Diacrin and GenVec. Dr. Dinsmore has research and clinical experience in the development of therapeutic products to treat Parkinson's disease, Huntington's disease, epilepsy, stroke, spinal cord injury, chronic intractable pain, liver disease, and cardiovascular disease. Dr. Dinsmore received a B.S. in Biology from Boston College followed by a Ph.D. in Biology from Dartmouth College. Dr. Dinsmore was a Post-doctoral fellow at MIT from 1989 to 1992. His extensive accomplishments include numerous awarded and pending patents as well as diverse published studies on myoblast transplantation technology.
Mr. Wolkind joined the company in May 2005. Prior to joining Advanced Cell, he served as the Executive Vice President of Finance and Chief Financial Officer for Eyematic, a technology company providing software solutions for delivering animated content to cell phones. Between 1999 and July 2001, Mr. Wolkind was the Chief Financial Officer for eLease, a company providing software solutions and back end automation for the capital equipment leasing market. Prior to his appointment at eLease, Mr. Wolkind served as the Vice President of Finance for Ventro Corporation, where he was instrumental in the raising of capital in the company's initial public offering and subsequent debt offerings. Before his tenure at Ventro Corporation, Mr. Wolkind served as the Vice President of Finance at Onsale, Inc., a publicly traded Internet auction company. Prior to joining Onsale, he held key finance positions at two other companies after leaving KPMG, where he had worked in the financial services and banking audit group. Mr. Wolkind qualified as a Chartered Accountant in the United Kingdom.
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying cellular technology in the emerging field of regenerative medicine. The company operates facilities in California and Massachusetts.
Forward-Looking Statements
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended June 30, 2007. Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
SOURCE: Advanced Cell Technology, Inc.
Media: Chad Griffin Consulting, Inc. Jordan Markwith, 310-888-3523 or Investors: CEOcast, Inc. Andrew Hellman, 212-732-4300
Posted by BooDog on :
Couple good recent PRs. Let's see if they can do anything. Chart says this could dip a bit more but 1 little candle says this is ready to turn.
cover one eye while reading this one so you miss the grammer mistake...
News for 'ACTC' - (Advanced Cell Technology's Chief Scientific Officer Featured Speaker at American College of Rheumatology / Association of Rheumatology Health Professionals)
LOS ANGELES, Nov 06, 2007 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. (OTCBB: ACTC) announced today that Dr. Robert Lanza, M.D., the company's Chief Scientific Officer, will be a featured speaker, delivering the opening presentation at the 71st annual meeting of the American College of Rheumatology and the 42nd annual meeting of the Association of Rheumatology Health Professionals scheduled to be will held from November 6th to 11th at the new Boston Convention and Exhibition Center in Boston.
The ACR Annual Meeting is the rheumatology industry's leading conference, with over 14,000 scientists and attendees expected. Dr. Lanza will be delivering a presentation titled "The Use of Embryonic Stem Cells in Regenerative Medicine."
During the presentation, Dr. Lanza is expected to discuss the company's single biopsy technology that was recently identified by the Department of Health and Human Services as one of the technologies that merits further evaluation for potential financial support. About Advanced Cell Technology, Inc.
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying cellular technology in the emerging field of regenerative medicine. The company operates facilities in California and Massachusetts.
Advanced Cell Technology and the Casey Eye Institute at Oregon Health & Science University Present Results of Functional Studies for RPE Program at Neuroscience 2007 Monday November 5, 10:59 am ET GMP-compliant RPE cells show significant rescue of vision in the Royal College of Surgeons (RCS) Rat
LOS ANGELES--(BUSINESS WIRE)--Advanced Cell Technology, Inc. (OTCBB:ACTC) and the Casey Eye Institute at Oregon Health & Science University initiated a significant collaboration over a year ago that has culminated in a robust study of dosage and efficacy of the GMP-compliant RPE cells. Today at Neuroscience 2007, these researchers are presenting the results of the study using ACT’s embryonic stem cell derived RPE cells in the RCS Rat, a well validated animal model of retinal disease. The RPE cells were manufactured under GMP compliant conditions (21CFR211) at the company’s facility in Worcester, MA. The RPE cells have been thoroughly characterized and cryo-preserved by the company and were shipped to researchers at OHSU for transplantation. The transplanted rats were given a range of doses of the RPE cells and monitored and evaluated at multiple time points. The results of the study showed that the RPE cells demonstrated a statistically significant therapeutic effect compared to controls with a maximum efficacious effect at a medium dose level. Histological assessment showed integration of the human RPE cells into the rodent’s RPE layer without migration into the retina. The conclusions drawn by researchers were that visual function can be rescued and preserved in this animal model of disease utilizing GMP-compliant human ES-derived RPE cells with a functional dose threshold and that these cells may provide an effective donor cell source to rescue photoreceptors in conditions like Age-related macular degeneration (AMD), where RPE function is compromised. Advanced Cell Technology plans to present this data to the FDA when it files an IND for the RPE therapy. ADVERTISEMENT
“We are excited by the results of this study which demonstrated the efficacy of our RPE cells in an animal model,” said William M. Caldwell, IV, Chairman and CEO of Advanced Cell Technology. “The data generated by our ongoing collaboration with OHSU represents another milestone in bringing our stem cell therapies from the laboratory to the clinic and ultimately to patients in need of treatment.”
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying cellular technology in the emerging field of regenerative medicine. The company operates facilities in California and Massachusetts.
need volume need volume need volume need volume
Posted by IMAKEMONEY on :
CORRECTING and REPLACING Advanced Cell Technology's Chief Scientific Officer Featured Speaker at American College of Rheumatology / Association of Rheumatology Health Professionals
Nov 6, 2007 13:47:31 (ET)
LOS ANGELES, Nov 06, 2007 (BUSINESS WIRE) -- First graph, first sentence should read: Advanced Cell Technology, Inc. (ACTC, Trade ) announced today that Dr. Robert Lanza, M.D., the company's Chief Scientific Officer, will be a featured speaker at the 71st annual meeting of the American College of Rheumatology and the 42nd annual meeting of the Association of Rheumatology Health Professionals scheduled to be will held from November 6th to 11th at the new Boston Convention and Exhibition Center in Boston. (sted Advanced Cell Technology, Inc. (OTCBB: ACTC) announced today that Dr. Robert Lanza, M.D., the company's Chief Scientific Officer, will be a featured speaker, delivering the opening presentation at the 71st annual meeting of the American College of Rheumatology and the 42nd annual meeting of the Association of Rheumatology Health Professionals scheduled to be will held from November 6th to 11th at the new Boston Convention and Exhibition Center in Boston.)
The corrected release reads:
ADVANCED CELL TECHNOLOGY'S CHIEF SCIENTIFIC OFFICER FEATURED SPEAKER AT AMERICAN COLLEGE OF RHEUMATOLOGY / ASSOCIATION OF RHEUMATOLOGY HEALTH PROFESSIONALS
Advanced Cell Technology, Inc. (ACTC, Trade ) announced today that Dr. Robert Lanza, M.D., the company's Chief Scientific Officer, will be a featured speaker at the 71st annual meeting of the American College of Rheumatology and the 42nd annual meeting of the Association of Rheumatology Health Professionals scheduled to be will held from November 6th to 11th at the new Boston Convention and Exhibition Center in Boston.
The ACR Annual Meeting is the rheumatology industry's leading conference, with over 14,000 scientists and attendees expected. Dr. Lanza will be delivering a presentation titled "The Use of Embryonic Stem Cells in Regenerative Medicine."
During the presentation, Dr. Lanza is expected to discuss the company's single biopsy technology that was recently identified by the Department of Health and Human Services as one of the technologies that merits further evaluation for potential financial support. About Advanced Cell Technology, Inc.
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying cellular technology in the emerging field of regenerative medicine. The company operates facilities in California and Massachusetts.
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended June 30, 2007. Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
SOURCE: Advanced Cell Technology, Inc.
Media: Chad Griffin Consulting, Inc. Jordan Markwith, 310-888-3523 or Investors: CEOcast, Inc. Andrew Hellman, 212-732-4300
Posted by BooDog on :
"to be will held" lmao
You think after all that effort they would correct something so simple.
If they draw in the institutional buying it'll be A okay with me!
Posted by BooDog on :
.266 had nice volume yesterday.
Posted by IMAKEMONEY on :
CHIT- RUN YOU PIG!! HEY BOO. Posted by BooDog on :
A little early morning action. Just a pinch, but usually doesn't wake up 'till around lunch time.
Posted by BooDog on :
ADVANCED CELL TECHNOLOGY, INC. 1201 Harbor Bay Parkway Alameda, CA 94502
NOTICE OF ANNUAL MEETING OF STOCKHOLDERS DECEMBER [28], 2007
To Our Stockholders:
An Annual Meeting of Stockholders of Advanced Cell Technology, Inc., a Delaware corporation (the "Company"), will be held on [Wednesday], December [28], 2007 at 10:00 a.m., local time, at the offices of Pierce Atwood LLP, One Monument Square, Portland, Maine 04101, for the following purposes:
1. To elect five (5) members to our Board of Directors to serve a one-year term and until their respective successors are duly elected and qualified;
2. To amend the Company's 2005 Stock Incentive Plan (the "2005 Stock Plan") to increase the number of shares issuable thereunder by 25,000,000 shares (on a pre-reverse split basis); and
3. To consider and approve an Amended and Restated Certificate of Incorporation of the Company (the "Restated Certificate of Incorporation"), which amends and restates the Company's existing Certificate of Incorporation to effect a reverse split of the Company's outstanding shares of common stock, par value $.001 per share ("Common Stock"), at a ratio in the range from one-for-two to one-for-ten at any time before May 1, 2008.
4. To transact such other business as may properly come before the meeting or any adjournments thereof.
That splains the early action, as little as it was. LOL. Might get a nice dip from this and then who knows what.
Posted by BooDog on :
okay. I'm down to losing 60 shares long term. lol. where's my dip?
hurry up already!
Posted by IMAKEMONEY on :
HMM
Posted by jdiddy on :
.20 x .225 Posted by BooDog on :
see ya at the bottom. 1:10 or 1:2? imo the 25m will hit all at once sending this to the dog house. These guys lost their common sense imo. They only need to slow things down a little and keep hitting up through the administration for financing. I don't mind the dilution, I don't want the RS!
Posted by BooDog on :
intraday looks pretty good. If they had the right news (as in anything else duh!) this could really pop. If it weren't going down...
Posted by IMAKEMONEY on :
BUYING BUYING BUYING,LOL,POP!!!
Posted by BooDog on :
quote:Originally posted by IMAKEMONEY: BUYING BUYING BUYING,LOL,POP!!!
DAYTRADERS!! PHLEEEEEWY!!!
D Posted by IMAKEMONEY on :
LOL, BOO!
Posted by IMAKEMONEY on :
HMM, NEWS COMING?????
Posted by IMAKEMONEY on :
YOU WATCHING THIS BOO?
Posted by BooDog on :
No.
lol
Posted by IMAKEMONEY on :
LOOKS GOOD!! LOL
Posted by BooDog on :
yah. I though .20 or so would be a good bounce. I was waiting it out though to see if it would drop lower. We'll see.
Posted by IMAKEMONEY on :
SOMEONE IS BUYING BUYING BUYING, JUST SLOW UP-TREND NOW, SHHHHHH
Posted by BooDog on :
My server changed hands - i was out from before lunch and most of the afternoon! grrrr
Posted by IMAKEMONEY on :
Advanced Cell Technology's Chief Executive Officer Scheduled to Be Interviewed By Bloomberg Television Tonight
Nov 20, 2007 15:46:04 (ET)
LOS ANGELES, Nov 20, 2007 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. (ACTC, Trade ) announced today that William M. Caldwell, IV, the company's Chief Executive Officer is scheduled to be interviewed today by Bloomberg Television at 6:15 p.m. eastern time. Mr. Caldwell is expected to discuss the Company's Retinal Program, as well as other corporate developments and issues surrounding the stem cell industry.
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying cellular technology in the emerging field of regenerative medicine. The company operates facilities in California and Massachusetts.
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended June 30, 2007. Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
SOURCE: Advanced Cell Technology, Inc.
Media: Chad Griffin Consulting, Inc. Jordan Markwith, 310-888-3523 or Investors: CEOcast, Inc. Andrew Hellman, 212-732-4300
Posted by BooDog on :
quote:Originally posted by IMAKEMONEY: HMM, NEWS COMING?????
you da man IMAKE
Posted by IMAKEMONEY on :
I COULD SMELL IT BOO! LOL Posted by IMAKEMONEY on :
.2750
Posted by BooDog on :
Very nice. The news is all about stem cell. It should boost the whole sector imo. Thought it would do something for my NRGX for Parkinson’s and such. In time. Should speed things up considerably. These guys are trying to get (and somewhat succeeded) their name in the lime light to boost their research funding. Just poking their nose in the right places. Getting the word out that's for sure.
Posted by BooDog on :
.29
Posted by BooDog on :
.295 trying to break through... can it do it!
Posted by BooDog on :
Nice finish. Short day Friday but could be exciting. Broke .3 Would have liked to see .31
Posted by BooDog on :
break out yes or no? Not much volume but looking for .31 then maybe a breakout.
Posted by T e x on :
never understood this...gets front-page news around the world...nuthin'
but let some wild azz pink get a scwoowy PR and BAM!
Posted by BooDog on :
imo they were sponging off someone elses news that was great for the sector but not immediatly great for ACTC - still years to go. Could see more on this next week.
Posted by IMAKEMONEY on :
NEW YORK, Nov 27, 2007 (BUSINESS WIRE) -- The New York Society of Security Analysts (NYSSA) will present the 11th Annual Biotech/Specialty Pharma Conference on December 11-12, 2007.
The Nasdaq and AMEX biotech stock indexes have been consistently on the rise year over year. Small- and mid-cap companies have driven the growth, but big biotech has lagged behind big pharma. Although biotech has fallen behind most major indexes, some analysts believe that a turnaround is imminent. Leaders of small- and micro-cap companies will reveal plans to develop new drugs, diagnostics, and delivery technologies.
The following companies are presenting on day one:
BioSante Pharmaceuticals, Inc. (AMEX: BPA); DURECT Corporation (DRRX, Trade ); EntreMed, Inc. (ENMD, Trade ); GammaCan International, Inc. (GCAN, Trade ); Heska Corporation (HSKA, Trade ); Hollis-Eden Pharmaceuticals, Inc. (HEPH, Trade ); NovaBay Pharmaceuticals, Inc. (NBY, Trade ); and The Quigley Corporation (QGLY, Trade ).
The following companies are presenting on day two:
Advanced Cell Technology (ACTC, Trade ); Alseres Pharmaceuticals, Inc. (ALSE, Trade ); Cyclacel Pharmaceuticals, Inc. (CYCC, Trade ); Emergent BioSolutions, Inc. (EBS, Trade ); Hemispherx Biopharma, Inc. (HEB, Trade ); Immtech Pharmaceuticals, Inc. (IMM, Trade ); Neuralstem, Inc. (CUR, Trade ); Ortec International, Inc. (OTCI, Trade ); and Transdel Pharmaceuticals, Inc. (TDLP, Trade ).
The conference will be held on December 11, 2007, 8:30 a.m. to 4:40 p.m., and December 12, 2007, 8:30 a.m. to 4:10 p.m. at NYSSA, 1177 Avenue of the Americas, 2nd Floor, NYC. Registration deadline is December 4, one day, $265 NYSSA members, $365 nonmembers; two days, $365 NYSSA members, $465 nonmembers. No charge for press with credentials. A complete agenda is available at http://www.nyssa.org/Biotech2007 .
About NYSSA
The New York Society of Security Analysts (NYSSA) is celebrating 70 years as a leading forum for the investment community. NYSSA's mission is to promote best practices and the highest professional and ethical standards in the industry. NYSSA is the largest of the more than 135 societies worldwide that make up CFA Institute, which has more than 90,000 members.
SOURCE: The New York Society of Security Analysts
NYSSA Dawn Cavalieri, 646-871-3420 press*nyssa.org
Posted by IMAKEMONEY on :
NEW YORK, Nov 29, 2007 (BUSINESS WIRE) -- The New York Society of Security Analysts (NYSSA) will present the 11th Annual Biotech/Specialty Pharma Conference on December 11-12, 2007.
The Nasdaq and AMEX biotech stock indexes have been consistently on the rise year over year. Small- and mid-cap companies have driven the growth, but big biotech has lagged behind big pharma. Although biotech has fallen behind most major indexes, some analysts believe that a turnaround is imminent. Leaders of small- and micro-cap companies will reveal plans to develop new drugs, diagnostics, and delivery technologies.
New companies have been added to the agenda:
Chelsea Therapeutics (CHTP, Trade ); EpiCept Corporation (EPCT, Trade ); and YM BioSciences Inc. (YMI, Trade ).
The following companies are presenting on day one:
BioSante Pharmaceuticals, Inc. (BPAX, Trade ); Chelsea Therapeutics (CHTP, Trade ); DURECT Corporation (DRRX, Trade ); EntreMed, Inc. (ENMD, Trade ); Heska Corporation (HSKA, Trade ); Hollis-Eden Pharmaceuticals, Inc. (HEPH, Trade ); NovaBay Pharmaceuticals, Inc. (NBY, Trade ); The Quigley Corporation (QGLY, Trade ) and YM BioSciences Inc. (YMI, Trade ).
The following companies are presenting on day two:
Advanced Cell Technology (ACTC, Trade ); Alseres Pharmaceuticals, Inc. (ALSE, Trade ); Cyclacel Pharmaceuticals, Inc. (CYCC, Trade ); Emergent BioSolutions, Inc. (EBS, Trade ); EpiCept Corporation (EPCT, Trade ); Hemispherx Biopharma, Inc. (HEB, Trade ); Immtech Pharmaceuticals, Inc. (IMM, Trade ); Neuralstem, Inc. (CUR, Trade ); Ortec International, Inc. (OTCI, Trade ); and Transdel Pharmaceuticals, Inc. (TDLP, Trade ).
The conference will be held on December 11, 2007, 8:30 a.m. to 4:40 p.m., and December 12, 2007, 8:30 a.m. to 4:40 p.m. at NYSSA, 1177 Avenue of the Americas, 2nd Floor, NYC. Registration deadline is December 4, one day, $265 NYSSA members, $365 nonmembers; two days, $365 NYSSA members, $465 nonmembers. No charge for press with credentials.
The New York Society of Security Analysts (NYSSA) is celebrating 70 years as a leading forum for the investment community. NYSSA's mission is to promote best practices and the highest professional and ethical standards in the industry. NYSSA is the largest of the more than 135 societies worldwide that make up CFA Institute, which has more than 90,000 members.
SOURCE: The New York Society of Security Analysts
NYSSA Dawn Cavalieri, 646-871-3420 press*nyssa.org
Posted by IMAKEMONEY on :
Related Quotes Sym. Price Chg. ACTC Trade News 0.215 0.001 Advanced Cell Technology Seeking International Partners for Its Therapeutic Programs
Dec 6, 2007 08:00:09 (ET)
LOS ANGELES, Dec 06, 2007 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. (ACTC, Trade ) announced today that it is seeking international partners for each of its three lead therapeutic programs, including its Myoblast program for treating heart failure, its Retinal Pigment Epithelium program for treating degenerative retinal disease, and the Hemangioblast program for the treatment of blood and cardiovascular indications. The company is making significant progress in the development of each of these therapeutic programs within the United States.
Advanced Cell Technology has made a strategic decision to seek partners for each of these programs internationally, including regions such as Europe, the Middle East and Asia, as the company recognizes that there is strong interest in the field of stem cells worldwide. ACT has asked Burrill & Company, which it hired last year to advise on a number of strategic initiatives, to renew its focus on seeking international partners. Interested parties worldwide should contact Mr. William Caldwell, IV, Chairman and CEO of Advanced Cell Technology at 310-481-5124.
"We recognize that there is material interest in the stem cell and regenerative medicine field globally and will seek strong partners from the worldwide medical community to pursue our programs outside of the United States and complement the work we are doing at home. We are very pleased to continue our successful relationship with Burrill & Company and utilize their extensive global network to further these discussions," said Mr. William M. Caldwell, IV, Chairman and CEO of Advanced Cell Technology.
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying cellular technology in the emerging field of regenerative medicine. The company operates facilities in California and Massachusetts.
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended September 30, 2007. Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
SOURCE: Advanced Cell Technology, Inc.
Chad Griffin Consulting, Inc. Jordan Markwith, 310-888-3523 or Investors: CEOcast, Inc. Andrew Hellman, 212-732-4300
Posted by IMAKEMONEY on :
Advanced Cell Technology to Present at 11th Annual New York Society of Security Analysts Biotech/Specialty Pharma Conference on Wednesday, December 12th
Dec 12, 2007 08:01:03 (ET)
LOS ANGELES, Dec 12, 2007 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. (ACTC, Trade ) announced today that the Company will present at the 11th Annual Biotech/Specialty Pharma Conference hosted by the New York Society of Security Analysts (NYSSA) taking place on Tuesday and Wednesday, December 11 and 12, 2007. The conference will be held at the NYSSA headquarters located at 1177 Avenue of the Americas in New York City.
Advanced Cell Technology's presentation will take place on Wednesday, December 12 at 12:45 p.m.
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying cellular technology in the emerging field of regenerative medicine. The company operates facilities in California and Massachusetts.
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended September 30, 2007. Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
SOURCE: Advanced Cell Technology, Inc.
Chad Griffin Consulting, Inc. Jordan Markwith, 310-888-3523 or Investors: CEOcast, Inc. Andrew Hellman, 212-732-4300
Posted by BooDog on :
11th Annual Biotech/Specialty Pharma Conference DATE December 11-12, 2007
TIME Day 1 — 8:30 a.m.-4:40 p.m. Day 2 — 8:30 a.m.-3:15 p.m.
CHAIRS Sherry Lombardi, The Answer Factory Laurie Malen, The Answer Factory
LOCATION NYSSA 1177 Avenue of the Americas, 2nd Floor (between 45th and 46th Streets), NYC (Directions) Photo ID required for access to the building.
REGISTER/FEE Early Registration by November 27 One Day: Members $195 | Nonmembers $295 Two Days: Members $295 | Nonmembers $395 Registration November 28 to December 4 One Day: Members $265 | Nonmembers $365 Two Days: Members $365 | Nonmembers $465 After December 4 Register at the door: Additional $50 due (space permitting)
CREDIT PD/CE/CPE = 2
-------------------------------------------------------------------------------- Register Online Register via Mail/Fax Policies & Procedures
CONFERENCE DESCRIPTION The Nasdaq and AMEX biotech stock indexes have been on the rise during the last few years. Both hit record highs in Q2, only to give back some of their gains over the summer. Small- and mid-cap companies have driven the growth, while big biotech has lagged behind big pharma. The volume of biotech IPOs also continues to grow, up over 31% in 2006 from 2005. After-market returns of those offerings increased to an average of 40% versus 7% in the prior year.
In general, however, biotech has lagged behind most major indexes over the last year. Biotech stocks as a group have trailed the S&P 500 by more than 18 percentage points. Still, many analysts believe that the group is poised for a turnaround, considering the aging population that will continue to drive demand and innovation.
Don’t miss this chance to learn about the opportunities with specialty pharmaceutical and biotechnology stocks. The CEOs, CFOs, and other VIPs from many of the industry’s most innovative small- and micro-cap companies will discuss their plans to invent, develop, research, and market important new drugs, diagnostics, and delivery technologies.
AGENDA Day 1 8:30 Check-in & Continental Breakfast 8:55 Welcome & Introductory Remarks 9:00 Outlook for the Biotech and Specialty Pharma Industry George Fulop, MD, Managing Director, Stuyvesant Capital Management
9:35 Chelsea Therapeutics (Nasdaq: CHTP) Keith Schmidt, VP of Marketing and Sales Chelsea Therapeutics is a biopharmaceutical development company that acquires and develops innovative products for the treatment of a variety of human diseases.
10:10 Break 10:20 DURECT Corporation (Nasdaq: DRRX) Matthew Hogan, CFO DURECT is an emerging specialty pharmaceutical company developing pharmaceutical systems based on its proprietary drug delivery platform technologies. 10:55 The Quigley Corporation (Nasdaq: QGLY) Guy Quigley, Chairman, President, and CEO Quigley is a diversified natural health life science company.
11:30 BioSante Pharmaceuticals, Inc. (Nasdaq: BPAX) Stephen M. Simes, President and CEO BioSante Pharmaceuticals is developing a pipeline of hormone therapy products to treat both men and women.
12:00 Lunch
12:15 Luncheon Presentation Public Relations: Eight Simple Rules for Achieving Maximum Value for Your Company, Your Fund, or Yourself Dian Griesel, President and CEO, The Investor Relations Group 1:00 YM BioSciences Inc. (AMEX: YMI) Sean Thompson, VP, Corporate Development YM BioSciences is an oncology company that identifies, develops, and commercializes differentiated products for patients worldwide.
1:35 EntreMed, Inc. (Nasdaq: ENMD) James S. Burns, President and CEO EntreMed is a clinical-stage pharmaceutical company developing therapeutics primarily for the treatment of cancer and inflammation.
2:10 Heska Corporation (Nasdaq: HSKA) Robert Grieve, Chairman and CEO Heska sells advanced veterinary diagnostic and other specialty veterinary products. 2:45 Break
2:55 Hollis-Eden Pharmaceuticals, Inc. (Nasdaq: HEPH) Richard B. Hollis, Chairman and CEO Hollis-Eden Pharmaceuticals is a world leader in the development of a proprietary class of adrenal steroid hormones as novel pharmaceuticals for human health. 3:30 NovaBay Pharmaceuticals, Inc (AMEX: NBY) Jack O’Reilly, SVP, Corporate Development and CFO NovaBay Pharmaceuticals is developing nonantibiotic antimicrobial products for multiple indication with partnerships with leading companies.
4:05 Immtech Pharmaceuticals, Inc. (AMEX: IMM) Eric L. Sorkin, Chairman and CEO Immtech Pharmaceuticals is developing therapies to treat and prevent serious infectious diseases.
4:40 Closing Remarks & Adjournment
AGENDA Day 2 8:30 Check-in & Continental Breakfast 8:55 Welcome & Opening Remarks 9:00 Changing Investor Demands in the Specialty Pharmaceutical Sector Angela Larson, Susquehanna Financial Group
9:35 Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC) Spiro Rombotis, President and CEO Cyclacel Pharmaceuticals is a biopharmaceutical company dedicated to the discovery, development, and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious disorders.
10:10 Break
10:20 EpiCept Corporation (Nasdaq: EPCT) Jack Talley, CEO Epicept is a specialty pharmaceutical company focused on the development of pharmaceutical products for the treatment of cancer and pain.
10:55 Emergent BioSolutions, Inc. (NYSE: EBS) Robert G. Burrows, VP, Investor Relations Emergent BioSolutions is a profitable biopharmaceutical company with growing revenues that fund advanced and follow-on development pipelines addressing large markets. The company develops, manufactures, and commercializes immunobiotics consisting of vaccines and therapeutics that assist the body’s immune system to prevent or treat disease.
11:30 Hemispherx Biopharma, Inc. (AMEX: HEB) Anthony Bonelli, President and COO Hemispherx Biopharma is an advanced biopharmaceutical company engaged in the manufacture and clinical development of new drug entities for treatment of seriously debilitating disorders.
12:00 Lunch
12:45 Advanced Cell Technology (OTCBB: ACTC) William M. Caldwell, IV, Chairman and CEO Ivan Wolkind, SVP, Finance/Administration and Chief Accounting Officer Advanced Cell Technology is a leading biotechnology company in the field of regenerative medicine. 1:20 Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE) Kenneth L. Rice Jr., EVP and CFO Alseres Pharmaceuticals is developing groundbreaking regenerative therapeutics for devastating conditions such as spinal cord injury.
1:55 Break 2:05 Transdel Pharmaceuticals, Inc. (OTCBB: TDLP) Juliet Singh, PhD, President and CEO Transdel Pharmaceuticals is a specialty pharmaceutical company focused on the development and commercialization of noninvasive, topically targeted medications. 2:40 Ortec International, Inc. (OTCBB: OTCI) Costa Papastephanou, PhD, CEO Ortec International is a company focused on advancing regenerative medicine through the development of cellular technology and advanced biomaterial products.
3:15 Closing Remarks & Adjournment
NYSSA reserves the right to change any part of its published program or list of presenters due to unforeseen circumstances.
Posted by IMAKEMONEY on :
Related Quotes Sym. Price Chg. ACTC Trade News 0.16 -0.015 Advanced Cell Technology Issues Letter to Investors
Dec 19, 2007 11:53:01 (ET)
LOS ANGELES, Dec 19, 2007 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. (ACTC, Trade ) announced today that it has issued a letter to its investors from William M. Caldwell, IV, Chairman and CEO, updating the company's progress year-to-date. The text of the letter is available on the company's website at www.advancedcell.com and is included in this press release below:
Dear Stockholders,
As we move through 2007's holiday season and approach year end, I wanted to update all of you about the events that took place for our company this year. 2007 has been a year of significant scientific accomplishment and positive transformation for Advanced Cell Technology as well as one of great change for the regenerative medicine industry. I have broken this letter into four components. First and foremost, I would like to discuss our research, development, and clinical progress, as this is clearly the most important facet of our company. Second, I will discuss Advanced Cell Technology's transformation from a research and development organization into a biotechnology company with novel therapies in clinical trials for currently difficult or impossible to treat indications. Third, I will outline our interpretation of the state of the stem cell industry. And finally, I will discuss what our hopes and expectations are for 2008 and beyond.
Scientific Progress
Advanced Cell Technology has three primary therapeutic programs:
1) our Myoblast Program, an autologous adult stem cell therapy for the treatment of heart failure;
2) our Retinal Pigmented Epithelial (or RPE) cell Program, an embryonic stem cell therapy for the treatment of degenerative retinal disorders; and
3) our Hemangioblast (or HG) cell Program, an embryonic stem cell therapy for the treatment of blood and cardiovascular indications.
We have made progress in each of these programs this year and will exit 2007 with the Myoblast Program preparing to enter Phase II human clinical trials and our RPE and HG Programs in preclinical trials. In addition, our company has a number of proprietary technology platforms, including our single cell biopsy technique for creating embryonic stem cell lines without destroying embryos.
Myoblast Program
Milestones:
-- Acquired Mytogen, Inc., and its Myoblast therapy for the treatment of heart failure. Therapy successfully completed Phase I human clinical trials.
-- Presented 6-month data at TCT 2007 demonstrating safety and improvement in heart failure measures.
-- Presented 12-month data at the AHA's 2007 conference in Orlando demonstrating safety and persistence of therapeutic effect over an extended period of time.
-- Entered into a letter of intent with Catholic Healthcare West for a proposed exclusive business arrangement to establish a clinical trial research site and a North American regenerative medicine interventional cardiology training center for our Phase II Myoblast clinical trial.
-- Pursuing international partnerships for Phase II human clinical trials.
-- On schedule to begin Phase II human clinical trials at eight sites shortly.
We acquired our Myoblast Program in connection with our acquisition of privately-held Mytogen, Inc., which closed in September 2007. The myoblast therapy involves transplantation of expanded autologous myoblasts derived from a small biopsy of skeletal muscle from a patient's leg. The myoblasts are expanded into hundreds of millions of cells over a period of three weeks and then transplanted back into the patient's scarred heart tissue via a catheter-based procedure. The Myoblast Program to date has successfully completed four Phase I human clinical trials utilizing the therapy safely in over 40 patients. While the successful Phase I human clinical trials were focused on the safety of the therapy, the clinical data from those trials suggested that the myoblasts can improve heart function that leads to an improved quality of life for the patient.
In October and November of this year, Dr. Nabil Dib, one of the principal investigators for our Myoblast Program, presented 6-month and 12-month data for the program at TCT 2007, a leading interventional cardiology conference, and at the American Heart Association's annual meeting in Orlando, Florida, respectively. The two sets of data: 1) demonstrated myoblast safety with no evidence for increased risk of arrhythmia; 2) distinguished the ACT Myoblast Program as the leader in the industry as it is the only program not required to use anti-arrhythmia medications and/or an implanted defibrillator device; 3) showed that the effects of ACT's myoblast therapy persisted for an extended period of time, an effect that has not been demonstrated by any other cellular therapy for heart disease; 4) provided evidence that the hearts of the patients that received the therapy showed less cardiac remodeling in comparison to controls, remodeling being a progressive enlargement of the heart that signifies worsening of function; and 5) that by using the ACT technology doctors have for the first time the opportunity to successfully replace scarred heart tissue with healthy muscle via intracardiac injections of autologous skeletal myoblasts.
We are on schedule to begin the Phase II human clinical trial for the treatment of heart failure in approximately 160 patients. In that light, we entered into a letter of intent with Catholic Healthcare West, America's eighth largest hospital system, for a proposed exclusive business arrangement to establish a clinical trial research site and a North American regenerative medicine interventional cardiology training center for our Phase II Myoblast clinical trial. In addition, we are actively pursuing international partnerships to investigate our Myoblast Program and to commence international Phase II human clinical trials for the novel therapy. If the Phase II trials prove successful, we will proceed with a pivotal Phase III trial.
According to the National Heart, Lung, and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH), approximately 5 million people in the United States have congestive heart failure (CHF) and an estimated 400,000 new cases are diagnosed each year. Roughly 50% of CHF patients die within 5 years. The annual number of deaths directly from CHF increased from 10,000 in 1968 to 42,000 in 1993, with another 219,000 related to the condition. CHF is the first-listed diagnosis in 875,000 hospitalizations, and the most common diagnosis in hospital patients 65 years and older. Consequently, we are excited by both the market opportunity for our Myoblast Program as well as the potential to help the growing number of patients suffering from heart failure in the United States and abroad.
Retinal Pigmented Epithelial (RPE) Program
Milestones:
-- Demonstrated visual function rescue in Royal College of Surgeons (RCS) rats in 2006.
-- Entered into a research services agreement with the Casey Eye Institute at OHSU for preclinical studies.
-- Published OHSU dosage study results demonstrating a statistically significant positive therapeutic effect.
-- Began preliminary discussions with the FDA to initiate clinical studies.
-- Contracted with a leading contract research organization for an extensive preclinical program.
-- MPI Research initiated pilot studies under Good Laboratory Practices (GLP).
-- Provided we receive positive feedback from the FDA, plan to file IND in 2008.
Studies of our proprietary RPE cells have shown that the therapy may ultimately provide effective treatment of degenerative retinal disorders, including macular degeneration, which represents a $28 billion dollar market. Age-related macular degeneration (AMD) affects more than 30 million people worldwide and is the leading cause of blindness in people over 60 in the United States. The prevalence of AMD begins to increase after the age of 50. Approximately 15% of people over 75 have the condition. To date, AMD patients have had few if any effective therapies for treatment; thus, the need for novel therapies that we are developing is clear.
In 2006, we demonstrated visual function rescue in rat models using our RPE therapy. In February of this year, we entered into a research services agreement with Oregon Health and Science University (OHSU). Under the terms of the research agreement, we have been collaborating with Dr. Raymond Lund, Dr. Richard Weleber, and Dr. Peter Francis at the Casey Eye Institute at OHSU to conduct preclinical studies for the program. Specifically, the research team has been conducting dosage studies utilizing our RPE cells in the RCS rat model and plans to conduct similar studies in other rodent models of retinal degenerative disease. We are also in discussions with the OHSU team regarding future plans for a Phase I human clinical trial.
In November of this year at Neuroscience 2007, researchers at OHSU presented results of the study, which used ACT RPE cells that were manufactured under GMP compliant conditions (21CFR211) at our facility in Worcester, Massachusetts. The RPE cells were thoroughly characterized and cryo-preserved and shipped to researchers at OHSU for transplantation. The transplanted rats were given a range of doses of the RPE cells and monitored and evaluated at multiple time points. The results of the study showed that the RPE cells demonstrated a statistically significant therapeutic effect compared to controls with a maximum efficacious effect at an intermediate dose level. Histological assessment showed integration of the human RPE cells into the rodent's RPE layer without migration into the retina. The conclusions drawn by researchers were that visual function can be rescued and preserved in this animal model of disease utilizing GMP-compliant human ES-derived RPE cells with a functional dose threshold and that these cells may provide an effective donor cell source to rescue photoreceptors in conditions like AMD, where RPE function is compromised. We plan to present this data to the FDA when we file an IND for the therapy.
As we move closer to filing an IND for our RPE therapy, we decided to initiate preliminary discussions with staff from the Office of Cellular, Tissue, and Gene Therapies within the Center for Biologics Evaluation and Research at FDA. These discussions took place earlier this year. In addition, we contracted with a leading contract research organization to begin work on an extensive preclinical program. Furthermore, MPI Research, located in Mattawan, Michigan, initiated pilot studies under Good Laboratory Practices (GLP) for the ongoing RPE Program. We are hopeful that we can file an IND for the RPE therapy next year and begin human clinical trials soon thereafter.
Hemangioblast (HG) Program
Milestones:
-- Published research in Nature Methods demonstrating HG cells' ability to repair vascular damage in animals.
-- Seeking international partnerships for preclinical and clinical trials.
-- Targeting IND filing in 2008.
We continue to investigate the possibility of using our proprietary hemangioblast cells to treat blood and cardiovascular diseases, stroke and cancer. In May of this year, research conducted by our team of scientists and our collaborators from the University of Florida at Gainesville and the Memorial Sloan-Kettering Cancer Center in New York City was published in the journal Nature Methods. The research described an efficient method for generating large numbers of hemangioblasts derived from human embryonic stem cells that were capable of differentiating into blood vessels as well as into all blood and immune cell lineages. When the cells were injected into animals that had retinal damage from diabetes or ischemia-reperfusion injury (lack of adequate blood flow) of the retina, the cells homed to the site of injury and showed robust reparative function of the entire damaged vasculature within 24 to 48 hours. The cells showed a similar regenerative capacity in animal models of both myocardial infarction (50% reduction in mortality rate) and hind limb ischemia, with restoration of blood flow to near normal levels.
We are actively seeking international partnerships for our HG Program to assist with our preclinical research and, ultimately, human clinical trials. We are hopeful that we can file an IND next year for the program and move forward with human clinical trials.
Single Cell Biopsy Embryonic Stem Cell Development Technique
Milestones:
-- Last year we described our proprietary single cell biopsy technique for creating human embryonic stem cell lines without damaging embryos.
-- Announced the creation of the first human embryonic stem cell line without destroying an embryo this year, quelling much of the initial controversy.
-- The NIH is considering our single cell biopsy technique for federal funding.
Our single cell biopsy technique for creating human embryonic stem cell lines without damaging embryos continues to attract a significant amount of attention. Recall that in August of last year we announced that our scientists had published a paper in the journal Nature explaining how they had generated human embryonic stem cells using this approach. The method derives the cells from human blastomeres with a single-cell biopsy technique called Preimplantation Genetic Diagnosis (PGD). This technique is used by in vitro fertilization clinics to assess the genetic health of preimplantation embryos. The cell lines produced using this technique appeared to be identical to human embryonic stem cell lines derived from later stage embryos using techniques that destroy the embryo's developmental potential. A significant amount of controversy ensued after our announcement challenging the validity of the results, but we were pleased to report in June of this year that we had successfully produced a human embryonic stem cell line without destroying an embryo at our lab in Worcester, Massachusetts. Dr. Robert Lanza, M.D., our Chief Scientific Officer, definitively announced that he and his team had reproduced the work of removing a single cell blastomere from a human embryo with the surviving embryo cryo-preserved, quelling much of the initial controversy.
The technique is also beginning to attract the attention of our federal government. In June of this year, President Bush issued an Executive Order requiring that "The Secretary of Health and Human Services ... conduct and support research on the isolation, derivation, production, and testing of stem cells that are capable of producing all or almost all of the cell types of the developing body and may result in improved understanding of or treatments for diseases and other adverse health conditions, but are derived without creating a human embryo for research purposes or destroying, discarding, or subjecting to harm a human embryo or fetus." Roughly three months later, the NIH announced that it would begin implementing President Bush's Executive Order. Our single cell biopsy technique was cited by the NIH as an alternative method in its implementation plan. The NIH plan calls for "aggressively pursuing an assessment of the potential of alternative sources of pluripotent stem cell lines, including altered nuclear transfer; single cell embryo biopsy, and reprogramming, or dedifferentiation of somatic cells, such as skin cells."
We believe our single cell blastomere technology directly addresses the President's ethical concerns and, unlike the other potential solutions described in the order, is available today. We are encouraged by the NIH's willingness to explore ways to increase the federally approved stem cell lines available and hope they will consider our technique for federal funding. We believe that such consideration reflects the will of the American people to bring novel therapies derived from stem cell research to patients with few or no alternatives.
The Transformation of Advanced Cell Technology
Milestones:
-- Acquired Mytogen and transformed from a development stage to a clinical stage company.
-- Solidified our management team by naming Dr. Lanza Chief Scientific Officer, Dr. Dinsmore Senior VP - Clinical and Regulatory, and Ivan Wolkind Senior VP - Finance, Administration and Chief Accounting Officer.
-- Improved our patent portfolio to 380 owned or licensed patents and patent applications.
-- Received and/or participated in grants from the NIH and CIRM.
-- Raised $10 million in gross proceeds from the private placement of senior secured convertible debentures.
Earlier this year, our company was presented with a unique opportunity that culminated in a merger with Mytogen, Inc. We entered into a letter of intent to acquire Mytogen in May, signed a definitive merger agreement in July, and closed the acquisition in September. The Mytogen transaction was transformational for Advanced Cell Technology for several reasons. First, Mytogen helped us broaden our regenerative medicine technology platform from exclusively focused on embryonic stem cell therapies to research programs and therapies based on both embryonic and adult stem cell technology. This technology platform expansion has allowed us to not only investigate more new therapies for a larger set of indications, but it has also provided access to opportunities largely unavailable to companies focused exclusively on embryonic stem cell science. Second, what with the Myoblast Program having successfully completed Phase I human clinical trials and poised to begin Phase II human clinical trials shortly, the Mytogen acquisition immediately transformed ACT from a development stage to a clinical stage company.
With the merger closed and the Mytogen team fully integrated into the Advanced Cell Technology family, we solidified our management team. While I remain Chairman and CEO, we named Dr. Robert Lanza, M.D., our Chief Scientific Officer; Dr. Jonathan Dinsmore, Ph.D., our Senior VP - Regulatory and Clinical; and Ivan Wolkind our Senior VP - Finance, Administration & Chief Accounting Officer. Dr. Lanza has over 25 years of relevant research and industrial experience, including his position as Director of Transplantation Biology at BioHybrid Technologies, Inc. He is currently an Adjunct Professor at the Institute for Regenerative Medicine, Wake Forest University School of Medicine, and has several hundred scientific publications and patents and has authored and/or edited 16 books. Dr. Dinsmore was formerly responsible for all aspects of Mytogen's cell production operations, basic science program, and research and development efforts, and directed both clinical and preclinical research programs at Diacrin and GenVec. Mr. Wolkind joined ACT in March 2005 after serving as the Executive Vice President of Finance and CFO for Eyematic. Mr. Wolkind previously held senior financial positions at a number of large companies and worked in the financial services and banking audit group at KPMG.
Our corporate transformation also allowed us to consolidate and improve our patent portfolio. In February, we acquired the intellectual property assets of Infigen, Inc. relating to parthenogenesis, oocyte activation and other related technologies. We acquired a total of 26 issued patents and numerous pending patent applications for a combination of cash and shares of common stock. Three months later in May we announced an expanded, non-exclusive commercialization agreement with Wisconsin Alumni Research Foundation (WARF) that granted us rights to the commercial use of human embryonic stem cells to develop human therapies (with the exception of neuronal, pancreatic beta cells, and cardiac applications) and enabled the marketing of a broad array of research products. The agreement granted us commercial access to an additional 150 important stem cell technology patents and patent applications. As a result of the Infigen, WARF, and Mytogen deals, we now own or license over 380 patents and patent applications.
2007 was another challenging year for financing companies in our space, what with difficult public markets (especially in biotechnology) and the ban on federal funding for many areas of stem cell research. Nevertheless, we successfully exploited a handful of alternative financing opportunities. In January, our company was awarded a research grant from the NIH in conjunction with a research project currently underway with The Burnham Institute of Medical Research, one of our academic partners. The grant, titled "Directed Differentiation of Embryonic Stem Cells using Phage Displayed Ligands," further funds research by ACT and The Burnham Institute aimed at obtaining specialized cells of therapeutic interest from human embryonic stem cells using NIH-approved stem cell lines. Furthermore, as the $3 billion in funding to be distributed by CIRM (the California Institute for Regenerative Medicine) over 10 years from California's Proposition 71 begins to trickle out, we have seen some early positive developments including the use of ACT's human embryonic stem cells in a study to determine if the cells are safe and effective in animal models for heart attacks and heart failure.
Our most substantial capital raise this year came from the completion of a private placement of senior secured convertible debentures that closed in August resulting in gross proceeds of $10 million. The cash infusion provided us with capital necessary to continue our promising research and development platforms and has brought us closer to both additional clinical trials and, ultimately, to commercializing our therapies in the marketplace.
The State of the Stem Cell Industry
Politics
The legislative environment for stem cell research is complex and largely misunderstood; consequently, I'd like to outline for you the facts as well as how we see the legislative landscape unfolding going forward. In August 2001, President Bush enacted a ban on federal funding for deriving new embryonic stem cells from fertilized embryos. This does not mean that embryonic stem cell research is "illegal," rather that federally collected tax dollars cannot be used to fund the research. Unfortunately, however, because of the federal funding ban, research institutions (be they public, private, academic, etc.) have been forced to build entirely "clean" facilities to be used exclusively for such research. This has resulted in a significant (financial) barrier to research progress. Furthermore, while President Bush did allow research to continue on the embryonic stem cell lines existing at that time - often referred to as the "Presidential Lines" - (unbeknownst to the President) the lines are contaminated and largely unusable. Despite the challenging environment, we, as a company, have made the progress I've outlined in this letter.
Still, there have been a number of initiatives aimed at improving the landscape to further research in this field at both the federal and state levels. In July 2006, the Senate voted 63-37 in favor of a bill that passed in the House of Representatives to lift the ban on federal funding of stem cell research, but the bill did not have enough support to override the President's inevitable veto. In January and April of this year, the House and the Senate, respectively, passed the Stem Cell Research Enhancement Act of 2007. Once again, however, in each vote the bill came just a few "ayes" shy of a veto-proof majority. Despite these (largely expected) legislative defeats, we believe it is becoming increasingly clear that it is a matter of when, not if, federal support of embryonic stem cell research will become reality. According to some polls, roughly two thirds of the American populous is in favor of lifting the restrictions and with the 2008 Presidential election approaching swiftly we believe that change for the better is very near, especially considering the pro-embryonic stem cell research stance of a large number of the leading Presidential candidates. Should the election bring a change in the position of the executive branch, it would remove the last impediment to opening up the floodgate of billions of dollars in federal support for companies like ours.
While a lift on the federal funding ban would certainly benefit our company, our success does not rely solely on such change. In addition to the progress we've made in the current less-favorable environment, there are additional initiatives at the federal level that may benefit Advanced Cell Technology. Most specifically, as discussed above, the NIH announced this year that it would begin implementing President Bush's Executive Order to seek alternative sources of pluripotent stem cell lines, including lines created using our single cell blastomere technology. We are encouraged that our government is seriously considering our technology for funding.
We have also seen continued developments at the state level. Our experiences in California, where our headquarters is located, thus far have been positive including being named this year on a CIRM grant whose recipient will use ACT's human embryonic stem cells to determine if the cells are safe and effective in animal models for heart attacks and heart failure. CIRM funds are finally beginning to get distributed to grant winners. Furthermore, this year CIRM is beginning to award grants to for-profit organizations (like our own) - prior, all of the grants announced had been for non-profit organizations (who can subcontract as much as 50% of the grant to for-profit organizations). New Jersey had proposed a $450 million bond to fund stem cell research that, unfortunately, was defeated; however, we believe the vote was more a reflection of the voters' dissatisfaction with state government spending (New Jersey has a $3 billion budget deficit) rather than a referendum on the ethics and feasibility of stem cell science. In November of this year in Massachusetts, where in 2005 the state's congress overrode and passed a bill, which former-Governor Romney had vetoed, supporting embryonic stem cell research, Governor Deval Patrick proposed a $1 billion stem cell research funding initiative. Also, states including Connecticut, Florida, Illinois, Maryland, New York, and Missouri have passed or proposed similar initiatives. Again, it is our belief that we are nearing the moment when funding for stem cell research will begin to expand. We expect to be a direct beneficiary of the improving climate.
Scientific Developments
This year, scientists including our own as well as researchers outside our company announced a number of regenerative medicine breakthroughs. In addition to our single cell biopsy embryonic stem cell development technique, researchers around the world announced advances such as deriving stem cells from amniotic fluid and skin cells. In January of this year, scientists at Wake Forest University and Harvard University reported that stem cells from amniotic fluid donated by pregnant women may hold promise for pluripotency. We believe the cells may generate a broad range of important cell types, though they may not do as many tricks as embryonic cells. In addition, in November researchers in Japan and the United States announced that they had reprogrammed skin cells to behave like embryonic stem cells. Generating stem cells in this manner has several obstacles to overcome, including dealing with a carcinogenic effect, and likely will not be viable for years to come. Regardless, all of these scientific breakthroughs represent a giant steps forward for stem cell research.
Looking Forward
We expect to enter 2008 on solid footing and look forward to an exciting year. We remain on schedule to begin Phase II human clinical trials for our myoblast adult stem cell therapy for heart failure and are working diligently in preparation for IND filings for our RPE and HG embryonic stem cell therapies for retinal degenerative disorders and heart, blood, and cardiovascular indications, respectively. We are also excited to be seeking international partnerships for each of our clinical and preclinical programs to tap into global market prospects, international scientific expertise, and worldwide non-dilutive financing opportunities. We remain committed, determined, and focused on bringing novel treatments for difficult and impossible to treat indications from the lab to the bedside as well as on returning value to our shareholders.
Wishing you the best for the holiday season and the new year,
William M. Caldwell, IV
Chairman and CEO
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying cellular technology in the emerging field of regenerative medicine. The company operates facilities in California and Massachusetts.
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended September 30, 2007. Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
SOURCE: Advanced Cell Technology, Inc.
Media: Chad Griffin Consulting, Inc. Jordan Markwith, 310-888-3523 or Investors: CEOcast, Inc. Andrew Hellman, 212-732-4300
Posted by IMAKEMONEY on :
HMM, NICE BOUNCE, NEWS?
Posted by IMAKEMONEY on :
Advanced Cell Technology Awarded Grant from the NIH
Jan 8, 2008 08:00:14 (ET)
LOS ANGELES, Jan 08, 2008 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. (ACTC, Trade ) announced today that the National Institute of General Medical Sciences at the National Institutes of Health (NIH) has awarded the company an SBIR Phase 1 Small Business Grant. The company will use the grant proceeds to conduct research that will allow for rapid labeling and purification of specific lineage restricted cells (LRCs) in cultures of differentiating human embryonic stem cells. If successful, the research will help the company more rapidly develop new regenerative therapies for a variety of indications including cardiovascular disease as well for commercialization of the LRCs and their peptide-targeting agents as research reagents. The research aims to create a process by which specific markers can be identified that will act like nametags allowing LRCs to be identified and then purified. With such markers, unique populations of cells can be isolated so that the benefits of these cells can be tested. The research grant from the NIH follows a previous NIH STTR grant award to ACT for a research project from the organization's National Institute for Dental and Craniofacial Research (NIDCR) announced in January 2007.
"We are pleased that prestigious institutions such as the NIH continue to recognize and support our research and development programs," said William M. Caldwell, IV, Chairman and CEO of Advanced Cell Technology. "We will continue to work with the NIH and other organizations to raise awareness and capital to support our ongoing research and commercialization projects without diluting shareholder value. We also remain hopeful that the NIH will ultimately fund our single cell biopsy technique for generating human embryonic stem cell lines without damaging the developmental potential of the embryos."
In August 2006, ACT scientists published a paper in the journal Nature explaining its single-cell biopsy technique for generating hESC lines without destroying the developmental potential of the underlying embryos. In June 2007, the company announced that it had successfully produced such a line. That same month, President Bush issued an Executive Order requiring the Secretary of Health and Human Services to conduct and support research on the isolation of pluripotent stem cells derived without destroying or harming human embryos. In September 2007, the NIH announced that it would begin implementing President Bush's Executive Order and that ACT's single cell biopsy technique was one of the methods under consideration for funding.
"As we've stated before, we believe our single cell biopsy technology directly addresses the President's ethical concerns and, unlike the other potential solutions described in the Executive Order, is available today," continued Mr. Caldwell. "We are encouraged by the NIH's willingness to explore ways to increase the federally approved stem cell lines available. We believe that such consideration reflects the will of the American people to bring novel therapies derived from stem cell research to patients with few or no alternatives.
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying cellular technology in the emerging field of regenerative medicine. The company operates facilities in California and Massachusetts.
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended September 30, 2007. Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
SOURCE: Advanced Cell Technology, Inc.
Investors: CEOcast, Inc. for Advanced Cell Technology, Inc. Daniel Schustack, 212-732-4300 or Media: Chad Griffin Consulting, Inc. Jordan Markwith, 310-888-3523
Posted by Homersbud on :
Advanced Cell Technology Announces Creation of Human Embryonic Stem Cell Lines Without the Destruction of Embryos Thursday January 10, 12:00 pm ET -Breakthrough Approach Improves Efficiency to Levels Reported in the Conventional Stem Cell Derivation Techniques-
WORCESTER, Mass.--(BUSINESS WIRE)--Advanced Cell Technology, Inc. (OTC Bulletin Board: ACTC - News) together with colleagues announced today the development of five human embryonic stem cell (hESC) lines without the destruction of embryos. These new results have the potential to end the ethical debate surrounding the use of embryos to derive stem cells. In fact, the NIH report to the President refers to this technology as one of the viable alternatives to the destruction of embryos.
ADVERTISEMENT The new method will be published today in the journal Cell Stem Cells, published by Cell Press. The peer-reviewed technique was initially carried out by ACT scientists under the direction of Robert Lanza, M.D., and then independently replicated by scientists on the West Coast. Single cells were removed from the embryos using a technique similar to preimplantation genetic diagnosis (PGD). The biopsied embryos continued to develop normally and were then frozen. The cells that were removed were cultured utilizing a proprietary methodology that recreates the optimal developmental environment, which substantially improved the efficiency of deriving stem cells to rates comparable to using the traditional approach of deriving stem cells from the inner cell mass of a whole blastocyst stage embryo. The stem cells were genetically normal and differentiated into cell types of all three germ layers of the body, including blood cells, neurons, heart cells, cartilage, and other cell types of potentially therapeutic significance.
“This is a working technology that exists here and now,” said Robert Lanza, M.D., Chief Scientific Officer at Advanced Cell Technology and senior author of the paper. “It could be used to increase the number of stem cell lines available to federal researchers immediately. We could send these cells out to researchers tomorrow. If the White House approves this new methodology, researchers could effectively double or triple the number of stem cell lines available within a few months. Too many needless deaths continue to occur while this research is being held up. I hope the President will act now and approve these stem cell lines quickly.”
The paper published today also addresses several other important issues. First, the stem cells were derived without culturing multiple cells from each embryo together, and at efficiency levels similar to that reported for conventional stem cell derivation techniques using blastocysts. Second, it addresses ethical objections that the derivation system required co-culture with hESCs from other embryos that were destroyed. The current study demonstrates that hESC co-culture is not an essential part of the derivation procedure. The stem cell lines generated in the present study appear to have the same characteristics as other hESC lines, including expression of the same markers of pluripotency, self-renewing capacity, genetic stability, and ability to differentiate into derivatives of all three germ layers of the body.
“We are excited that our new method for generating human embryonic stem cell lines without the destruction of embryos has been accepted for inclusion by such a prestigious publication,” said William M. Caldwell IV, Chairman and CEO of Advanced Cell Technology. “This new approach addresses the President Bush’s ethical concerns. We are hopeful that the NIH will consider this new approach for federal funding. We believe that such consideration reflects the desire of the American people to bring therapies derived from stem cell research to patients with few or no alternatives.”
Other contributors to the study and publication include Young Chung and Irina Klimanskaya, Sandy Becker, Tong Li, Marc Maserati, and Shi-Jiang Lu of Advanced Cell Technology; Tamara Zdravkovic, Olga Genbacev, and Susan Fisher of the University of California, San Francisco; and Dusko Ilic and Ana Krtolica of StemLifeLine.
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts. For more information about the company, please visit http://www.advancedcell.com.
Forward-Looking Statements
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
Any statements that are not statements of historical fact (including statements containing the words “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates,” and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company’s periodic reports, including the report on Form 10-QSB for the quarter ended September 30, 2007.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company’s management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
Contact:
Media: Chad Griffin Consulting, Inc. Jordan Markwith, 310-888-3523 or Investors: CEOcast, Inc. Andrew Hellman, 212-732-4300 or Cell Stem Cells: Cell Press Cathleen Genova, 617-397-2802
Posted by BooDog on :
0.265 0.12 82.76% 6,582,169
not bad.
Posted by BooDog on :
we'll see what they can do this time.
Posted by Homersbud on :
Missed the close, but saw before I left it wasn't trading all that great.
Company dumping all they can before the R/S.
Posted by BooDog on :
Coming off bottom like it did I think it did well. NIH is the lead in this imo not ACTC. But actc is taking advantage. I have to learn to just play the TA. The news is spreading and this could have some nice momo in the am - met by convertibles and then an RS that still doesn't have a firm date - so many may not want to hold overnight - and as U said possible dumping. jmo.
like the new Graemlins!! Posted by IMAKEMONEY on :
Posted by IMAKEMONEY on :
Posted by IMAKEMONEY on :
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549
FORM 144
NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
ATTENTION: TRANSMIT FOR FILING 3 COPIES OF THIS FORM CONCURRENTLY WITH EITHER PLACING AN ORDER WITH A BROKER TO EXECUTE A SALE OR EXECUTING A SALE DIRECTLY WITH A MARKET MAKER.
-------------------------------------------------------------------------------- ---------------------------------------------------- 1(a) NAME OF ISSUER (Please type or print) (b) IRS IDENT. NO. (c) S.E.C. FILE NO. Advanced Cell Technology 87-0656515
-------------------------------------------------------------------------------- ---------------------------------------------------- (d) ADDRESS OF ISSUER STREET CITY STATE ZIP CODE (e) TELEPHONE NO. ------------------------ 1201 Harbor Bay Parkway Alameda CA 94501 (510) 748-4900
-------------------------------------------------------------------------------- ---------------------------------------------------- 2(a) NAME OF PERSON FOR WHOSE ACCOUNT THE (b) I.R.S. NO. (c) RELATIONSHIP (d) ADDRESS STREET CITY STATE ZIP CODE SECURITIES ARE TO BE SOLD TO ISSUER Bristol Investment Fund, Ltd. 98-0335509 Shareholder Caledonian Fund Services Limited Caledonian House 69 Dr. Roy's Dr. P.O. Box 1043 Grand Cayman KY1-1102 Cayman Islands -------------------------------------------------------------------------------- ---------------------------------------------------- INSTRUCTION: The person filing this notice should contact the issuer to obtain the I.R.S. Identification Number and the SEC File Number -------------------------------------------------------------------------------- ---------------------------------------------------- Name and Address of SEC USE Title of the Class Each Broker Through ONLY of Securities To whom the Securities Are --------- Number of Shares or Aggregate Market Be Sold (See instr. To Be Offered or Each Broker- Other Units To Be Value 3(a)) Market Maker who is Dealer Sold (See instr. 3(d)) Acquiring the Securities File (See instr. 3(c)) (See instr. 3(b)) Number -------------------------------------------------------------------------------- ---------------------------------------------------- Common Stock Citigroup Prime Broker 390 Greenwich Street, 3rd Floor 177,937 $44,484 New York, NY 10013 -------------------------------------------------------------------------------- ----------------------------------------------------
Number of Shares or Approximate Date of Name of Each Securities Other Units Sale Exchange Outstanding (See instr. 3(f)) (See instr. 3(g)) (See instr. (MO. DAY YR.) 3(e)) -------------------------------------------------------------------------------- ---------------------------------------------------- 81,333,064 1/10/2008 OTC BB -------------------------------------------------------------------------------- ----------------------------------------------------
INSTRUCTIONS: 1. (a) Name of issuer. (b) Issuer's IRS Identification Number. (c) Issuer's SEC file number, if any. (d) Issuer's address, including zip code. (e) Issuer's telephone number, including area code.
2. (a) Name of person for whose account the securities are to be sold. (b) Such person's or I.R.S. Identification number, if such a person is an entity. (c) Such person's relationship to the issuer (e.g., officer, director, 10 percent stockholder, or member of immediate family of any of the foregoing). (d) Such person's address, including zip code.
3. (a) Title of the class of securities to be sold (b) Name and address of each broker through whom the securities are intended to be sold. (c) Number of shares or other units to be sold (if debt securities, give the aggregate face amount). (d) Aggregate market value of the securities to be sold as of a specified date within 10 days prior to the filing of this notice. (e) Number of shares or other units of the class outstanding, or if debt securities the face amount thereof outstanding, as shown by the most recent report or statement published by the issuer. (f) Approximate date on which the securities are to be sold. (g) Name of each securities exchange, if any, on which the securities are intended to be sold.
Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:
-------------------------------------------------------------------------------- ---------------------------------------------------- Title of Date You Nature of Acquisition Name of Person From Amount of Date of Nature of Payment the Class Acquired Transaction Whom Acquired Securities Payment (If Gift, Also Give Acquired Date Donor Acquired) -------------------------------------------------------------------------------- ---------------------------------------------------- Common Stock 9/6/06 Convertible Note Issuer 177,937 9/6/06 Cash
INSTRUCTIONS: 1. If the securities were purchased and full payment therefore was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid. 2. If within two years after the acquisition of the securities the person for whose account they are to be sold had any short positions, put or other option to dispose of securities referred to in paragraph (d)(3) of Rule 144, furnish full information with respect thereto.
TABLE II--SECURITIES SOLD DURING THE PAST THREE MONTHS
Furnish The Following Information as to All Securities of The Issuer Sold During The Past Three Months By The Person For Whose Account The Securities Are To Be Sold.
-------------------------------------------------------------------------------- ---------------------------------------------------- Name and Address of Seller Title of Securities Sold Date of Sale Amount of Gross Proceeds Securities Sold -------------------------------------------------------------------------------- ---------------------------------------------------- Caledonian Fund Services Limited Caledonian House 69 Dr. Roy's Drive P.O. Box 1043 Grand Cayman KY1-1102 Cayman Islands Advanced Cell Technology, Inc. 11/16/2007 20,000 $4,033 Advanced Cell Technology, Inc. 11/19/2007 20,000 $3,927 Advanced Cell Technology, Inc. 11/20/2007 20,000 $4,033 Advanced Cell Technology, Inc. 11/21/2007 102,937 $27,248 Advanced Cell Technology, Inc. 11/21/2007 15,000 $3,961 Advanced Cell Technology, Inc. 12/10/2007 135,000 $28,995 Advanced Cell Technology, Inc. 12/12/2007 70,000 $14,010 Advanced Cell Technology, Inc. 12/17/2007 20,000 $3,840 Advanced Cell Technology, Inc. 12/20/2007 59,699 $10,089
INSTRUCTIONS: See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice. January 10, 2008 ---------------------------------------- (DATE OF NOTICE) ATTENTION: The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the issuer of the securities to be sold which has not been publicly disclosed. /s/ Paul Kessler ---------------------------------------- (SIGNATURE)
The notice shall be signed by the persons for whose account the securities are to be sold. At least one copy of the notice shall be manually signed. Any copies not manually signed shall bear typed or printed signatures.
ATTENTION: INTERNATIONAL MISSTATEMENTS OR OMISSION OF FACTS CONSTITUTE FEDERAL CRIMINAL VIOLATIONS (SEE 18 U.S.C. 1001).
Posted by T e x on :
What else is Bristol into?
Posted by BooDog on :
Caledonian Fund Services Limited Caledonian House 69 Dr. Roy's Drive P.O. Box 1043 Grand Cayman KY1-1102 Cayman Islands
Very interesting indeed.
Posted by BooDog on :
And...
This proxy, when properly executed, will be voted in the manner directed herein by the undersigned stockholder. If no direction is given, this proxy will be voted FOR the proposal to increase the number of shares issuable under the Company's 2005 Stock Incentive Plan by 25,000,000. Attendance of the undersigned at the Meeting will not be deemed to revoke this proxy unless the undersigned shall revoke this proxy in writing or shall deliver a subsequently dated proxy to the Secretary of the Company or shall vote in person at the Meeting.
Beacon Research's TraderNotes are brief analyses on the active stocks each day that are affecting the markets. These include breaking news, insider activity, recent 52-week highs/lows, technical breakouts, and other market driving information. Beacon is the authority on research in the small cap sector, and our analysts strive each day to find the stocks that are poised to be the biggest movers before the rest of the market is aware of them.
We encourage investors to subscribe to our FREE newsletter filled with daily trading ideas by visiting: http://www.BeaconEquityResearch.com -- Click on TraderNotes
Beacon Equity Research is one of the industry's largest small cap research providers. Beacon strives to provide a balanced view of many promising small cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the publicly available information available on them. For more information on Beacon Research, please visit: http://www.BeaconEquityResearch.com CRD# 1755680
Beacon Equity Research Disclosure
The companies that are discussed have not always approved the statements made in this opinion. These reports are for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell any securities mentioned. We are not a licensed or registered broker dealer, investment advisor, analyst or underwriter. Please consult a registered broker before purchasing or selling any securities viewed or mentioned here. Beacon Equity Research has not been compensated by any of the companies covered in this release.
Beacon Equity Research Jeff Bishop, (469)-252-3505 press*beaconequityresearch.com
Reuben Sushman of Beacon Equity Research is a member of the National Association of Securities Dealers, CRD number 1755680.
Available Topic Expert(s): For information on the listed expert(s), click appropriate link. JEFF BISHOP
quote:Originally posted by T e x: What else is Bristol into?
I have found quite a bit out there Tex. Another Steve Carnes??? Still researching.
Posted by T e x on :
post 'em when you got 'em Posted by BooDog on :
Universal Communication Systems Inc • SB-2/A • On 7/13/06
(5) Bristol Capital Advisors, LLC is the investment adviser to Bristol Investment Fund, Ltd. Paul Kessler is the manager of Bristol Capital Advisors and, accordingly, may be deemed to have voting and investment control over these securities. Mr. Kessler disclaims beneficial ownership of these securities.
Bristol Investment Fund, Ltd. (5) Caledonian Fund Services Limited 69 Dr. Roy’s Drive George Town, Grand Cayman Cayman Islands N/A 156,626,600(2) 30.67% 156,626,600(2) 0%
This is just for starters - Don't want to trash ACTC but some of the action over the last few days is from the major pumping and dumping - not all from Kessler imo.
a couple others - just search results - haven't had a chance to convert to current charts and data. Nabi Biopharmaceuticals JAWS Technologies EPICEPT CORP ADVANCED MAMMOGRAPHY SYSTEMS, INC.
There are plenty more - is there a simple way to find out just how many companies someone is holding major shares? lol
Posted by IMAKEMONEY on :
KEEP TRASHING IT BOO! GOING UP AGAIN! Posted by BooDog on :
lol so is vsur!
Posted by BooDog on :
If it has enough buying power it won't matter right IMAKE? You dagone daytraders don't do any DD anyway!! j/k lol!!!
Posted by IMAKEMONEY on :
NOPE, JUST SLAM BAMM, THANK YOU MAMM! LOL
Posted by IMAKEMONEY on :
NEWS COMING???? Posted by IMAKEMONEY on :
UP AND GREEN!
Posted by IMAKEMONEY on :
Posted by IMAKEMONEY on :
Posted by IMAKEMONEY on :
Advanced Cell Technology Announces Completion of Pre-IND Meeting with the FDA for RPE Therapy for the Treatment of Retinal Degenerative Disease
Feb 1, 2008 09:28:01 (ET)
LOS ANGELES, Feb 01, 2008 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. (ACTC, Trade ) today announced that it completed discussions with the Food and Drug Administration (FDA) regarding its retinal pigmented epithelial (RPE) cell therapy through a type B, pre-Investigational New Drug (pre-IND) meeting concerning the regulatory pathway and requirements to file an IND to initiate human clinical trials. ACT is working with the agency to fulfill the FDA's requirements to bring its RPE cell therapy into human clinical trials for the treatment of retinal degenerative diseases such as Retinitis Pigmentosa, Stargardt's disease, and dry age-related macular degeneration (AMD). The RPE cells are derived from human embryonic stem cells created from ACT single blastomere cell lines under GMP compliant conditions. ACT is moving forward with its characterized RPE manufacturing process to complete the final stages of the company's preclinical testing. Should ACT successfully file an IND for its RPE therapy, the company plans to move forward with Phase I human clinical trials. ACT's Myoblast therapy, an autologous adult stem cell therapy for the treatment of heart failure, has already successfully completed Phase I human clinical trials and is moving into Phase II human clinical trials shortly.
Studies of the company's proprietary RPE cells have shown that the therapy may ultimately provide effective treatment of degenerative retinal disorders including macular degeneration, which represents a $28 billion dollar market. AMD affects more than 30 million people worldwide and is the leading cause of blindness in people over 60 in the United States. The prevalence of AMD begins to increase after the age of 50. Approximately 15% of people over 75 have the condition. To date, AMD patients have had few if any effective therapies for treatment; thus, the need for novel therapies is clear.
In November at Neuroscience 2007, researchers at Oregon Health and Science University (OHSU) presented results of a study that used ACT RPE cells manufactured under GMP conditions (21CFR211) at the company's facility in Worcester, Massachusetts. The RPE cells were thoroughly characterized and cryo-preserved and shipped to researchers at OHSU for transplantation. The conclusions drawn by researchers were that visual function can be rescued and preserved in this animal model of disease utilizing ACT's GMP-manufactured human ES-derived RPE cells with a functional dose threshold and that these cells may provide an effective donor cell source to rescue photoreceptors in conditions like AMD, where RPE function is compromised.
The next step in the development of the program will be to complete several safety studies utilizing the GMP-manufactured RPE cells. Pilot studies to date have shown the cells to be safe, well tolerated, and non-migratory. The Good Laboratory Practice (GLP) compliant studies are required prior to filing an IND. The safety studies will include several key areas of examination, including, tumorigenicity potential, cell tolerability, cell survival, general safety, and potential for biodistribution.
"We are pleased to complete this key milestone as we move our RPE program toward the clinic," said William Caldwell, IV, Chairman and CEO of Advanced Cell Technology. "Based upon our cell characterization data, pharmacology studies, and the overall safety profile, we are excited by the prospects for this program and the potential to treat a large unmet medical need. The successful completion of our Pre-IND meeting represents another step forward towards the filing of the IND for our RPE Program and ultimately bringing the therapy to the bedside. We are one step closer to bringing our second stem cell therapy to patients in need."
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying embryonic stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts.
Forward-Looking Statements
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended September 30, 2006. Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
SOURCE: Advanced Cell Technology, Inc.
Media: Chad Griffin Consulting, Inc. Jordan Markwith, 310-888-3523 or Investors: CEOcast, Inc. Dan Schustack, 212-732-4300
Posted by IMAKEMONEY on :
Related Quotes Sym. Price Chg. ACTC Trade News 0.24 0 Advanced Cell Technology Announces Presentation of Results from Myoblast Study at ISCTR World Symposium
Feb 11, 2008 09:13:01 (ET)
LOS ANGELES, Feb 11, 2008 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. (OTCBB: ACTC - News) announced today that principal investigator Dr. Nabil Dib, M.D., M.Sc., FACC, presented results from a 23-patient study of ACT's myoblast therapy for the treatment of congestive heart failure (CHF) over the weekend at the International Society for Cardiovascular Translational Research (ISCTR) World Symposium in San Diego, CA. Dr. Dib presented the results as a case study of the successful translation of a therapy from scientific research to the bedside. The results of the study demonstrate long term cell survival in heart failure patients as well as strong quality of life improvements as measured by the New York Heart Association third party questionnaire, the Minnesota Living with Heart Failure Questionnaire, and the 6 minute walk results (compared to continued deterioration by the control group). Moreover, ACT's myoblast trial has been the only cell-based, FDA-approved human clinical trial that has not required the administration of anti-arrhythmic drugs or assist devices, which is in contrast to trials for bone marrow-derived and other adult stem cell therapies.
ISCTR is an annual meeting for basic and clinical scientist practicing cardiovascular disease research sponsored by the University California, San Diego, Catholic Healthcare West and the International Society for Cardiovascular Translational Research. Dr. Dib is Director, Clinical Cardiovascular Cell Therapy, University of California, San Diego, and Director of Cardiovascular Research of Catholic Health Care West's Chandler Regional Hospital and Mercy Gilbert Medical Center near, Phoenix, Arizona.
Dr. Dib enrolled 23 patients at Arizona Heart Institute with poor heart function and congestive heart failure. The control group consisted of 11 patients on standard drug therapy while the treatment group was given varying doses of 30, 100, 300, or 600 million autologous skeletal myoblast (ASM) cells. After one year, the myoblast therapy showed a favorable safety profile as compared to the control group. Likewise, secondary measures showed improvements in quality of life measures, improvements in measures of tissue regrowth and potential improvement in heart function, while the control group showed signs of heart failure progression on the same measures. The data from the study support conducting larger double-blind, placebo controlled studies. A Phase II human clinical trial has been reviewed and cleared to commence by the FDA. The planned Phase II trial will be conducted at multiple clinical centers across the country including in Arizona and California.
Patients with CHF due to myocardial infarction (damage in heart muscle) often have scar tissue in the heart, which limits the heart's ability to pump blood. In spite of optimal medical therapy and other current heart failure treatments, in the United States alone 2 million patients per year are admitted to the hospital for CHF and almost one-half million die annually. Doctors may now have the opportunity to successfully replace scarred heart tissue with healthy muscle via intracardiac injections of ASM stem cells from the skeletal muscle.
"In this study, we learned that ASM cell transplantation using a minimally invasive catheter system is safe, showed improvement in measures of quality of life, and may have the potential to improve cardiac function and electrical activity," said Dr. Dib. By using a catheter and transplanting ASM cells into scarred tissue, new living muscle can potentially be formed with limited risk to the patient. Since the transplanted stem cells are harvested from the patient's own skeletal muscles, the cells are compatible with the body, avoiding possible immune system and tissue compatibility complications. The procedure poses less risk than surgical procedures because no anesthesia is required and only a small incision is necessary for catheter access. Patients can be discharged within 24 hours of the procedure.
"We are honored that the ISCTR chose our myoblast therapy as the centerpiece for discussing how best to translate research from the bench to the bedside," stated William M. Caldwell, IV, Chairman and CEO of Advanced Cell Technology, Inc. "We remain encouraged by the data Dr. Dib presented and believe the positive 12-month data represent another step in our process of initiating a Phase II human clinical trial for our myoblast therapy. We look forward to moving the myoblast and other stem cell therapies through the clinic and ultimately to patients in need of treatment." In addition to nearing the commencement of Phase II human clinical trials for the myoblast therapy, ACT recently completed a pre-IND meeting with the FDA for its RPE program for the treatment of retinal degenerative disease. Should ACT successfully file an IND for its RPE therapy, the company plans to move forward with Phase I human clinical trials, which would position ACT with two therapies in human clinical trials as well as a third, the hemangioblast program for the treatment of blood and cardiovascular indications, in preclinical trials.
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying cellular technology in the emerging field of regenerative medicine. The company operates facilities in California and Massachusetts.
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended September 30, 2007. Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
SOURCE: Advanced Cell Technology, Inc.
Chad Griffin Consulting, Inc. Media: Jordan Markwith, 310-888-3523 or Investors: CEOcast, Inc. Daniel Schustack, 212-732-4300
Posted by BooDog on :
14-Feb-2008
Other Events
ITEM 8.01 Other Events. Subject to market conditions, Advanced Cell Technology, Inc. (the "Company") plans to privately offer up to $3,000,000 of convertible promissory notes (the "Securities"). The Company is providing this report in accordance with Rule 135c of the Securities Act of 1933, as amended (the "Securities Act"). The timing of the closing of the offering will be subject to market conditions. The Company plans to use the net proceeds to fund working capital, including costs associated with planned clinical trials.
The financing is expected to be in the form of up to $3,000,000 principal amount of convertible promissory notes. The notes are expected to have a term of no more than 24 months and are anticipated to be convertible into the Company's common stock, with conversion prices based on market conditions. All terms are subject to market conditions and may vary materially from those set forth above. No assurance is given that the Company will be able to close the financing described herein, or that if a financing is closed that the terms and conditions of the financing will not differ materially from those described herein.
The offering will be conducted as a private placement made only to accredited buyers in accordance with Section 4(2) of the Securities Act. The Securities will not be registered under the Securities Act and may not be offered or sold without registration unless an exemption from such registration is available.
This notice is issued pursuant to Rule 135c of the Securities Act, and does not constitute an offer to sell the Securities, nor a solicitation for an offer to purchase the Securities.
Statements in this report regarding future financial and operating results, future growth in research and development programs, potential applications of the Company's technology, opportunities for the Company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of the Company's intellectual property, and economic conditions generally. Additional information on potential factors that could affect the Company's results and other risks and uncertainties are detailed from time to time in the Company's periodic reports, including the report on Form 10-QSB for the quarter ended September 30, 2007.
Forward-looking statements are based on the beliefs, opinions, and expectations of the Company's management at the time they are made, and the Company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
ADVANCED CELL TECHNOLOGY, INC.
By: /s/ William M. Caldwell, IV William M. Caldwell, IV Chief Executive Officer
Posted by IMAKEMONEY on :
SOUNDS GOOD TO ME BOO.
Posted by IMAKEMONEY on :
Related Quotes Sym. Price Chg. ACTC Trade News 0.22 0.02 Advanced Cell Technology Demonstrates Efficient Generation of Functional Hepatocytes (Liver Cells) From Human Embryonic Stem Cells
Feb 21, 2008 12:00:02 (ET)
WORCESTER, Mass., Feb 21, 2008 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. (ACTC, Trade ) reported today for the first time a robust and highly efficient process for the generation of high-purity hepatocytes (liver cells). The research, described online (ahead of print) in the journal STEM CELLS, signifies a significant step towards the efficient generation of hepatocytes for use in regenerative medicine and drug discovery. Moreover, the research represents another one of Advanced Cell Technology's efforts aimed at the large-scale differentiation of human embryonic stem cells (hESCs) into critical replacement cell types. In addition to demonstrating the efficient generation of hepatocytes in research published today, the company has made significant progress in the generation of retinal pigmented epithelial (RPE) cells to treat retinal degenerative diseases and the generation of hemangioblasts to treat vascular disease as well as to create a large-scale and donorless source of red blood cells and platelets.
Two hallmarks of embryonic stem cells, their versatility and capacity for unlimited self renewal, suggest the cells could serve as a potentially inexhaustible source of cells for replacement therapy. As with other tissues, there is a scarcity of donor livers and hepatocytes, which is compounded by the low recovery and proliferative capacity of adult hepatocytes. In addition to the cells' potential use for the treatment of liver disease, hESC-derived hepatocytes could also provide a valuable model for novel pharmaceutical drug discovery assays as well as new drug metabolism and cytotoxicity screens, particularly because the liver is a major site for detoxification.
"We have established a highly-efficient method for deriving hepatocytes from stem cells that mirrors events in embryonic development," said Robert Lanza, M.D., Chief Scientific Officer at Advanced Cell Technology, Inc. and senior author of the study. "Large scale production of hepatocytes using this method should greatly bolster their applications in basic research, clinical medicine and preclinical drug discovery."
The method reported yielded synchronous populations of hepatocytes that were generated in clinically preferred conditions with minimum use of serum and cell feeders. Highly enriched populations of definitive endoderm (DE) were generated from hESCs and then induced to differentiate along the hepatic lineage by the sequential addition of inducing factors implicated in physiological hepatogenesis. The differentiation process was largely uniform with cell cultures progressively expressing increasing numbers of hepatic lineage markers. The hepatocytes exhibited functional hepatic characteristics such as glycogen storage, indocyanine green uptake and release, and albumin secretion. In an animal model of acute liver injury, the hESC-DE cells differentiated into hepatocytes and successfully repopulated the damaged liver.
"I am delighted with the tremendous progress our scientists are making to generate a variety of important functional cells types and refine our cell differentiation process," stated William M. Caldwell IV, CEO and Chairman of Advanced Cell Technology. "These cells have the potential to benefit many Americans suffering from serious and potentially life-threatening diseases with few if any alternatives. We are committed to developing new methods to help translate our stem cell technology into the clinic and are seeking partners for some of our newest scientific advances."
Other authors on the paper were Dr. Sadhana Agawal (first author of the study) and Katherine Holton, a senior research associate at Advanced Cell Technology, Inc.
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying cellular technology in the emerging field of regenerative medicine. The company operates facilities in California and Massachusetts.
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended September 30, 2007. Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
SOURCE: Advanced Cell Technology, Inc.
Media: Chad Griffin Consulting, Inc. Jordan Markwith, 310-888-3523 or Investors: CEOcast, Inc. Daniel Schustack, 212-732-4300
Posted by IMAKEMONEY on :
Pharming concludes license agreement with Advanced Cell Technology
Feb 28, 2008 12:07:29 (ET)
LEIDEN, THE NETHERLANDS, Feb 28, 2008 (MARKET WIRE via COMTEX) -- Biotech company Pharming Group NV ("Pharming") (NYSE Euronext: PHARM) announced today that it has concluded a license agreement with Advanced Cell Technology Inc to obtain exclusive rights on patents in the field of transgenic technology, to which it already had non-exclusive rights. Financial details of the agreement were not disclosed.
These patents were previously owned by Infigen Inc and cover a wide range of technologies including for Pharming relevant elements of nuclear transfer, which is an essential step in generating transgenic cattle. The agreement provides Pharming strict control over the generation of its transgenic cattle, while, at the same time, increasing the barriers of entry for others.
Protecting its technology platforms via patents and licenses is an essential element of Pharming's strategy. This is done not only to maintain 'freedom to operate', but also to limit others in using the technology without a license, thereby protecting the investments that Pharming has made in developing its technology.
About Pharming Group NV
Pharming Group NV is developing innovative products for the treatment of genetic disorders, ageing diseases, specialty products for surgical indications, intermediates for various applications and nutritional products. Pharming has two products in late stage development - Rhucin(R) (recombinant human C1 inhibitor) for Hereditary Angioedema and human lactoferrin for use in food products. The advanced technologies of the Company include innovative platforms for the production of protein therapeutics, technology and processes for the purification and formulation of these products, as well as technologies in the field of tissue repair (via its collaboration with Novathera) and DNA repair (via DNage). Additional information is available on the Pharming website, http://www.pharming.com and on http://www.dnage.nl .
This press release contains forward looking statements that involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the Company to be materially different from the results, performance or achievements expressed or implied by these forward looking statements. The press release also appears in Dutch. In the event of any inconsistency, the English version will prevail over the Dutch version.
Copyright Copyright Hugin AS 2008. All rights reserved.
Contact:
Rein Strijker (NL) Pharming Group NV T: +31 (0)71 52 47 400
SOURCE: Pharming Group N.V.
Posted by IMAKEMONEY on :
Advanced Cell Technology, Inc. Enters into License Agreement with Pharming Group N.V.
Feb 29, 2008 07:38:01 (ET)
LOS ANGELES, Feb 29, 2008 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. (ACTC, Trade ) announced today that it has entered into an agreement with Pharming Group N.V. giving Pharming an exclusive, global license to non-human use of certain patents associated with but not limited to oocyte activation patents held by Advanced Cell Technology. According to the terms of the license agreement, Pharming will pay Advanced Cell Technology a one-time license fee. Prior, Pharming had a nonexclusive license to these patents. Based in the Netherlands, Pharming Group N.V. is focused on developing treatments for genetic and aging diseases, specialty products for surgical indications, and intermediates for various applications and nutritional products.
Advanced Cell Technology has been focused on building a broad intellectual property portfolio since its inception. In early 2007, the company strengthened its IP portfolio by acquiring the intellectual property assets of its former competitor Infigen, Inc. relating to somatic cell nuclear transfer, parthenogenesis, and other related technologies. Upon the closing of its Mytogen, Inc. acquisition later that year, ACT absorbed Mytogen's patent portfolio as well. Advanced Cell Technology now owns or has exclusive licenses to over 380 patents and patent applications worldwide in the field of regenerative medicine and stem cell therapy. In addition, ACT has non-exclusive rights to a portfolio of patents and patent applications that support its core intellectual property.
"We are pleased to be able to monetize our intellectual property portfolio in a number of ways," stated William M. Caldwell IV, Chairman and CEO of Advanced Cell Technology. "Our intellectual property and the research and science that our employees perform remain the foundation of our company. Using this foundation as a basis for developing commercial therapeutics and entering into licensing agreements allows us to finance the company in profitable and nondilutive manners. We plan on continuing to leverage our IP portfolio."
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying cellular technology in the emerging field of regenerative medicine. The company operates facilities in California and Massachusetts.
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended September 30, 2007. Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
SOURCE: Advanced Cell Technology, Inc.
Media: Chad Griffin Consulting, Inc. Jordan Markwith, 310-888-3523 or Investors: CEOcast, Inc. Daniel Schustack, 212-732-4300
Posted by IMAKEMONEY on :
Advanced Cell Technology Announces Catheter Supply Agreement with Biologics Delivery Systems Group
Mar 5, 2008 08:00:10 (ET)
LOS ANGELES, Mar 05, 2008 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. (ACTC, Trade ) announced today that it has reached a supply agreement with Biologics Delivery Systems Group, Cordis Corporation (a Johnson & Johnson company), in which Biologics Delivery Systems will supply catheters for the Phase II human clinical trial of ACT's myoblast therapy for the treatment of heart failure. Advanced Cell Technology's myoblast therapy successfully completed Phase I human clinical trials in 2007 utilizing the therapy safely in more than forty patients. Safety of the therapy was demonstrated in four independent studies. The U.S. Food and Drug Administration has given the company clearance to proceed with Phase II human clinical trials. The company expects its Phase II human clinical trial (CAuSMIC II) to begin shortly.
ACT's myoblast therapy involves the transplantation of expanded autologous myoblasts (adult progenitor stem cells) derived from a small biopsy of skeletal muscle from a patient's leg. The technology allows for the expansion of myoblasts into hundreds of millions of cells over a period of two to three weeks. The resulting myoblasts are then transplanted back into the patient's scarred heart tissue through the use of a catheter-based procedure. Over one million new patients with heart attacks are treated annually in the United States alone, representing a multi-billion dollar market opportunity. Current therapies do not result in rebuilding of heart muscle and do not prevent progression of congestive heart failure, poor quality of life, and long-term deterioration. According to the National Heart, Lung, and Blood Institute, a division of the National Institutes of Health, approximately 5 million people in the United States have congestive heart failure and an estimated 400,000 new cases are diagnosed each year. Roughly 50% of CHF patients die within 5 years.
The Phase II human clinical trial will be a multi-center study following a similar protocol to the one used in the company's Phase I study. That study demonstrated safety and evidence of significant heart function improvement in congestive heart failure patients as a result of the implantation of the ACT's proprietary autologous skeletal myoblasts using the Biologics Delivery Systems NOGA(R) Cardiac Navigation System and MyoStar(R) Injection Catheter. "The NOGA(R) System created highly precise, three-dimensional images of the heart. These images gave us a clear 'map' that helped us to successfully deliver the adult stem cells where we intended them to go," commented Dr. Nabil Dib, the lead investigator for the myoblast phase I study. "This imaging technology was critical to making this study possible." The Phase II human clinical trial will use the latest generation catheters provided as a result of ACT's ongoing relationship with the Biologics Delivery Systems.
"The supply commitment for NOGA mapping and Myostar injection catheters from Biologics Delivery Systems Group represents another step toward commercializing our myoblast therapy and bringing novel treatment to patients with few effective alternatives," commented William M. Caldwell IV, Chairman and CEO of Advanced Cell Technology. "We are excited to commence our Phase II human clinical trials soon."
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying cellular technology in the emerging field of regenerative medicine. The company operates facilities in California and Massachusetts.
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended September 30, 2007. Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
SOURCE: Advanced Cell Technology, Inc.
Media: Chad Griffin Consulting, Inc. Jordan Markwith, 310-888-3523 or Investors: CEOcast, Inc. Daniel Schustack, 212-732-4300
Posted by IMAKEMONEY on :
Advanced Cell Technology and Catholic Healthcare West Sign Clinical Agreement
Mar 12, 2008 09:15:01 (ET)
LOS ANGELES, Mar 12, 2008 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. (ACT) (ACTC, Trade ) announced today that it has signed a clinical trial agreement with Chandler Regional Medical Center and Mercy Gilbert Medical Center, members of Catholic Healthcare West (CHW), the nation's eighth largest healthcare system, to become ACT's first clinical trial sites for the Phase II myoblast study. In addition, CHW has received Institutional Review Board approval for the clinical trial, which is expected to begin soon. ACT's myoblast program is an autologous adult stem cell therapy for the treatment of heart disease that has successfully completed four Phase I clinical trials and received clearance from the Food and Drug Administration to begin Phase II trials.
In November 2007, ACT and CHW announced that the two parties had entered into a letter of intent for a proposed exclusive business arrangement to establish a clinical trial research site and a North American regenerative medicine interventional cardiology training center for the Phase II clinical trial. The study, which will utilize 3-Dimensional Guided Catheter-Based Delivery of Autologous Skeletal Myoblasts for Ishemic Cardiomyopathy (CAuSMIC), will soon be open for enrollment. Led by principal investigator Nabil Dib, M.D., M.Sc., F.A.C.C., director of Cardiovascular Research for Chandler Regional Medical Center and Mercy Gilbert Medical Center, enrollment in the CAuSMIC trial will focus on patients who are not eligible for angioplasty or coronary artery bypass surgery, and who continue to have poor quality of life despite receiving optimal medical therapy or cardiac resynchronization therapy with a pacemaker or defibrillator device.
"The agreement with CHW signifies our readiness to begin the Phase II clinical trial," said William M. Caldwell, IV, chairman and CEO of ACT. "We are excited to begin the trial, which has the potential to be a major advance for the field of regenerative medicine and, more importantly, to patients in need of care. We look forward to working with such a prominent healthcare group."
"Currently, there are no treatment options available to correct heart failure, only those that can slow its progression," said David G. Covert, president and CEO of the CHW East Valley Service Area and Chandler Regional Medical Center. According to Covert, Dr. Dib's findings are the culmination of seven years of prior clinical work to demonstrate the safety and utility of taking a patient's own muscle stem cells to repair heart muscle damage. "Chandler Regional Medical Center and Mercy Gilbert Medical Center are proud to participate in developing this innovative treatment option for people living with heart failure. As we continue to develop our research program, our main focus is to translate this type of research into bedside standard of care."
About Catholic Healthcare West
Catholic Healthcare West (CHW) is the eighth largest hospital system in the nation and one of the largest not-for-profit hospital providers in the West. Founded in 1986, the CHW network of more than 8,500 physicians and approximately 50,000 employees serve a population spanning 22 million people at 43 hospitals across California, Arizona, and Nevada. CHW is committed to delivering compassionate, high-quality, affordable healthcare services with special attention to the poor and underserved. In fiscal year 2007, CHW provided $922 million in charity care, community benefits, and unreimbursed patient care. CHW facilities in Arizona include Chandler Regional Medical Center, Mercy Gilbert Medical Center, St. Joseph's Hospital and Medical Center and Barrow Neurological Institute, CHW Urgent Cares in Ahwatukee, Gilbert and Queen Creek, Sun Lakes Laboratory, Warner Outpatient Surgery and the Arizona Orthopedic Surgical Hospital. For more information, please visit our Website at www.chwHEALTH.org .
About Chandler Regional Medical Center
Chandler Regional Medical Center is a 225-bed, acute-care, non-for-profit provider of emergency care, maternal child services, cardiovascular services, wound healing, cancer treatment, diabetes treatment, and diagnostic services. It is located at 475 S. Dobson Road (corner of Dobson Road and Frye Road) in Chandler. For more information, please visit www.chandlerregional.org or call (480) 728-3000. Chandler Regional Medical Center is an Equal Opportunity Employer (EOE). For employment opportunities please contact the Human Resources Department at (480) 728-3424.
About Mercy Gilbert Medical Center
Mercy Gilbert Medical Center is located at the intersection of Val Vista Drive and Loop 202 (south of Pecos Road and east of Val Vista Drive). Mercy Gilbert Medical Center is a four-story, full-service acute-care facility with 182 beds. For more information, please visit www.mercygilbert.org or call (480) 728-8000. Mercy Gilbert Medical Center is an Equal Opportunity Employer (EOE). For employment opportunities please contact the Human Resources Department at (480) 728-8396.
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying cellular technology in the emerging field of regenerative medicine. The company operates facilities in California and Massachusetts.
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended September 30, 2007. Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
SOURCE: Advanced Cell Technology, Inc.
Media: Chad Griffin Consulting, Inc. Jordan Markwith, 310-888-3523 or Investors: CEOcast, Inc. Daniel Schustack, 212-732-4300
Posted by IMAKEMONEY on :
LOS ANGELES, Mar 31, 2008 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. (ACTC, Trade ) announced today that it completed a private placement with institutional and other accredited investors. The company intends to use the proceeds of the offering towards for general corporate purposes, including additions to working capital, and to finance the further development of the company's clinical programs.
Advanced Cell Technology closed on the private placement of $3,855,360 principal amount of amortizing senior secured convertible debentures. The issuance of the debentures generated $3,072,000 in gross proceeds.
William M. Caldwell, IV, Chairman and CEO of Advanced Cell Technology remarked, "This transaction represents a significant event for Advanced Cell Technology and reflects the growing recognition of the potential of the company's stem cell technology. The proceeds from this financing will allow ACTC to accelerate its development programs focused on novel therapies for diseases and indications that have few medical alternatives. Cardiovascular disease and regenerative retinal disorders represent substantial unmet medical needs that we believe our cell based therapies address."
Additional details regarding the financing will be included in a Current Report on Form 8-K to be filed by the Company with the Securities and Exchange Commission.
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts. For more information about the company, please visit www.advancedcell.com .
Forward-Looking Statements
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended June 30, 2007.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
SOURCE: Advanced Cell Technology, Inc.
Media: Chad Griffin Consulting, Inc. Jordan Markwith, 310-888-3523 or Investors: CEOcast, Inc. Dan Schustack, 212-732-4300
Posted by IMAKEMONEY on :
Advanced Cell Technology to be Featured Tonight on ABC Television's Special Report ''Live to 150, Can You Do It? Secrets to Living Longer''
Apr 1, 2008 08:30:07 (ET)
LOS ANGELES, Apr 01, 2008 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. (ACTC, Trade ) announced today that the company will be featured on ABC Television's special report titled, "Live to 150, Can You Do It? Secrets to Living Longer," hosted by Barbara Walters. The report is scheduled to air tonight on ABC Television throughout the country at 10 PM eastern time. The report will include an interview with Dr. Robert Lanza, MD, Chief Scientific Officer at Advanced Cell Technology. During the interview, Dr. Lanza and Ms. Walters will discuss a number of Advanced Cell Technology's research platforms including its blastomere program for creating human embryonic stem cell (hESC) lines without impacting the developmental potential of embryos as well as the company's research into developing a universal O negative red blood cell bank using human embryonic stem cell science.
Advanced Cell Technology, Inc. is a biotechnology company applying cellular technology in the emerging field of regenerative medicine. The company operates facilities in California and Massachusetts.
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended September 30, 2007. Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
SOURCE: Advanced Cell Technology, Inc.
Media: Chad Griffin Consulting, Inc. Jordan Markwith, 310-888-3523 or Investors: CEOcast, Inc. Daniel Schustack, 212-732-4300
Posted by Spectacles on :
If I'm not mistaken this stock was at about .70 a year ago. I guess .13 is a good buy in point cosidering it's going to be highlighted tonite by Baba Wawa... I'm in for 20K shares to start. Lets see what happens this week. GL
Posted by BooDog on :
I smacked the ask. IMAKE keeps this one goin pretty good!! lmao! Posted by BooDog on :
5 * .128
Posted by BooDog on :
hdsn acting like a magnet took everyone to .125
Posted by BooDog on :
nite taking back over.. tomorrow should be interesting.
Posted by BooDog on :
Double bottom bouncer - 3 month chart. Gotta eat through more convertibles GRRRRRRR!!
On ABC 10PM tonight!
Posted by BooDog on :
Quick notes from the presentation... -Cloned the first endangered animal - the wild ox, as well as a herd of cows - said to possibly be the longest living cows on the planet. - New blood created from stem cells - Universal blood type. -Manufacturing heart valves, arteries and muscles
other foot notes to follow up on Sirtris (not actc but something I need to research). Also Dr. Darvis Taylor from the University of Minnesota.
Posted by BooDog on :
Already going pre market. .13
Posted by Happy Valley on :
In a few at .092...Trying to catch the knife...lol
Posted by IMAKEMONEY on :
Barbara Walters' ABC Network Television Special Highlights Role that Advanced Cell Technology's Embryonic Stem Cells Play in Preventing Aging
Apr 2, 2008 07:30:02 (ET)
LOS ANGELES, Apr 02, 2008 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. (ACTC, Trade ) announced today that an ABC Television's special report titled, "Live to 150, Can You Do It? Secrets to Living Longer," which aired last night and was hosted by Barbara Walters, highlighted the role that the company's blastomere program for creating human embryonic stem cell (hESC) lines without impacting the developmental potential of embryos could play in extending life and slowing down the aging process. The special also highlighted Advanced Cell Technology's research into developing a universal O negative red blood cell bank using human embryonic stem cell science. The report, which included an interview with Dr. Robert Lanza, MD, Chief Scientific Officer at Advanced Cell Technology, featured the company's research platforms and included a discussion of the role that the company's stem cell science could play in treating various diseases.
The show profiled the lives of several people who are currently 100 years old or older and described some of the most promising scientific developments that could extend life. Advanced Cell Technology's technology platform was included among the scientific breakthroughs.
In August 2006, Advanced Cell Technology reported in the journal Nature that company scientists had successfully generated hESCs using its blastomere technology, an approach that does not destroy the developmental potential of embryos. The blastomere technology has been reproduced and peer-reviewed on several occasions. In June 2007, ACT announced at the fifth annual meeting of the International Society for Stem Cell Research in Cairns, Australia, that it had reproduced its work by successfully producing an hESC line without destroying an embryo at its lab in Worcester, Massachusetts. In January 2008, ACT together with colleagues announced the development of five hESC lines without the destruction of embryos. The method was published in the journal Cell Stem Cells, published by Cell Press. The peer-reviewed technique was initially carried out by ACT scientists under the direction of Dr. Lanza and then independently replicated by scientists on the West Coast. In addition, the NIH announced in 2007 that it would begin implementing President George W. Bush's Executive Order to explore methods to expand the number of approved pluripotent stem cell lines "without creating a human embryo for research purposes or destroying, discarding, or subjecting to harm a human embryo or fetus." ACT's blastomere program was cited by the NIH as an alternative method in its implementation plan; therefore, should the company's blastomere technique satisfy NIH qualifications, ACT could qualify for federal funding from the NIH.
In addition to its blastomere research platform, Advanced Cell Technology has made progress on the therapeutic front. ACT published positive data in the journal NATURE Methods for its HG (hemangioblast) cell program for the treatment of blood and cardiovascular diseases. The company published positive data from animal studies for its RPE (retinal pigment epithelial) cell program for the treatment of retinal degenerative disorders completed in collaboration with the Casey Eye Institute at Oregon Health and Science University. The company also has GLP Safety Studies in process for its RPE Program. Finally, ACT's Myoblast program, an autologous adult stem cell therapy for the treatment of heart disease, has successfully completed four Phase I clinical trials and has clearance from the FDA to begin Phase II trials shortly.
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying cellular technology in the emerging field of regenerative medicine. The company operates facilities in California and Massachusetts.
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended September 30, 2007. Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
SOURCE: Advanced Cell Technology, Inc.
Media: Chad Griffin Consulting, Inc. Jordan Markwith, 310-888-3523 or Investors: CEOcast, Inc. Daniel Schustack, 212-732-4300
Posted by BooDog on :
quote:Originally posted by Happy Valley: In a few at .092...Trying to catch the knife...lol
averaged out. Convertibled are killing this thing.
Posted by IMAKEMONEY on :
BOUNCE PLAY IT!
Posted by BooDog on :
I did. Prolly for the last time. Convertibles were re-written. And I was thinking they would at least stick to their price. Still could get a pop IMAKE, was thinking it would. ----------------------------------- · The Conversion Price set forth in each outstanding 2005 debenture, 2006 debenture, and 2007 debenture held by Prior Purchasers who participated in the 2008 Financing was reset to $0.15;
· The Exercise Price set forth in each outstanding 2005 warrant, 2006 warrant, and 2007 warrant held by Prior Purchasers who participated in the 2008 Financing was reset to $0.165; and
Posted by BooDog on :
lotta buys going thru now at .105 and then one sell takes it back to .103.
Posted by ski3272 on :
I baught in at 13 thinking this sucker would go but oh no poof crash bang boom. Im ready to go back to playing black jack the odds were better.
Posted by BooDog on :
ask 1 * .105, .108, .109, 5 * .11
Posted by ski3272 on :
you would thing barbara waa waa could have done this stock some good , i mean what more do you want for a stock to shoot through the roof. A tv show all sorts of good news cows that will live forever I dont know what to do anymore.
Posted by ski3272 on :
Whats everyones thoughts on this one up down I dont understand why this share didnt go up today after all the news and tv show.
Posted by BooDog on :
quote:Originally posted by ski3272: Whats everyones thoughts on this one up down I dont understand why this share didnt go up today after all the news and tv show.
This is a very big part of it.
quote:Originally posted by BooDog: · The Conversion Price set forth in each outstanding 2005 debenture, 2006 debenture, and 2007 debenture held by Prior Purchasers who participated in the 2008 Financing was reset to $0.15;
· The Exercise Price set forth in each outstanding 2005 warrant, 2006 warrant, and 2007 warrant held by Prior Purchasers who participated in the 2008 Financing was reset to $0.165; and
Posted by invester on :
When is the R/S happening? The board approved it to be executed mid April, correct?
Posted by ski3272 on :
R/S is that good? Im new to these micro's I satrted out good then poof
Posted by invester on :
R/S means reverse split. It typically is bad, especially in the Pinks, or BB. This company is the new IBM in there field, but without government funding, they have to raise capital. The only real way is dilution.
Posted by invester on :
The next congress will most assuredly approve stem cell funding. I would get in this after the split and after the initial drop after the split.
Posted by BooDog on :
quote:Originally posted by invester: When is the R/S happening? The board approved it to be executed mid April, correct?
Not sure, But the way these convertibles were changed I wouldn't put it past them to also change the value from 1:2 - 1:10 to something like 1:100.
Posted by IMAKEMONEY on :
ITS A PLAY GUYS, PLAY IT THAT WAY, DONT FALL IN LOVE HERE! LOL, HI BOO Posted by BooDog on :
No doubt IMAKE. I thought today would be that play, my guess is the insiders knew what I was thinking (and many others). Out for now but I'm watching.
Cheers M8.
Posted by ski3272 on :
wow the good news sure stopped fast lol I wish the bad news was posted first i wouldnt have baught a bunch of shares at 13. is there any chance it hits 13 again before the split?
Posted by ski3272 on :
ADVANCED CELL TECHNOLOGY INC Daily Commentary
Our system posted a WAIT today. The previous SELL recommendation was issued on 04.01.2008 (1) day ago, when the stock price was 0.1600. Since then ACTC has fallen -36.25% .
Our WAIT tag says all that is to say. Stay at cash or check the other stocks while waiting the next signal. Do not bother with buying or short selling this stock as long as the WAIT tag stays.
Posted by invester on :
quote:Originally posted by ski3272: ADVANCED CELL TECHNOLOGY INC Daily Commentary
Our system posted a WAIT today. The previous SELL recommendation was issued on 04.01.2008 (1) day ago, when the stock price was 0.1600. Since then ACTC has fallen -36.25% .
Our WAIT tag says all that is to say. Stay at cash or check the other stocks while waiting the next signal. Do not bother with buying or short selling this stock as long as the WAIT tag stays.
Don't buy or sell on another individuals Short or Long signals. I am a seasoned trader, and if you just read the 10k it will clearly tell you that there is a Reverse Split coming before the end of April. Any knowledgeable trader should know that they pumped the Barbra W. interview to unleash some funding "stock". Just be cautious if you are a newbie as the R/S is coming and your account will get hurt. As a season trader, I tell you to wait for the R/S, then the drop after, then buy when it hits the bottom. I feel they are fully funded till congress passes approval on stem cells. This truly will be the IBM of the stem cell market. IMHO.
Posted by ski3272 on :
Thank You, do you thik it will go back up to 13 even before this happens?
Posted by Happy Valley on :
quote:Originally posted by ski3272: I baught in at 13 thinking this sucker would go but oh no poof crash bang boom. Im ready to go back to playing black jack the odds were better.
Did you buy on the gap today???
Posted by ski3272 on :
i baught right away at the open thinking it waS going up right away. do you think it will hit the 13 again ? soon
Posted by BooDog on :
quote:Originally posted by ski3272: i baught right away at the open thinking it waS going up right away. do you think it will hit the 13 again ? soon
There is a chance. Dam crazy 8 ball quit working for me yesterday! Couple factors, first - we know about the convertibles and their price so there is a major resistance level there. Second there is a major seller on top of this right now that obviously doesn't give a crap about the pps. The only thing that stopped this from crashing major yest is people realized they were up to the same tricks they were pulling the last time we thought they had real good news so people quit loading up looking for the bounce. Still had decent buys all through yest but the seller was just too much. Check the filings and you'll see the deal Advance cut. When he's out then this will have a chance imo - at least until it gets back to the conversion price.
Anyway - just my WAG.
Posted by Happy Valley on :
Press Release Source: Advanced Cell Technology, Inc.
Advanced Cell Technology Platform Yields Over 140 Cell Types from Human Embryonic Stem Cells Thursday April 3, 8:30 am ET Research Represents a Breakthrough in the Mapping and Characterization of the Cells of Early Human Development; Company to provide differentiated embryonic progenitor cell lines from its ACTCellerate Platform for therapeutic applications, research tools, and drug discovery
ALAMEDA, Calif.--(BUSINESS WIRE)--Advanced Cell Technology, Inc. (OTCBB: ACTC; www.advancedcell.com) reported today on a large-scale differentiation process that has generated panels of differentiating human progenitor cell lines from human embryonic stem cells (hESCs). The research will be published in the April issue of Regenerative Medicine (Vol. 3[3] e-pub ahead of print) and will be freely available at www.futuremedicine.com/loi/rme. ADVERTISEMENT
Since the first isolation of hESCs, scientists and industry alike have been working to harness the power of these cells for the purpose of restoring and regenerating body systems that have been damaged by disease or injury
One of the hurdles has been a commercially viable means for the expansion of sufficient numbers of the cell types needed for tissue regeneration. With the publication of work entitled “The ACTCellerate Initiative: large-scale combinatorial cloning of novel human embryonic stem cell derivatives,” ACT scientists have solved some of these problems. The paper describes a system that was established to isolate and clonally expand tissue specific precursors that heretofore could only be isolated from aborted human fetal tissue.
Dr Chris Mason (UCL), Associate Editor of Regenerative Medicine said, “This is an enormously exciting development for the regen sector. The research reported… represents a quantum leap forward in embryonics, the mapping and characterization of the cells of early human development. Without any doubt, the ACTCellerate technology will greatly hasten the translation of human embryonic stem cell-based therapies into safe and effective products for routine clinical practice.”
The benefits of the ACTCellerate technology transcend therapeutics and extend as well into revolutionary applications for drug discovery, drug toxicity testing, and cancer research. This advance holds great promise for future research and may one day lead to many new cell-based therapies in the emerging field of regenerative medicine.
Another important finding in this publication is that these normal embryonic progenitor cell types show the expression of certain genes (such as oncofetal markers) often associated in the literature with malignant cancer. However, when these progenitor cells were injected into supportive mice, no malignant tumors could be observed. This indicates that expression of such genes is a function of these cells’ normal primitive stage of differentiation and not linked to any disease potential.
William M. Caldwell IV, Chairman and CEO of Advanced Cell Technology, Inc., stated, “We are greatly indebted to Mike West for his insight in initiating this program during his tenure with ACT and to the entire ACT scientific team for their perseverance in bringing this groundbreaking research to the conclusions described in this publication. ACT has taken great strides in identifying both clinical applications for this approach as well as for the ACTCellerate cell line library for drug target discovery, assay development, and direct therapeutics development across a wide spectrum of clinical indications. We are now in a position to offer our refined technology and know-how to potential partners and licensees.”
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying cellular technology in the emerging field of regenerative medicine. The company operates facilities in California and Massachusetts.
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended September 30, 2007. Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
Contact: Media: Chad Griffin Consulting, Inc. Jordan Markwith, 310-888-3523 or Investors: CEOcast, Inc. Daniel Schustack, 212-732-4300
-------------------------------------------------------------------------------- Source: Advanced Cell Technology, Inc.
Posted by IMAKEMONEY on :
Posted by Happy Valley on :
Posted by IMAKEMONEY on :
SEE THERE YOU GO! FUN ISNT IT,LOL
Posted by IMAKEMONEY on :
Advanced Cell Technology's Executive Invited to Present Today to FDA Advisory Committee on Cellular Tissue Therapies
Apr 10, 2008 09:18:01 (ET)
ALAMEDA, Calif., Apr 10, 2008 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. (ACTC, Trade ) announced today that Jonathan H. Dinsmore Ph.D., Senior Vice President - Regulatory and Clinical, has been invited to present to the U.S. Food and Drug Administration's Center for Biologics Evaluation and Research Advisory Committee on Cellular, Tissue and Gene Therapies. Dr. Dinsmore will deliver a presentation today titled, "Safety Considerations for the Clinical Application of Human Embryonic Stem Cells" to the FDA panel, which will convene at the Hilton Hotel in Gaithersburg, Maryland. The presentation is scheduled for 10 a.m. eastern time. The panel is expected to conduct hearings on Cellular Therapies Derived from Human Embryonic Stem Cells Scientific Considerations for Pre-Clinical Safety Testing. Other companies invited to present include Geron Corporation (GERN, Trade ) and Novocell, Inc.
During Dr. Dinsmore's presentation, he is expected to discuss cell sourcing, manufacturing and delivery of human embryonic stem cells. He will also present certain conclusions from pre-clinical activities surrounding the company's retinal pigmented epithelial (RPE) cell therapy. Advanced Cell recently completed discussions with the FDA regarding this program through a type B, pre-Investigational New Drug (pre-IND) meeting concerning the regulatory pathway and requirements to file an IND to initiate human clinical trials. The entire presentation will be available on the company's web site at http://www.advancedcell.com/conference-presentations after 11 a.m. eastern time today.
"We are honored that the FDA has invited us to participate in this panel, which could be influential in shaping the clinical pathway for the testing of embryonic stem cells," said William M. Caldwell IV, Chairman and CEO of Advanced Cell Technology, Inc. "As one of the few stem cell companies that is preparing for later-stage clinical trials, we are pleased that we will be able to share our views with FDA executives and other distinguished members of the scientific community on the safety issues surrounding human embryonic stem cell development."
Additional details on the FDA meeting may be found at http://www.fda.gov/ohrms/dockets/ac/cber08.html#CellularTissueGene Therapies (Due to its length, this URL may need to be copied/pasted into your Internet browser's address field. Remove the extra space if one exists).
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying cellular technology in the emerging field of regenerative medicine. The company operates facilities in California and Massachusetts.
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended September 30, 2007. Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
SOURCE: Advanced Cell Technology, Inc.
CEOcast, Inc. for Advanced Cell Technology Daniel Schustack, 212-732-4300
Posted by BooDog on :
movin
Posted by IMAKEMONEY on :
RELOAD!
Posted by Bottomfeeder on :
Which is the correct symbol...ACTC or ACTCE?
Posted by BooDog on :
quote:Originally posted by Bottomfeeder: Which is the correct symbol...ACTC or ACTCE?
ACTCE
Posted by BooDog on :
quote:Originally posted by BooDog:
quote:Originally posted by Bottomfeeder: Which is the correct symbol...ACTC or ACTCE?
![[Big Grin]](biggrin.gif)
![[Eek!]](eek.gif)
![[Cool]](cool.gif)
wtg imake. I thought this would happen but not in one day. lol. end of week gapper? or more conversions to drive it lower? many were waiting for this. Bush's veto didn't help matters but twill be business as usual finding financing. getting warmer on their research as well so finding the money shouldn't be too difficult. imo
![[Razz]](tongue.gif)
![[Wink]](wink.gif)
![[Smile]](smile.gif)
i am new to the forum thanks for all the positive info
![[Frown]](frown.gif)
![[Good Luck]](graemlins/goodluck.gif)
![[Were Up]](graemlins/wereup.gif)
![[BadOne]](graemlins/headbash.gif)